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The highly reactive electrophile, Methylglyoxal (MG), a break down product 
of carbohydrate is a major environmental mutagen and has potential genotoxic effects. 
It is ubiquitous in beverages and foods, such as coffee, toast and soy sauce, as well as 
in cigarette smoke. Its mutagenicity has also been reported in Escherichia coli, 
wherein it causes mutations at G:C base pairs, as well as in Sacharomyces cerevisiae. 
Previous studies have suggested that MG reacts with free amino groups of proteins 
and DNA under physiological conditions and forms advanced glycation end products 
resulting in the generation of hydroxyl (OH) and superoxide (02*) ions which play 
an important role in the pathophysiology of ageing and diabetic complications. 
Moreover, in glycation reaction the free carbonyl groups of the sugar react with the 
free amino residues of the macromolecules in a series of chemical processes known as 
Maillard reaction. Initiation of glycation occurs by the formation of acid-labile Schiff 
base adducts which undergoes Amadori or Heyn's rearrangements into more stable 
products. Glycated DNA has attracted much attention in the past few years and is 
considered to be a pathogenic factor for diabetes mellitus. During the disorder in the 
metabolism of reducing sugars, the sugar molecules can initiate glycation of DNA in 
vivo. Previous investigations by several scientists using biochemical and molecular 
biological methods have shown that DNA structure and function are affected by the 
addition of sugars and carbonyls (MG), resulting in deleterious modifications and 
other mutations. 
Diabetes mellitus refers to group of common metabolic disorders that share 
the phenotype of hyperglycemia. Several types of diabetes mellitus exist and are 
caused by a complex interaction of genetics and environmental factors and viral 
infection. Increased oxidative stress is a widely accepted participant in the 
development and progression of diabetes and its complications. Mechanisms by 
which increased oxidative stress is involved in the diabetic complications are partly 
known, including activation of transcription factors, advanced glycated end products 
(AGEs) and protein kinase C. In diabetes mellitus, low insulin levels prevent cells 
from absorbing glucose; as a result glucose builds up in the blood. Absolute insulin 
deficiency caused by autoimmune-mediated destruction of pancreatic p-cells 
characterizes type I diabetes. The main cause of the beta cell loss is a T-cell mediated 
immune attack. There is a strong association of type I diabetes with individuals who 
possess particular HLA haplotypes. Viruses, such as enteroviruses, coxackie virus and 
rubella, have been proposed as culprits but have not been definitively shown to induce 
type I diabetes. None of these theories has evolved into a clear cause-and-effect 
initiator of diabetes. By whatever initiating mechanism, the autoimmune destruction 
of j3-cells leads to a progressive decline in the body's insulin secretory capacity. 
Like type I diabetes, type II diabetes also involves both genetic susceptibility 
and environmental factors. It is caused by a combination of insulin resistance and 
relative insulin deficiency with increased hepatic glucose production. Insulin resis-
tance is generally thought to precede insulin deficiency. Before type II diabetes 
develops, the pancreatic |3-cells increase their production of insulin to compensate for 
increased insulin resistance. For unclear reasons, p-cell secretory capacity gradually 
declines in some individuals, leading to the development of type II diabetes. The 
cause of p-cell failure in type II diabetes is unknown. 
In the present study, commercially available human DNA was modified by 
MG and lysine in the presence of Cu^ "". DNA modifications were analyzed by various 
spectroscopic and analytical techniques like, UV, Fluorescence, CD, thermal 
denaturation studies, HPLC, NMR, LC-MS and ESI-MS. Moreover, agarose gel 
electrophoresis, nuclease SI digestibility and comet assays were also performed to 
assess the modification of the MG-Lys-Cu^"^ system. Furthermore, antibodies were 
induced in rabbits against native and modified DNA. The induced antibodies were 
characterized with respect to antigen binding specificities by direct binding and 
inhibition ELISA. Antigen binding specificities were fiarther confirmed by band shift 
assay. These antibodies have been used as an immunochemical probe to detect 
reactive carbonyl species (RCS) induced DNA damage in diabetes patients. In order 
to assess the possible role of MG-Lys-Cu^"^ modified DNA in the etiology of type 1 
diabetes mellitus, sera from patients were assessed for their binding to native and 
MG-Lys-Cu^"^ modified human DNA. Furthermore, binding of serum antibodies for 
type II diabetes patients with native and MG-Lys-Cu^"" modified human DNA was 
also evaluated. 
The UV &. CD spectroscopical analysis, agarose gel electrophoresis, nuclease 
SI digestibility assay and thermal denaturation studies, suggest structural perturbation 
in DNA as a result of modification. This might be due to the generation of single-
stranded regions, destabilization of hydrogen bonds and modification of nitrogenous 
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bases which result in the destruction of chromophoric groups through attack on the 
sugar-phosphate back bone. The fluorescence spectroscopy study suggests formation 
of advanced glycation end-products. This is further proved by anti-glycation study 
and UV- spectroscopy. The genotoxicity of MG-Lys-Cu^"" formed AGEs was 
confirmed by using the comet-assay as an endpoint for DNA damage. This is evident 
from the DNA breakage and subsequent formation of the comet tail. Moreover, the 
adduct (CEdG) formed due to the glycation reaction of MG-Lys-Cu^^ with human 
DNA was detected by HPLC, supported by NMR and further confirmed by LC-MS. 
The reaction of MG and lysine generates free radicals which were confirmed 
by quantitation of hydroxyl and superoxide radicals. The generation of these free 
radicals was further proved by quenching studies. Therefore, results presented here 
indicate that the glycation reaction of MG with lysine in the presence of Cu'^ '^  may 
lead to oxidative damage of DNA through a mechanism that involves hydroxyl 
radicals. 
The MG-Lys-Cu^"" modified human DNA proved to be a potent antigen, 
eliciting high titre immunogen specific antibodies in rabbits. The antigenic specificity 
of anti-MG-Lys-Cu^^ modified human DNA IgG was ascertained by competitive 
binding assay. A maximum of 88.5% inhibition in the antibody activity at inhibitor 
(immunogen) concentration of 20 |ig/ml and just 2.8 ng/ml of the inhibitor 
concentration caused 50% inhibition, clearly indicating very high specificity and 
affinity of the induced antibodies towards the immunogen, i.e. the MG-Lys-Cu"" 
modified human DNA. Affinity purified immune IgG showed higher specificity as 
compared to serum. Moreover, visual detection of interaction between immune IgG 
and the immunogen was done by band shift assay. The result shows high affinity of 
the induced antibodies for the immunogen. The induced antibodies though highly 
specific for MG-Lys-Cu^^ modified human DNA also exhibited polyspecificity, 
recognizing various nucleic acid conformers and nitrogenous bases in competitive 
inhibition assay. The results suggest that MG modification of DNA in presence of 
lysine and Cu^^ caused structural perturbations generating new epitopes thus 
transforming it into a potential immunogen. The modified DNA may be one of the 
factors for the induction of circulating anti-DNA antibodies in diabetes. 
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The clinical study focuses on the possible involvement of MG-Lys-Cu -^
modified and the unmodified human DNA in diabetes mellitus (both type I & II) was 
probed. Out of 40 sera in type I diabetes, 67.5% showed preferentially high binding to 
MG-Lys-Cu^ "^  modified human DNA as compared to its native analogue. These 
results indicate substantial recognition of MG-Lys-Cu^ "^  modified human DNA by the 
auto-antibodies in diabetic (type-I) patients. The affinity purified IgG from diabetic 
patients showed appreciably high binding towards MG-Lys-Cu^ "*^  modified human 
DNA, reiterating the results obtained with serum antibodies. The strong binding of 
auto-antibodies from diabetes type I patients to MG-Lys-Cu^ "^  modified human DNA 
is evidence towards the involvement of modified bases and single strand regions in 
disease pathogenesis. The spontaneous production of auto-antibodies in type I 
diabetes might be a result of the generation of the antigenic epitopes on the DNA 
molecules that are recognized as 'non self by the body's immune system. It could, 
therefore, be one of the factors of the immune response in diabetes. In type II 
diabetes, out of 45 sera only 35.5% showed low to moderate binding to MG-Lys-Cu^ "^  
modified human DNA as compared to its native analogue. In type II diabetes, the 
recognition of auto-antibodies against MG-Lys-Cu^^ modified human DNA is quite 
low as compared to type I diabetes. The results show ample evidence of the 
involvement of MG-Lys-Cu^ "^  modified human DNA in type I diabetes while the same 
is less established for the type II. 
In view of all the above studies it could be concluded that MG-Lys-Cu"" 
modification of human DNA resulted in the formation of single strand breaks and 
base modification causing perturbation in the structure of DNA. Moreover, modified 
human DNA was highly immunogenic in experimental animals. The induced 
antibodies, though highly specific for the immunogen, also exhibited polyspecific 
binding. The antibodies showed significant binding with various nucleic acid 
conformers and nitrogenous bases. Higher recognition of MG-Lys-Cu^^ modified 
human DNA by diabetes type I autoantibodies is a clear indication of MG-Lys-Cu^^ 
induced DNA damage in these patients. It could, therefore, be one of the factors for 
the autoimmune response leading to the induction of circulating anti-DNA 
autoantibodies in diabetes mellitus, type I Furthermore, antibodies from type U 
diabetes patients exhibited low to moderate binding with MG-Lys-Cu"^ modified 
human DNA. 
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The highly reactive electrophile, Methylglyoxal (MG), a break down product 
of carbohydrate is a major environmental mutagen and has potential genotoxic effects. 
It is ubiquitous in beverages and foods, such as coffee, toast and soy sauce, as well as 
in cigarette smoke. Its mutagenicity has also been reported in Escherichia coli, 
wherein it causes mutations at G:C base pairs, as well as in Sacharomyces cerevisiae. 
Previous studies have suggested that MG reacts with free amino groups of proteins 
and DNA under physiological conditions and forms advanced glycation end products 
resulting in the generation of hydroxyl (OH) and superoxide (O2') ions which play 
an important role in the pathophysiology of ageing and diabetic complications. 
Moreover, in glycation reaction the free carbonyl groups of the sugar react with the 
free amino residues of the macromolecules in a series of chemical processes known as 
Maillard reaction. Initiation of glycation occurs by the formation of acid-labile Schiff 
base adducts which imdergoes Amadori or Heyn's rearrangements into more stable 
products. Glycated DNA has attracted much attention in the past few years and is 
considered to be a pathogenic factor for diabetes mellitus. During the disorder in the 
metabolism of reducing sugars, the sugar molecules can initiate glycation of DNA in 
vivo. Previous investigations by several scientists using biochemical and molecular 
biological methods have shown that DNA stmcture and function are affected by the 
addition of sugars and carbonyls (MG), resulting in deleterious modifications and 
other mutations. 
Diabetes mellitus refers to group of common metabolic disorders that share 
the phenotype of hyperglycemia. Several types of diabetes mellitus exist and are 
caused by a complex interaction of genetics and environmental factors and viral 
infection. Increased oxidative stress is a widely accepted participant in the 
development and progression of diabetes and its complications. Mechanisms by 
which increased oxidative stress is involved in the diabetic complications are partly 
known, including activation of transcription factors, advanced glycated end products 
(AGEs) and protein kinase C. In diabetes mellitus, low insulin levels prevent cells 
from absorbing glucose; as a result glucose builds up in the blood. Absolute insulin 
deficiency caused by autoimmune-mediated destruction of pancreatic |3-cells 
characterizes type I diabetes. The main cause of the beta cell loss is a T-cell mediated 
immune attack. There is a strong association of type I diabetes with individuals who 
possess particular HLA haplotypes. Viruses, such as enteroviruses, coxackie virus and 
rubella, have been proposed as culprits but have not been definitively shown to induce 
type I diabetes. None of these theories has evolved into a clear cause-and-effect 
initiator of diabetes. By whatever initiating mechanism, the autoimmune destruction 
of p-cells leads to a progressive decline in the body's insulin secretory capacity. 
Like type I diabetes, type II diabetes also involves both genetic susceptibility 
and environmental factors. It is caused by a combination of insulin resistance and 
relative insulin deficiency with increased hepatic glucose production. Insulin resis-
tance is generally thought to precede insulin deficiency. Before type II diabetes 
develops, the pancreatic p-cells increase their production of insulin to compensate for 
increased insulin resistance. For unclear reasons, P-cell secretory capacity gradually 
declines in some individuals, leading to the development of type II diabetes. The 
cause of p-cell failure in type II diabetes is unknown. 
In the present study, commercially available human DNA was modified by 
MG and lysine in the presence of Cu^ "^ . DNA modifications were analyzed by various 
spectroscopic and analytical techniques like, UV, Fluorescence. CD, thermal 
denaturation studies, HPLC, NMR, LC-MS and ESI-MS. Moreover, agarose gel 
electrophoresis, nuclease SI digestibility and comet assays were also performed to 
assess the modification of the MG-Lys-Cu^ "^  system. Furthermore, antibodies were 
induced in rabbits against native and modified DNA. The induced antibodies were 
characterized with respect to antigen binding specificities by direct binding and 
inhibition ELISA. Antigen binding specificities were further confirmed by band shift 
assay. These antibodies have been used as an immunochemical probe to detect 
reactive carbonyl species (RCS) induced DNA damage in diabetes patients. In order 
to assess the possible role of MG-Lys-Cu modified DNA in the etiology of type I 
diabetes mellitus, sera from patients were assessed for their binding to native and 
MG-Lys-Cu^ "*" modified human DNA. Furthermore, binding of serum antibodies for 
type II diabetes patients with native and MG-Lys-Cu^ "" modified human DNA was 
also evaluated. 
The UV &. CD spectroscopical analysis, agarose gel electrophoresis, nuclease 
SI digestibility assay and thermal denaturation studies, suggest structural perturbation 
in DNA as a result of modification. This might be due to the generation of single-
stranded regions, destabilization of hydrogen bonds and modification of nitrogenous 
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bases which result in the destruction of chromophoric groups through attack on the 
sugar-phosphate back bone. The fluorescence spectroscopy study suggests formation 
of advanced glycation end-products. This is further proved by anti-glycation study 
and UV- spectroscopy. The genotoxicity of MG-Lys-Cu formed AGEs was 
confirmed by using the comet-assay as an endpoint for DNA damage. This is evident 
from the DNA breakage and subsequent formation of the comet tail. Moreover, the 
adduct (CEdG) formed due to the glycation reaction of MG-Lys-Cu^ "^  with human 
DNA was detected by HPLC, supported by NMR and further confirmed by LC-MS. 
The reaction of MG and lysine generates free radicals which were confirmed 
by quantitation of hydroxyl and superoxide radicals. The generation of these free 
radicals was further proved by quenching studies. Therefore, results presented here 
indicate that the glycation reaction of MG with lysine in the presence of Cu^ "^  may 
lead to oxidative damage of DNA through a mechanism that involves hydroxy! 
radicals. 
The MG-Lys-Cu^ "*' modified human DNA proved to be a potent antigen, 
eliciting high titre immunogen specific antibodies in rabbits. The antigenic specificity 
of anti-MG-Lys-Cu^^ modified human DNA IgG was ascertained by competitive 
binding assay. A maximum of 88.5% inhibition in the antibody activity at inhibitor 
(immunogen) concentration of 20 )ag/ml and just 2.8 )ag/ml of the inhibitor 
concentration caused 50% inhibition, clearly indicating very high specificity and 
affinity of the induced antibodies towards the immunogen, i.e. the MG-Lys-Cu^^ 
modified human DNA. Affinity purified immune IgG showed higher specificity as 
compared to serum. Moreover, visual detection of interaction between immune IgG 
and the immimogen was done by band shift assay. The result shows high affinity of 
the induced antibodies for the immunogen. The induced antibodies though highly 
specific for MG-Lys-Cu^ "^  modified human DNA also exhibited polyspecificity, 
recognizing various nucleic acid conformers and nitrogenous bases in competitive 
inhibition assay. The results suggest that MG modification of DNA in presence of 
lysine and Cu^ "^  caused structural perturbations generating new epitopes thus 
transforming it into a potential immunogen. The modified DNA may be one of the 
factors for the induction of circulating anti-DNA antibodies in diabetes. 
IV 
The clinical study focuses on the possible involvement of MG-Lys-Cu^"^-
modified and the unmodified human DNA in diabetes raellitus (both type 1 & II) was 
probed. Out of 40 sera in type I diabetes, 67.5% showed preferentially high binding to 
MG-Lys-Cu modified hurnan DNA as compared to its native analogue. These 
results indicate substantial recognition of MG-Lys-Cu^"^ modified human DNA by the 
auto-antibodies in diabetic (type-I) patients. The affinity purified IgG from diabetic 
patients showed appreciably high binding towards MG-Lys-Cu^* modified human 
DNA, reiterating the results obtained with serum antibodies. The strong binding of 
auto-antibodies fi*om diabetes type I patients to MG-Lys-Cu modified human DNA 
is evidence towards the involvement of modified bases and single strand regions in 
disease pathogenesis. The spontaneous production of auto-antibodies in type I 
diabetes might be a result of the generation of the antigenic epitopes on the DNA 
molecules that are recognized as 'non self by the body's immune system. It could, 
therefore, be one of the factors of the immune response in diabetes. In type II 
diabetes, out of 45 sera only 35.5% showed low to moderate binding to MG-Lys-Cu^^ 
modified human DNA as compared to its native analogue. In type II diabetes, the 
recognition of auto-antibodies against MG-Lys-Cu^"^ modified human DNA is quite 
low as compared to type I diabetes. The results show ample evidence of the 
involvement of MG-Lys-Cu^"^ modified human DNA in type I diabetes while the same 
is less established for the type II. 
In view of all the above studies it could be concluded that MG-Lys-Cu^"^ 
modification of human DNA resulted in the formation of single strand breaks and 
base modification causing perturbation in the structure of DNA. Moreover, modified 
human DNA was highly immunogenic in experimental animals. The induced 
antibodies, though highly specific for the immunogen, also exhibited polyspecific 
binding. The antibodies showed significant binding with various nucleic acid 
conformers and nitrogenous bases. Higher recognition of MG-Lys-Cu^* modified 
human DNA by diabetes type I autoantibodies is a clear indication of MG-Lys-Cu^^ 
induced DNA damage in these patients. It could, therefore, be one of the factors for 
the autoimmxme response leading to the induction of circulating anti-DNA 
autoantibodies in diabetes mellitus, type I. Furthermore, antibodies from type II 
diabetes patients exhibited low to moderate binding with MG-Lys-Cu^^ modified 
human DNA. 
LC^of-fi^iAre^^ 
Page No. 
Fig. 1 Formation, metabolism and toxicity of methyglyoxal. 12 
Fig. 2 Global prevalence of diabetes. 32 
p. , Ultraviolet absorption spectra of native and MG-Lys-Cu^^ 
modified human DNA. 
Fig. 4 Agarose gel electrophoresis of native and MG-Lys-Cu^* __ 
modified human DNA. 
Fig. 5 Fluorescence emission spectra of native and MG-Lys-Cu 
modified human DNA. 
.2+ 
.2+ Fig. 7 Comet assay of native and MG-Lys-Cu modified human 
DNA. 
.2+ 
Fig. 9 Percent DNA in tail in control and MG-Lys-Cu^"^ modified 
human DNA. 
Fig. 10 Tail length of control and MG-Lys-Cu^* modified human 
DNA. 
Fig. 11 Nuclease SI digestibility of native and MG-Lys-Cu^"" 
modified human DNA. 
Fig. 12 Thermal melting profile of native and MG-Lys-Cu^"^ modified 
human DNA. 
Fig. 13 Effect of free radical scavengers, metal ion chelator and 
antioxidants on the modification of human DNA. 
Fig. 14 Hydroxyl radical quantitation in control and MG-Lys-Cu^"^ 
system. 
Fig. 15 Quenching of hydroxyl radical generated in MG-Lys-Cu^* 
system. 
Fig. 16 Superoxide radical quantitation in control and MG-Lys 
system. 
58 
Fig. 6 Circular dichroic profile of native and MG-Lys-Cu modified „ 
human DNA. 
60 
Fig. 8 Olive tail moment of control and MG-Lys-Cu modified , -
human DNA. 
63 
64 
65 
67 
69 
70 
71 
73 
VI 
Fig. 17 Quenching of superoxide radical generated in MG-Lys 
system. 
Fig. 18 Effect of antiglycating agent on the modification of human 
DNA. 
Fig. 22 HPLC chromatogsam of acid hydrolysate of MG-Lys-Cu 
modified human DNA. 
2+ 
,2+ 
.2+ Fig. 28 Level of induced antibodies against MG-Lys-Cu modified 
human DNA. 
Fig. 31 Inhibition ELISA of preimmune and immune sera against 
native human DNA. 
Fig. 32 Elution profile of anti-MG-Lys-Cu "^^  modified human DNA 
IgG on Protein-A agarose affinity column. 
Fig. 33 Direct binding ELISA of preimmune and immune IgG with 
MG-Lys-Cu^ "*^  modified human DNA. 
74 
75 
Fig. 19 HPLC chromatogram of the standard, CEdG. 77 
Fig. 20 ' H NMR spectra of the standard CEdG. 78 
Fig. 21 HPLC chromatogram of acid hydrolysate of native human 
DNA. / 
80 
Fig. 23 LC-MS spectra of CEdG standard. 82 
Fig. 24 LC-MS spectra of acid hydrolyzed native human DNA. 83 
Fig. 25 LC-MS spectra of acid hydrolyzed MG-Lys-Cu modified „. 
human DNA. 
Fig. 26 ESI-MS spectra of native human DNA. 85 
Fig. 27 ESI-MS spectra of MG-Lys-Cu^^ modified human DNA. 86 
88 
Fig. 29 Inhibition ELISA of preimmune and immune sera against 
MG-Lys-Cu^ "*" modified human DNA. 
Fig. 30 Level of induced antibodies against native human DNA. 90 
91 
92 
93 
Fig. 34 Inhibition of anti-MG-Lys-Cu "^^  modified human placental 
DNA IgG binding by native human DNA and modified human 94 
placental DNA. 
vu 
Fig. 35 (a) Band shift assay of anti-MG-Lys-Cu "^^  modified human 
DNA-IgG binding to MG-Lys-Cu^ "^  modified human DNA. 
(b) Band shift assay of anti-MG-Lys-Cu^ "*^  modified human 
DNA-IgG binding to native human DNA. 
Fig. 39 Inhibition of anti-MG-Lys-Cu^* modified human DNA IgG 
binding by guanii 
modified guanine 
Fig. 40 Inhibition of anti-MG-Lys-Cu "^^  modified human DNA IgG 
binding by adenin 
modified adenine. 
96 
Fig. 36 Inhibition of anti- MG-Lys-Cu^ "^  modified human DNA IgG 
binding by calf thymus DNA, ROS modified calf thymus 
DNA, ROS modified human DNA and MG-Lys-Cu^^ 
modified calf thymus DNA. 
Fig. 37 Inhibition of anti-MG-Lys-Cu "^^  modified human DNA IgG 
binding by plasmid DNA, ROS modified plasmid DNA and 98 
MG-Lys-Cu^^ modified plasmid DNA. 
Fig. 38 Inhibition of anti-MG-Lys-Cu "^^  modified human DNA IgG 
binding by lymphocyte DNA, ROS modified lymphocyte 99 
DNA and MG-Lys-Cu^ "*" modified lymphocyte DNA. 
ne, ROS modified guanine and MG-Lys-Cu^^ 101 
e, ROS modified adenine and MG-Lys-Cu^^ 102 
Fig. 41 Inhibition of anti-MG-Lys-Cu^^ modified human DNA IgG 
binding by thymine, ROS modified thymine and MG-Lys- 103 
Cu^ "^  modified thymine. 
Fig. 42 Inhibition of anti-MG-Lys-Cu^ "*" modified human DNA IgG 
binding by cytosine, ROS modified cytosine and MG-Lys- 104 
Cu^"*" modified cytosine. 
Fig. 43 Direct binding ELISA of type I diabetes patients (no. 1-10) 
anti-DNA autoantibodies to native and MG-Lys-Cu^^ 107 
modified human DNA. 
Fig. 44 Direct binding ELISA of type I diabetes patients (no. 11-20) 
anti-DNA autoantibodies to native and MG-Lys-Cu^* 108 
modified human DNA. 
Fig. 45 Direct binding ELISA of type I diabetes patients (no. 21-30) 
anti-DNA autoantibodies to native and MG-Lys-Cu^^ 109 
modified human DNA. 
Fig. 46 Direct binding ELISA of type I diabetes patients (no. 31 -40) 
.anti-DNA autoantibodies to native and MG-Lys-Cu^ "^  110 
modified human DNA. 
V l l l 
Fig. 47 Competitive inhibition of Serum (no. 1, 3 and 4) autoantibodies in 
type I diabetes patients by native human DNA and MG-Lys-Cu^^ 111 
modified human DNA. 
Fig. 48 Competitive inhibition of Serum (no. 7, 8 and 9) autoantibodies in 
type I diabetes patients by native human DNA and MG-Lys-Cu^^ 112 
modified human DNA. 
Fig. 49 Competitive inhibition of Serum (no. 10, 11 and 14) 
autoantibodies in type I diabetes patients by native human DNA 113 
and MG-Lys-Cu^^ modified human DNA. 
Fig. 50 Competitive inhibition of Serum (no. 15, 17 and 18) 
autoantibodies in type I diabetes patients by native human DNA 114 
and MG-Lys-Cu^"^ modified human DNA. 
Fig. 51 Competitive inhibition of Serum (no. 20, 21 and 22) 
autoantibodies in type I diabetes patients by native human DNA 115 
and MG-Lys-Cu^"^ modified human DNA. 
Fig. 52 Competitive inhibition of Serum (no. 23, 24 and 25) 
autoantibodies in type I diabetes patients by native human DNA 116 
and MG-Lys-Cu^^ modified human DNA. 
Fig. 53 Competitive inhibition of Serum (no. 28, 29 and 31) 
autoantibodies in type I diabetes patients by native human DNA 117 
and MG-Lys-Cu^"^ modified human DNA. 
Fig. 54 Competitive inhibition of Serum (no. 32, 34 and 36) 
autoantibodies in type I diabetes patients by native human DNA 118 
and MG-Lys-Cu^* modified human DNA. 
Fig. 55 Competitive inhibition of Serum (no. 37, 38 and 39) 
autoantibodies in type I diabetes patients by native human DNA 119 
and MG-Lys-Cu^^ modified human DNA. 
Fig. 56 Elution profile of type I diabetes IgG on protein-A-agarose 
column. 
Fig. 57 Inhibition of IgG samples 3, 7 and 8 isolated from type I diabetic 
patients by native and MG-Lys-Cu^"^ modified human DNA. 
Fig. 58 Inhibition of IgG samples 14, 15 and 17 isolated from type I 
diabetic patients by native and MG-Lys-Cu^ "*^  modified human 124 
DNA. 
Fig. 59 Inhibition of IgG samples 18, 21 and 24 isolated from type 1 
diabetic patients by native and MG-Lys-Cu^ "*" modified human 125 
DNA. 
IX 
Fig. 60 Inhibition of IgG samples 25, 31 and 32 isolated from type I 
diabetic patients by native and MG-Lys-Cu^ "^  modified human 126 
DNA. 
Fig. 61 Inhibition of IgG samples 34, 37, 38 and 39 isolated from type I 
diabetic patients by native and MG-Lys-Cu^ "^  modified human 127 
DNA. 
Fig. 62 (a) Band shift assay of diabetic patient IgG binding to native 
human DNA. 
(b) Band shift assay of diabetic patient IgG binding to MG-Lys-
Cu^ * modified human DNA. 
Fig. 66 Direct binding ELISA of type II diabetes patients (no. 34-45) anti 
DNA 
DNA. 
129 
Fig. 63 Direct binding ELISA of type II diabetes patients (no. 1-11) anti-
DNA autoantibodies to native and MG-Lys-Cu^^ modified human 130 
DNA. 
Fig. 64 Direct binding ELISA of type II diabetes patients (no. 12-22) anti-
DNA autoantibodies to native and MG-Lys-Cu^ "^  modified human 131 
DNA. 
Fig. 65 Direct binding ELISA of type II diabetes patients (no. 23-33) anti-
DNA autoantibodies to native and MG-Lys-Cu ^ modified human 132 
DNA. 
autoantibodies to.native and MG-Lys-Cu modified human 133 
Fig. 67 Competitive inhibition of serum (no. 2, 7 and 8) autoantibodies in 
type II diabetes patients by native human DNA and MG-Lys-Cu^* 135 
modified human DNA. 
Fig. 68 Competitive inhibition of serum (no. 10, 12 and 15) autoantibodies 
in type II diabetes patients by native human DNA and MG-Lys- 136 
Cu^ "^  modified human DNA. 
Fig. 69 Competitive inhibition of serum (no. 19, 20 and 24) autoantibodies 
in type II diabetes patients by native human DNA and MG-Lys- 137 
Cu^"*^  modified human DNA. 
Fig. 70 Competitive inhibition of serum (no. 26, 29 and 31) autoantibodies 
in type II diabetes patients by native human DNA and MG-Lys- 138 
Cu^"*^  modified human DNA. 
Fig. 71 Competitive inhibition of serum (no. 32, 37, 38 and 45) 
autoantibodies in type II diabetes patients by native human DNA 139 
and MG-Lys-Cu^ "^  modified human DNA. 
Fig. 72 Elution profile of type II diabetes IgG on protein-A-agarose 
column. 141 
Fig. 73 Inhibition of IgG samples 2, 7 and 8 isolated from type II diabetic 
patients by native and MG-Lys-Cu^ "^  modified human DNA. 
Fig. 74 Inliibition of IgG samples 10, 19 and 29 isolated from type II 
diabetic patients by native and MG-Lys-Cu^ "^  modified human 143 
DNA. 
Fig. 75 Inhibition of IgG samples 31 and 38 isolated from type II diabetic 
patients by native and MG-Lys-Cu^ "^  modified human DNA. 
LCitofTcMe^ 
XI 
Table 1 Etiologic classification of diabetes mellitus. 
Table 2 Major autoantigens in type I diabetes. 
Table 3 Top Ten countries in diabetes. 
Table 4 Fluorescence characteristics of native and modified human 
DNA. 
Tables Ultraviolet and thermal denaturation characteristics of 
native and modified human DNA. 
Table 6 Cross-reaction of anti-MG-Lys-Cu^* modified human DNA 
IgG. 
Table 7 Competitive inhibition data of serum autoantibodies in type 
I diabetes patients. 
Table 8 Competitive inhibition data of IgG isolated fi-om type I 
diabetes patients. 
Table 9 Competitive inhibition data of serum autoantibodies in type 
II diabetes patients. 
Table 10 Competitive inhibition data of IgG isolated from type II 
diabetes patients. 
Page No. 
21 
23 
33 
57 
68 
105 
120 
128 
140 
145 
Xll 
Ahhre^/CcUioviy 
A260 
A2gO 
AGEs 
APS 
bp 
BSA 
CTDNA 
CEdG 
DNA 
DHAP 
DMSO 
DTPA 
EDTA 
ELISA 
gm 
G3P 
hr 
H2O2 
•OH 
HPLC 
IgG 
L 
Lys 
HL 
M 
mBSA 
MG 
NO 
nM 
NHS 
nDNA 
: Absorbance at 260 nm 
Absorbance at 280 nm 
Advanced glycation end products 
Ammonium persulphate 
Base pair 
Bovine serum albumin 
Calf thymus deoxyribonucleic acid 
Carboxyethyl-2'-deoxy guanosine 
Deoxyribonucleic acid 
Dihydroxyacetone phosphate 
Dimethyl sulfoxide 
Diethylenetriamine pentacetic acid 
Ethylene diamine tetracetic acid 
Enzyme linked immunosorbent assay 
Gram 
Glyceraldehyde -3-phosphate 
Hour 
Hydrogen peroxide 
Hydroxy! radical 
High performance liquid chromatography 
Immunoglobulin G 
Litre 
Lysine 
Microlitre 
Molar 
Methylated bovine serum albumin 
Methylglyoxal 
Nitric oxide 
Nanometer 
Normal human sera 
Native DNA 
Xll l 
02-
PAGE 
PBS 
RCS 
ROS 
SSC 
SDS 
SOD 
Tris 
TBS-T 
Tm 
TEMED 
UV 
Superoxide anion radical 
Polyacrylamide gel electrophoresis 
Phosphate buffer saline 
Reactive carbonyl species 
Reactive oxygen species 
Saline sodium citrate 
Sodium dodecyl sulphate 
Superoxide dismutase 
Tris (hydroxymethyl) amino methane 
Tris buffer saline with 0.05% Tween-20 
Melting temperature 
N,N,N',N'-tetraethylmethylene diamine 
Ultraviolet 
Wavelength maxima 
Wavelength minima 

In 1953, the discovery of the structure of DNA was landmark in the history of 
DNA biology which sheds light on the inheritance of genetic material, replication, 
DNA damage, repair, diversity and the evolution of species. Its discovery has united 
genetics with biochemistry, free radical biology, medicine and physiology. Briefly, 
the model proposed by James Watson and Francis Crick is based on two paired DNA 
strands that are complementary in their nucleotide sequence. The model has striking 
implications for the process of DNA replication and recombination. The DNA in a 
fully hydrated medium is found in B form (Langridge et a/., 1960) and this is the most 
accepted structure of DNA molecule in solution. X-ray diffraction studies have shown 
that a number of variations in conformation of this basic structure can occur (Adams 
et al, 1981). It is well known that the right handed double helical DNA can exist in 
A, B, C and D conformations, whereas the left handed polynucleotide can adopt the Z 
structure (Saenger, 1984), so called because phosphate groups in the backbone are 
zig-zagged (Rich et al., 1984). The importance of DNA lies in its unique property to 
adopt multiple conformations depending on its bioenvironment. The DNA double 
helix is both deformed and made deformable by its local base sequence, whereas other 
regions may be made especially susceptible to a change in conformation when the 
helix interacts with protein, or an adjacent DNA helix in a crystal lattice. 
Antigenicity of native and modified DNA 
Anti-DNA autoantibodies permanently attract the attention of researchers. In 
spite of numerous investigations aimed to determine their potential targets and role in 
the disease, origins of anti-DNA autoantibodies and their pathological role remain to 
be established. Moreover, taking into account of such newly described features of 
anti-DNA antibodies as the ability to penetrate into tlie living cell (Alarcon et a/., 
1996) and DNA-hydrolyzing activity (Schuster et al, 1992), one may under estimate 
pathogenic potential of DNA-specific autoantibodies. In general, antibodies that bind 
DNA do not display strict disease specificity. It is, however, widely accepted that 
healthy individuals usually express low-affinity antibodies with specificity to single-
stranded DNA, while presumably pathogenic high-affinity autoantibodies to double-
stranded DNA are frequently overrepresented on the background of systemic 
autoimmune abnormalities (Paul et al, 1990) and their presence appears a diagnostic 
criterion for SLE (Bootsma et al, 1996). Some blood tumours and even AIDS are 
also characterized by the increase in production of DNA-specific antibodies (Hamblin 
et ah, 1986; Rodriguez et al., 1994). The major known pathogenic process induced by 
anti-DNA antibodies is the inflammatory response due to their deposition in kidney in 
form of the immune complexes (Suenanga et al, 1996). However, DNA specific 
autoantibodies can also trigger apoptosis in cultured mesangial and endothelial cells 
(Tsai et al, 1993; Lai et al, 1997) and are cytotoxic to the primary cultures of 
lymphocytes (Shoenfeld et al, 1985). Non-immunogenic status of native DNA has 
led to the assumption that natural anti-DNA antibodies may be formed against DNA-
protein complexes, such as nucleosomes, persisting in blood as a result of disease 
mediated increase in cellular destruction (Jacob et al, 1992; Mohan et al, 1993). 
Cross reactivity wdth proteinaceous nuclear antigens, displayed by anti-DNA 
antibodies, contributed to this hypothesis and even allowed to specify a pool of anti-
nuclear antibodies (ANA) (Tan et al, 1988). Described cross-reactivity of anti-DNA 
antibodies with membrane antigens (Raz et al, 1993) may potentially result in 
triggering of certain cellular responses through signal transduction pathways. 
Polyspecificity of anti-DNA antibodies was also shown to favor to their capacity of 
penetration into living cell (Avrameas et al, 1998). Entry of anti-DNA 
autoantibodies into living cell is shown to be accompanied by certain cellular 
dysfunctions (Tsai et al, 1993; Lai et al, 1997; Yu et al, 1998). In some cases, 
penetration of antibodies into the cells is connected with either induction (Tsai et al, 
1993) or suppression of apoptosis (Yanase et al, 1997), however, precise 
consequences of antibody entry into the cell and its pathogenic significance remain to 
be determined. Catalytic activity of anti-DNA autoantibodies (DNA-abzymes) in vitro 
was described in a number of studies (Schuster et al, 1992; Gololobov et al, 1997), 
however, physiological essence of antibody DNA-hydrolyzing activity remains 
elusive. It is evident, that any detrimental effect to the cell that the DNA-abzyme may 
cause, requires direct contact between DNA-hydrolyzing autoantibodies and 
chromatin of the living cell. 
In 1957, anti-DNA antibodies was identified as a biomarker for systemic lupus 
erythematosus (SLE) autoantibodies, since then antigenic property of nucleic acids 
received much attention (CepelUni et al, 1957; Meischer and Strassie, 1957; Robbins 
et al., 1957). DNA is a complex molecule whose immunologic properties vary with 
base sequence and encompass both stimulation and inhibition (Messina el al, 1991; 
Krieg et al., 1998; Pisetsky and Reich, 2000). The problem of how an individual can 
immunologically distinguish between self and non self has fascinated and perplexed 
immunologists. When this distinction cannot be made, autoimmune diseases such as 
systemic lupus erythematosus (SLE) occur and are associated with the appearance of 
large amounts of autoantibodies. In the case of lupus, antibodies that react with 
double-stranded DNA are one of the hallmarks of the disease (Kofler, 1984). In the 
early 1960s, methods were developed for the experimental induction of antibodies to 
nucleic acids (Levine et al, 1960; Erlanger and Beiser, 1964; Plescia et al, 1964; 
Halloran and Parker, 1966) which until then had been considered widely to be non-
immimogenic. Studies on the antigenic specificity of anti-DNA antibodies have 
enforced the view that DNA is immtmologically 'simple and bland'. It has been well 
established that native DNA in B-conformation is not immunogenic. Nevertheless, 
various modified forms of DNA, DNA in complexes with DNA-binding proteins are 
immunogenic and induce antibodies. Origin of anti-ds DNA autoantibodies in cancer 
patients and tumour-bearing mice has been demonstrated (Zhang et al, 2002). 
Exogenous native B-DNA has not been found immunogenic in experimental animals. 
Immunization of experimental animals with denatured DNA, synthetic nucleic acid 
polymers like poly (dT), poly (dC), poly (dA), poly (A), poly (I), poly (6), dsRNA, 
left handed Z-DNA, chemically modified DNA and certain helical synthetic 
polynucleotides with the exception of native B-DNA, induced antibodies that react 
selectively with the immunogen and do not cross react with native DNA (StoUar, 
1986; Anderson et al, 1988). 
Mammalian DNA elicit poor responses to single stranded DNA and fails to 
induce antibodies against native or double stranded DNA, the serologic hallmark of 
SLE (Madaio et al, 1984). However, it has been shown that DNA complexes with 
synthetic peptide FUS-I can induce anti-dsDNA response in mice (Desai et al, 1993). 
Since the antibody reactivity to both single and double stranded form appears 
independent of DNA species origin, these finding suggest recognition of conserved 
conformational determinants i.e., helical backbone of B-DNA and a lack of DNA 
sequence micro heterogeneity on antigenicity (Stollar, 1975; Pisetsky, 1993). Anti-
DNA antibodies may also result by autoimmunization with chromatin, rather than 
native DNA (Theofilopoulos, 1995). The left handed Z-DNA is an example of a 
helical DNA that is a much more potent immunogen than native B-helical DNA 
(Lafer et al., 1981; Madaio etal., 1984). The antibodies induced by Z-DNA have high 
degree of selectivity and specificity as they react with immunogen but not with B-
DNA or ssDNA. The DNA modified by either chemically or physically that differ 
significantly from B-DNA are much stronger immunologic stimuli than nDNA and 
most of the antibodies induced by modified nDNA do not react with unmodified DNA 
(Anderson et al., 1988). Polynucleotides in B-conformation acquired immunogenicity 
after modification with furocouramin (Arif and AH, 1996). DNA modified with drugs, 
hormones, free radicals etc, has been reported to induce antibodies against the 
immunogen (Moinuddin and ali, 1994; Dixit et al, 2005; Habib et al., 2005; Khan et 
al., 2006). Recently, the role of peroxynitrite (ONOO") modified human placental 
DNA in the induction of circulating cancer autoantibodies has been reported (Habib et 
al., 2009). 
Glycation of biomacromolecules 
Glycation is the nonenzymatic addition of reducing sugars (glucose, fructose, 
mannose, etc. and their phosphate derivatives) as well as compounds related to sugais 
(e.g. ascorbic acid, methylglyoxal (MG), glyoxal and 3-deoxyglucosone etc.) into 
biological macromolecules (proteins, DNA and lipids) (Bucala, 1985; Suarez, 1989; 
Sengupta, 2005). The free carbonyl groups (-C=0) of the sugar and related moieties 
react with the free amino (-NH2) residues of the macromolecules in a series of 
chemical processes known as Maillard reaction. Initiation of glycation occurs by the 
formation of acid-labile Schiff base adducts which undergoes Amadori or Heyn's 
rearrangements into more stable products. The early glycation products undergo slow 
transformation to yield the irreversible advanced glycation end products (AGEs). 
These reactions have attracted significant attention in recent days because of their 
association with the production of free radicals, which play roles in the development 
of cancer, diabetes, heart disease, cataract, atherosclerosis and neurodegenerative 
disorder (e.g., Parkinson's disease, Alzheimer's disease), etc. 
The products of non enzymatic glycation and oxidation of proteins, DNA and 
lipids, the advanced glycation end products (AGEs), accumulate in a wide variety of 
environments. AGEs may be generated rapidly or over long times stimulated by a 
range of distinct triggering mechanisms, thereby accounting for their roles in multiple 
settings and disease states. A critical property of AGEs is their ability to activate 
receptor for advanced glycation end products (RAGE), a signal transduction receptor 
of the immunoglobulin superfamily. Due to such interaction, AGEs impart a potent 
impact in tissues, stimulating processes linked to inflammation and its consequences. 
Therefore, AGEs cause perturbation in a diverse group of diseases, such as diabetes, 
inflammation, neurcdegeneration and aging (Ramasamy et al., 2005). 
A large body of evidence suggests that AGE formation and accumulation are 
enhanced in diabetes (Brownlee, 1992). AGEs are a heterogeneous class of 
compounds that are composed of both fluorescent and non-fluorescent species. 
Glycation adducts of proteins are formed when proteins react with glucose-reactive 
alpha-oxoaldehydes such as glyoxal, methylglyoxal and 3-deoxygIucosone (3-DG) 
(Brownlee, 1996). The initial Schiff base adducts formed from glucose and lysine and 
N-terminal amino acid residues may rearrange to form the key intermediate, 
fructosamine. Fructosamine degradation and the direct reaction of alpha oxoaldehydes 
with proteins may form many AGEs. Of the various types of AGEs that may be 
generated, it has been shovm that both cross-linked and noncross-linked AGEs may 
be generated. In vivo, a diverse array of AGE products has been detected and 
characterized such as bis(lysyl) imidazolium cross-links, hydroimidazolones and 
monolysyl adducts (Wautier and Schmidt, 2004). It has been shown that both 
carboxymethyl lysine (CML) adducts of proteins or lipids, as well as AGEs derived 
through the generation of hydroimidazolone, species that accumulate in diabetes, are 
specific ligands for RAGE (Thomalley, 1998; Kislinger et al., 1999). Indeed, 
evidence indicates that CML-AGEs are highly prevalent in diabetes, as well as in 
aging and renal failure (Reddy et al., 1995; Ikeda et al., 1996; Schleicher et al., 1997; 
Tauere/a/., 2001). 
DNA glycation and AGEs 
Glycated DNA has attracted much attention in the past few years and is 
considered to be a pathogenic factor for diabetes mellitus. During the disorder in the 
metabolism of reducing sugars, the sugar molecules can initiate glycation of DNA in 
vivo (Lee and Cerami, 1989; Levi and Werman, 2003; Dutta et al., 2005). Previous 
investigations by several scientists (Bucala et al., 1985; Lee, 1989; Dutta et al., 2005) 
using biochemical and molecular biological methods have shown that DNA structure 
and function are affected by the addition of sugars, resulting in deleterious 
modifications and other mutations. 
Advanced glycation end-products (AGEs) of DNA are formed spontaneously 
by the reaction of carbonyl compounds such as sugars, methylglyoxal or 
dihydroxyacetone in vitro and in vivo. After a complex cascade of dehydration, 
condensation, fragmentation, oxidation and cyclization reactions, a diverse and 
largely undefined group of compounds termed AGEs are formed (Schleicher et al, 
2001). Only few AGEs have been characterized chemically and identified in tissues, 
the most investigated of which has been carboxymethyllysine (CML). In renal disease 
AGE accumulation is ascribed both to the impaired elimination of AGEs and to 
enhanced formation due to oxidative stress (Heidland et al, 2001). Accumulation of 
AGEs in tissues is a common phenomenon of normal aging and occurs at accelerated 
rates in patients with diabetes mellitus (Schleicher et al., 1997; Baynes, 2001). In in 
vitro studies, mutagenic effects of DNA-AGE such as deletions, insertions and 
transposon activation were shown in bacterial model systems (Pischetsrieder et al., 
1999). Furthermore, it is shown that DNA can be glycated in vitro yielding 
carboxyethylguanosine as major products. However, little is known about the 
biological consequences of DNA-AGEs. 
In vitro, nucleobases and dsDNA react with sugars in a similar way as proteins 
(Lee and Cerami, 1987; Knerr and Severin, 1993; Singh et al., 2001). The exocyclic 
amino group of 2'-deoxyguanosine is particularly prone to glycation reactions, 
leading to the formation of N^-carboxyethyl, N^-carboxymethyl, N^-(l-carboxy-3-
hydroxypropyl), and N^-(l-carboxy-3,4,5-trihydroxypentyl) modifications, as well as 
cyclic dicarbonyl adducts (Ochs and Severin, 1994). The two diastereomers of N -^
carboxyethyl- 2'-deoxyguanosine (CEdG A.B) are stable reaction products that are 
formed from a variety of glycating agents, such as glucose, ascorbic acid, 
glyceraldehyde, dihydroxyacetone (DHA), or methylglyoxal (Larisch et al, 1998; 
Frischmann et al., 2005). Recently, carboxyethylated nucleobases were detected in 
human urine (Schneider et al., 2004) indicating the formation of DNA AGEs in the 
healthy human organism. A significantly increased number of CEdG positive cells 
were immunostained in glomeruli of patients with diabetic nephropathy as compared 
to healthy controls (Li et al., 2006) as well as in glomeruli of diabetic rats (Nakamura 
et ai, 2007). DNA AGEs are potentially genotoxic compounds because they induce 
depurination as well as single strand breaks and lead to mutations (Pischetsrieder, 
1999) in vitro. In vivo, it was shown, for example, that 3-deoxyglucosone, a glucose 
degradation product, induces embryonic malformation and teratogenicity, effects that 
may be related to DNA AGEs (Eriksson et a/., 1998). DNA glycation in cultured cells 
I T 
was observed using radioactively labeled glucose (Shires et al., 1990) or a P-
postlabeling technique (Vaca et ai, 1998). Furthermore, the presence of CEdG .^B was 
detected in cultured cells by HPLC-diode array detector (DAD) after immunoaffmity 
chromatography (Schneider et al., 2006). 
Formation of AGEs 
Maillard first described the non-enzymatic reaction of glycine with glucose in 
1912 (Maillard, 1912). The reducing sugars and other a-dicarbonyl compounds 
(glyoxal, MG and 3-deoxyglucosone) form a range of heterogeneous AGE adducts on 
fi-ee amine and thiol groups within proteins, lipoproteins and nucleic acids. These 
adducts alter the structure and function of their target molecules but also form ligands 
for the receptor for AGEs, RAGE (Nass et al., 2007) and other known AGE receptors 
(Ahmed and Thomalley, 2007). Structural and inflammatory damage by AGEs is 
implicated in propagation of diabetes vascular and neuronal complications. MG is a 
potent AGE precursor, forming adducts on arginine (Arg), lysine (Lys), cysteine 
(Cys) and deoxyguanosine (dG) residues. The most prevalent MG adduct in proteins 
is the MG-derived hydroimidazolone (MG-H), but carboxyethyl lysine (CEL), N5- (4-
carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)-ornithine) and 
argpyrimidine are also formed, as well as the crosslinking dimer MOLD 
(methylglyoxal lysine dimer). MG-H and CEL equivalents are also found on dG 
residues within DNA (dG-MG and CEdG), and MG forms a hemithioacetal with 
thiols, such as that in Cys, MG-AGEs are common in human tissues and are known to 
play critical roles in diabetes vascular complications (Thomalley, 2008). MG-H is 
thought to be a ligand for RAGE (Thomalley, 1998), but the role of MG-AGEs in 
other AGE receptor systems is unclear. 
Detection of AGEs 
AGE detection can be based on the fluorescent properties of AGEs (Monnier 
and Cerami, 1981). After the excitation at 370 nm, fluorescence emission wavelength is 
typically at 440 nm due to the presence of heterocyclic compounds. However, the exact 
quantitation of AGEs is difficult to achieve due to the lack of proper means to represent 
the whole diverse AGE family. Candiano et ah (1986) have suggested an alternative 
method for quantitation involving the formation of a chromophore after reacting AGEs 
with diazonium salts and subsequently measuring absorbance at 490 nm wavelength. 
Recently, the use of immunoassays has been incorporated into many AGE 
investigations, including research on pyrraline (Miyata and Monnier, 1992), lipoprotein 
AGEs (Doucet et al, 1995), CML (Reddy et al, 1995), pentosidine (Miyata et al, 
1996), ribonuclease AGEs, AGE crosslinks (Vasan et al, 1996) and imidazolones 
(Niwa et al, 1997). However, the antibodies produced may recognize only a limited 
number of AGEs and leave others undetected. 
Reactive carbonyl species 
Reactive carbonyl species (RCS) are potent mediators of cellular carbonyl 
stress originating from endogenous chemical processes such as lipid peroxidation and 
glycation. RCS are a heterogeneous group of small molecular weight carbonyls 
activated by a, P-unsaturation as in 4-hydroxynonenal and acrolein, a-oxo-substitution 
as in glyoxal and methylglyoxal, an P-oxo-substitution as in malondialdehyde 
'(Thomalley, 1996). DNA adducts formed by RCS are known to possess strong 
miscoding potential in vitro and of the DNA adducts formed by MDA, pyrimido(l,2a) 
purin-10(3H) one (M G) is readily detected in many human tissues. Adducts formed by 
HNE have been detected in healthy human colon tissue (Wacker et al, 2000). Etheno-
DNA adducts are formed from the epoxides of enals and elevated levels of this type 
reflect the extent of oxidative stress (Bartsch and Nair, 2000) Antibodies, both poly-
and mono-clonal, have been generated against RCS-modified DNA bases. For example, 
MDA-deoxyguanosine (Sevilla et al, 1997), deoxycytidine-glyoxal (Mistry et al, 
2003). These specific RCS-DNA antibodies have been successfully used to measure 
carbonyl stress in human and animal studies following oxidative and peroxidative insult 
(Cooke et al, 2003). 
Carbonyls produced via lipid peroxidation 
The peroxidation of membrane-derived lipid molecules is a well-studied 
consequence of increased intracellular oxidant levels (Esterbauer et al, 1991). The most 
commonly characterized products are aldehydes, derived from co- 6 polyunsaturated 
fatty acids, such as malondialdehyde (MDA), hexanal, acrolein, glyoxal, 
crotonaldehyde, trans-2-nonenal, 4-oxo-2-nonenal and 4-hydroxy-2- nonenal (HNE) 
(Esterbauer et al, 1991). MDA is the most common aldehyde produced, comprising of 
70% of the total produced by lipid peroxidation (Esterbauer et al, 1991). Hexanal 
contributes 15% and HNE contributes 5% of total aldehydes (Benedetti el al., 1980). 
Acrolein was identified as a lipid peroxidation product more recently through studies 
that examined the oxidation of low density lipoprotein (LDL) but was previously 
characterized as an environmental pollutant (Uchida et al., 1998). 
Carbonyls produced via glycoxidation 
Reducing sugars such as glucose can form Schiff bases with amino groups on 
the amino acids lysine and arginine, through the Maillard reaction. This can, through a 
series of rearrangements, give rise to advanced glycation endproducts (AGEs) (Munch 
et al., 1998). Oxidation of these glycation products can release dicarbonyls, such as the 
a-oxoaldehydes, MG, glyoxal, and 3-deoxyglucosone, as well as short-chain aldehydes, 
such as diacetyl, acetol, pyruvaldehyde and acrolein (Tliomalley, 2005). 
Reactivity of carbonyls 
Many of the carbonyls that are produced as a result of either lipid peroxidation 
or glycoxidation are extremely reactive alkanals, such as hexanal, are the least reactive 
and have weaker effects than unsaturated aldehydes. Alkenals containing a C = C 
unsaturated bond, such as acrolein, are usually an order of magnitude more reactive 
than the alkanals. This is particularly the case if they contain an a,p- unsaturated (C2-
C3) double bond, in addition to the CI aldehyde. This makes the C3 carbon a strong 
electrophile that undergoes Michael addition by nucleophilic groups on proteins, DN A 
and lipids (Mamett et al, 1985), thereby causing damage to these molecules. The 
aldehyde group is also reactive and can form Schiff bases with amino acids. 4-hydroxy-
2-alkenals, such as HNE, are extremely reactive because of the interaction between the 
electrophilic double bond, the aldehyde moiety and the hydroxy! group (Witz, 1989). 
Cytotoxicity of reactive carbonyls 
Cytotoxicity is generally measured by examining loss of viability. Reactive 
aldehydes, such as HNE, interact directly with proteins and membranes, causing 
10 
significant loss of function to membrane transporters, enzymes, signalling components, 
transcription factors, microtubules and other proteins, such as tau (Karlhuber et al, 
1997, Picklo et al, 2002). Acrolein is also cytotoxic and, in neuronal cells, causes 
changes in Ca^ "^  concentrations, altering glucose transport and glutamate uptake (Li et 
al, 1997, Lovell et al, 2001). As described earlier, other aldehydes, such as MG, can 
rapidly form Schiff bases with amino acids, which leads to the production of AGE at a 
much faster rate than from sugars, such as glucose (Thornalley, 1996). MG therefore 
causes significant toxicity to a range of cell types, including neuronal cells (Suzuki et 
al, 1998). 
Antibody production against RCS 
DNA adducts formed by RCS are known to possess strong miscoding 
potential in vitro and of the DNA adducts formed by MDA, pyrimido (i,2a) purin-
10(3H) one (MiG) is readily detected in many human tissues. Other propano-adducts 
also originate from a, p-unsaturated aldehydes or enals such as acrolein (Acr), 
crotonaldehyde (Cro), glyoxal (Gly) and 4- hydroxyl-nonenal (HNE). Adducts formed 
by HNE have been detected in healthy human colon tissue (Wacker et al, 2000). 
Etheno-DNA adducts are formed from the epoxides of enals and elevated levels of 
this type reflect the extent of oxidative stress (Bartsch and Nair., 2000). Antibodies, 
both poly- and monoclonal, have been generated against RCS-modified DNA bases. 
For e.g., MDA-deoxyguanosine (Sevilla et al, 1997), deoxycytidine-glyoxal (Mistry 
et al, 2003) deoxyadenosine-acrolein (Kawai et al, 2003), 1, N (6)-
ethenodeoxyadenosine (Frank et al, 2004) and ethenodeoxyguanosine (Foiles et al, 
1993). These specific RCS-DNA antibodies have been successfully used to measure 
carbonyl stress in human and animal studies following oxidative and peroxidative 
insuh (Zhang e/ al, 2002, Cooke et al, 2003). 
Methylglyoxal 
Methylglyoxal (MG) is a metabolite of sugar and is highly reactive a-
oxoaldehyde. It is a small molecule with molecular weight of 72. MG has a ketone 
group and an aldehyde moiety. The aldehyde group is more reactive than the ketone. 
It is a yellow liquid with characteristic pungent odor. It has 3 forms in aqueous 
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solution: unhydrated (1%), monohydrate (71%) and dehydrate (28%), which are in 
rapid equilibrium (Rae, et al., 1990). 
Methylglyoxal is inevitably produced in the course of metabolism even under 
normal conditions. It is formed mainly from the spontaneous transformation of triose 
phosphates. Therefore, MG is an intrinsic component of the glycolytic pathway in 
mammalian cells, including vascular smooth muscle cells (VSMCs) (Ekblom, 1998). 
An increased MG formation may occur because of an increased availability of 
precursors such as increased plasma glucose or administration of ethanol or threonine 
(Thomalley and Tisdale, 1988). It is also formed during the non-enzymatic glycation, 
an early stage of the Maillard reaction (Monnier and Cerami, 1981), which is one of 
the post-translation modification processes between free reducing sugars and free 
amino groups of proteins. This compound is more reactive than parent sugar with 
respect to its ability to react with amino groups of proteins to form cross-links and 
AGEs (Brownlee et al., 1988). MG has been implicated in secondary diabetic 
complications promoting formation of AGEs (Uchida et al., 1998). On the other hand, 
MG is detoxified by the ubiquitous glyoxalase system that highly relies on the cellular 
level of reduced glutathione (GSH). Reduced availability of GSH also contributes to 
the increased levels of MG. Numerous studies showed that levels of MG were 
elevated in patients with diabetes mellitus (Beisswenger et al., 1999). MG levels were 
correlated with the glycated hemoglobin (HbAlc) (Thomalley et al., 1989) and 
reflected glycemic fluctuation (Nemet et al., 2005) in diabetic patients. 
Endogenous MG formation 
Major Pathway 
MG is produced during the metabolism of carbohydrates, lipids and proteins. 
Several enzymatic or non-enzymatic pathways are involved in the endogenous 
formation of MG (Fig.l). Endogenous MG is formed from metabolic intermediates of 
carbohydrates, proteins and fatty acids. The majority of MG is derived from the 
metabolites of carbohydrate, such as glucose and fructose. MG is formed during 
glycolysis. Glucose is phosphorylated by glucokinase to form glucose-6-phosphate 
(G-6-P). This reaction decreases the intracellular glucose levels and promotes 
continuous transportation ofglucose into the cell through the glucose transporter on 
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Fig. 1 Formation, metabolism and toxicity of methyglyoxal. 
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the cell membrane. G-6-P is then converted to fructose-6-phosphate (F-6-P) via 
glucose phosphate isomerase. This step is reversible but easily driven to F-6-P due to 
the lower levels of F-6-P. Subsequently, fructose-1, 6- biphosphate (F-l,6-P) is 
irreversibly formed from F-6-P and G-6-P due to catalysis by phosphofructokinase-1 
(PFK-1). This reaction is the key point in the glycolytic process. F-l,6-P, then, is split 
by aldolase into two triose sugars, dihydroxyacetone phosphate (DHAP), a ketone, 
and glyceraldehyde-3-phosphate (G-3-P). DHAP and G-3-P can spontaneously 
convert to MG (Phillips and Thomalley, 1993). 
MG is mainly formed nonenzymatically from DHAP and G-3-P, and the non-
enzymatic formation of MG occurs in all cells and organisms. For example, MG 
formation in human red blood cells in vitro under normal glycemic conditions is due 
to nonenzymatic fragmentation of triosephosphates (Phillips and Thomalley, 1993). 
The formation of MG in early glycation was investigated by Thomalley et al. 
(Thomalley et al, 1999). Glucose (50 mM) degraded slowly at 37 "C to form MG 
throughout a period of 3 weeks. Therefore, a short period of hyperglycemia may be 
sufficient to induce MG formation in vivo (Thomalley et al., 1999). Bovine retinal 
endothelial cells exposed to D-glucose (30 mM) for 7 days produced significantly 
higher levels of MG than cells cultured with L-glucose or control cells (Padayatti et 
al, 2001). In addition, high glucose caused increased MG formation and MG 
modification of the corepressor mSin3A in mouse kidney endothelial cells. 
Consequently, MG-modified mSin3A mediated high glucose-induced expression of 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1) in cells and high sensitivity of endothelial cells to tumour necrosis factor-
a (TNF-a). It was shown that glucose induced vascular inflammation and disease via 
the formation of MG (Yao et al, 2006). 
Fructose as a precursor for MG has been investigated in vivo (Wang et al, 
2008). Increased serum and aortic levels of MG have been observed in fructose-fed 
rats (Wang et al, 2008). MG induced stmctural remodeling in mesenteric artery and 
ROS production in aorta of fructose-fed rats. MG is also responsible for the high 
blood pressure and hypertriglyceridemia seen in those rats. In addition, MG impairs 
insulin signaling in adipose tissue of fructose-fed rats through decreasing insulin-
induced insulin-receptor substrate-1 (IRS) tyrosine phosphorylation and reducing the 
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activity of phosphatidylinositol (PI) 3-kinase (Jia and Wu, 2007). MG can also be 
formed enzymatically from G-3-P and DHAP. Triosephosphate isomerase hydrolyses 
G-3-P and DHAP and removes phosphate to yield MG (Pompliano et ai, 1990). 
Minor path ways 
MG is a byproduct of acetone metabolism. Acetone monooxygenase catalyzes 
acetone to acetol, and acetol monooxygenase (AMO) converts acetol to MG (Casazza 
et al., 1984). In addition, formation of MG is also found during the metabolism of 
aminoacetone, which is a metabolite of proteins. Semicarbazide-sensitive amine 
oxidase (SSAO) is able to convert aminoacetone into MG (Lyles, 1996). Increased 
serum SSAO activities have been found in patients with diabetes and vascular 
disorders, and treatment with selective SSAO inhibitors reduced atherogenesis in 
diabetic mice fed with a high-cholesterol diet (Yu et al., 2003). 
MG in food and beverages 
MG is formed in food and beverages during the processing, cooking and 
prolonged storage (Nemet et al, 2006). MG can be formed from carbohydrates by 
jfragmentation of the sugar moiety during retro-aldol condensation and auto-oxidation. 
In addition, the formation of MG was observed during the heating process of glucose, 
fructose and maltose, where the amount of MG obtained from monosaccharides was 
markedly higher than that from disaccharides (Nemet et al., 2006). Moreover, 
decomposition of different lipids, caused by storage and processing, can also affect 
the accumulation of MG in food. A broad range of MG levels was obtained during 
accelerated storage (60°C for 3 and 7 days) or cooking (200°C for 1 h) of oil, 
depending on oil origin (salmon, cod liver, soybean, olive and corn oils) (Fujioka and 
Shibamoto, 2006). For instance, the formation of MG ranged from 2.03 ppm in cod 
liver oil to 2.89 ppm in tuna oil heated at 60 °C for 7 days. However, olive oil is the 
only vegetable oil that yields MG under the accelerated storage conditions. 
Coffee is a widely consumed beverage. It is interesting to know whether MG 
is present in green and roasted coffee beans. The amount of MG is small in green 
coffee beans, but increases in the early phases of the roasting process and then 
declines. Thus, mild or medium toasted coffee beans have the highest amount of MG 
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content (Daglia et al., 2007). About 100 jag of MG has been determined to be present 
in one gram of coffee. MG owns the strongest mutagenicity in dicarboyls in coffee 
(Nagao et al., 1986). Besides food and beverages, drinking water can also be an 
exogenous source of MG. Ozonation and chlorination of natural water, the applied 
process in the treatment of drinking water, can lead to the formation of MG (Matsuda 
etai, 1992). 
Toxicity of MG 
MG is inextricably linked to oxidative stress 
Generation of reactive oxygen species (ROS) is associated with MG 
metabolism. Production of MG from acetone and aminoacetone yields hydrogen 
peroxide (H2O2) and superoxide radicals (O2'") as by products, and degradation of MG 
by glyoxal oxidase or photolysis produces H2O2 and other radical species (Kalapos, 
2008). In addition, treatment of various cell types with MG induces their ROS 
production (Kalapos, 2008). MG also hinders antioxidant defence by reacting with 
functional thiol groups of glutathione (GSH) and plasma albumin to reduce their 
activity (Faure et al., 2005; Kalapos, 2008). MG inhibits the antioxidant enzyme 
superoxide dismutase by altering its structure (Kang, 2003) and impedes glyoxalase 
and GSH peroxidase function. Through above mechanisms, MG promotes oxidative 
stress in cellular systems and encourages its own survival. Oxidative stress is 
implicated in apoptosis of pancreatic P-cells and impaired insulin signalling in 
diabetes (Newsholme et al., 2007), as well as in cell and tissue damage. Whereas 
limited amounts of ROS are used by the immune system for functions, such as 
signalling and microbicidal activity, unregulated ROS production leads to oxidative 
protein and DNA damage, which promotes tissue dysfunction, apoptosis and 
premature cell aging. Cell aging can encourage ill health, as senescence of immune 
cells is associated with increased incidence of infection and cancer (Martin and 
Grotewiel, 2006). 
Modification of protein 
Under physiological conditions, more than 90% of MG is bound reversibly 
with cellular proteins (Lo et al., 1994). MG reacts with arginine, lysine and cysteine 
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residues of proteins to form advanced glycation endproducts (AGEs). Arginine-
derived hydroimidazolone and lysine-derived N-e-carboxyethyi-lysine (CEL) and N-
8-carboxymethyl-lysine (CML) are products of irreversible reactions of protein 
residues with MG (Lo et al., 1994). The concentration of AGEs in mammalian 
tissues, plasma and extracellular matrix in vivo depends on the protein substrate, 
tissue location and type of AGEs. For instance, the highest concentration of 
hydroimidazolone was found in the lens of older individuals and CML accumulates 
on lens, skin and cartilage (Ahmed et al., 1997; Verzijl et al., 2000). 
MG-induced AGEs are involved in the pathogenesis of many diseases, such as 
diabetes, hypertension and neurodegenerative diseases (Desai and Wu, 2007; Munch 
et al., 2003). AGEs induce cross-linkage of proteins to decrease arterial and 
myocardial compliance and promote vascular stiffness, leading to the alteration of 
vascular structure and fimction, which contributes to the development of hypertension 
and diabetic vascular complications (Goh and Cooper, 2008). AGEs also have been 
seen accumulated in diabetic kidney, retina and atherosclerotic plaques (Makita et al., 
1994; Bucala and Vlassara, 1995; Hammes et al., 1999), and are closely linked to the 
development of diabetic complications. In addition, AGEs interact with some 
receptors, like the receptor for AGEs (RAGE), where they interfere with cell signaling 
and nuclear factor-icB (NF-KB) mediated pathway, leading to enhanced oxidative 
stress and generation of proinflammatory cytokines. 
MG-induced AGEs formation impairs anti-oxidant enzymes, leading to the 
excessive accumulation of reactive oxygen species (ROS). Arginine, lysine and 
cysteine are residues involved in the active sites of enzymes, and the irreversible 
reaction of MG with residues may alter the activity of those enzymes. For example, 
activities of glutathione reductase and glutathione peroxidase were reduced 
significantly, accompanied by the increased MG-induced AGEs formation in aorta 
from adult SHR (Wang et al., 2005). MG also modifies Cu/Zn-SOD by covalent 
cross-linking of the proteins, leading to the release of copper ions from the enzyme 
and the inactivity of the enzyme (Kang, 2003). Furthermore, decreased extracellular 
SOD activity was due to excessive glycation, not to the impaired synthesis of this 
enzyme in patients with diabetes (Ciechanowski et al., 2005). Aminoguanidine, a 
scavenger of MG and AGEs, increased the activities of catalase, glutathione reductase 
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and glutathione peroxidase in insulin-dependent diabetic rats and prevented the 
impairment of blood antioxidant systems (Stoppa et al., 2006). 
Modification of nucleic acid 
MG can be a mutagen since it modifies nucleotides poly A, poly G and poly 
C, but not poly-U (Krymkiewicz, 1973). MG inhibited skin cell proliferation and 
caused extensive DNA strand cleavage by the extensive formation of DNA-protein 
cross-links (Roberts et al., 2003). MG-induced cytotoxicity and mutation were 
concentration dependent. Multi-base deletions were predominant (50%) in MG-
induced mutations, followed by base-pair substitutions (35%), in which G:C to C:G 
and G:C to T:A transversions were predominant (Murata-Kamiya et al, 2000). 
Furthermore, MG increased point mutations in Salmonella typhimurium (Migliore et 
ah, 1990), and the occurrence of point mutations correlated with the glycation rate of 
DNA (Pischetsrieder et al, 1999). The cross-link formation of protein with DNA by 
glycation with MG has been investigated. A protein-DNA cross-link was observed 
after 90 min exposure to MG (1.5 mM) in Chinese hamster ovary cells (Brambilla et 
ah, 1985). In addition, MG cross-linked a guanine residue of the substrate DNA and 
lysine and cysteine residues near the binding site of the DNA polymerase during 
DNA synthesis, and that DNA replication was severely inhibited by the MG-induced 
DNA-DNA polymerase cross-link in E.coli (Murata-Kamiya and Kamiya, 2001). 
Apart from these modifcations, DNA-AGEs are also formed by the reaction of 
MG and nucleic acids. The major AGE adducts found in DNA are MG-derived dG 
modifications (Bidmon et al., 2007 and Synold et al., 2008), leading to the formation 
of carboxyethyl deoxyguanosine (CEdG). CEdG is the major adduct of the glycation 
reaction of MG and DNA. MG-glycation of dG residues seems to increase the 
frequency of dG deletion (Seidel and Pischetsrieder, 1998), leading to abasic sites, 
which are potentially mutagenic. MG treatment of cells leads to reduced DNA 
replication and increased mutations, the most prominent being multibase deletions 
and base-pair substitutions (Murata-Kamiya et al., 2000). MG also has the potential to 
crosslink DNA to proteins, for example between the dG of DNA and Lys or Cys 
residues close to the DNA polymerase binding site (Murata-Kamiya and Kamiya, 
2001). Therefore, any mutations or DNA damage/cross-linking caused by MG could 
f 
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result in reduced or altered transcription, which might affect genes/proteins involved 
in immune defence or any other bodily function. Furthermore, because PARP plays a 
role in DNA repair and is activated by DNA damage, dG glycation or other MG-
related DNA damage could also negatively impact glycolysis. 
Scavengers of MG 
To date, specific MG scavengers are not available in the market, but some 
agents like aminoguanidine, alagebrium and metformin including some AGE 
inhibitors like D-lysine, D- penicillamine, diclofenac and desferrioxamine are capable 
of reducing MG levels. In addition to these scavengers, vitamins like pyridoxamine, 
thiamine and thiamine pyrophosphates, pyridoxal phosphate also play crucial role in 
inhibiting post amadori glycation cascade and as carbonyl trapping AGE inhibitors. 
These inhibitors are currently used in different studies, although the mechanism is 
unclear. 
Physiological and pathological levels of MG 
The levels of MG in plasma of normal human subjects vary from 123 nM to 
650 nM depending on different studies (Beisswenger, et al., 1999; Odani, et ai, 1999; 
Lapolla, et ai, 2005; Nemet, et al., 2005). The inconsistency of those values seems 
dependent on different methods used to test the compound. 
Elevated levels of MG have been observed in different kinds of diseases, such 
as hypertension, diabetes and renal failure. MG was significantly elevated in patients 
with diabetes mellitus versus normal subjects (212 nM vs. 160 nM) (Beisswenger, et 
al., 1999). The data from another laboratory indicated that plasma MG levels were 
significantly higher in patients with diabetes mellitus (194 ng/ml) and patients with 
chronic renal failure (128 ng/ml) than those from normal subjects (59 ng/ml) (Odani 
et al., 1999). In addition, MG levels were significantly elevated in patients with end-
stage renal disease versus normal controls (24 vs. 9 |xg/ml) (Lapolla, et al., 2005). 
Numerous studies demonstrated that MG played an important role in the 
pathogenesis of diabetes and diabetic complications. It has been observed that the plasma 
levels of MG in diabetic patients were significantly increased compared with those in 
normal controls (742 ± 141 vs. 520 ± 42 nM,). MG was also a parameter reflecting 
glycemic fluctuation (Nemet, et al., 2005). 
Diabetes mellitus 
Advances in clinical science over a single professional lifetime during the 
second half of the 20* century have led to improvements in understanding the causes 
and complications of diabetes, together with alleviation of suffering to an 
extraordinary degree. Diabetes mellitus refers to a group of common metabolic 
disorders that share the phenotype of hyperglycemia. Several types of diabetes 
mellitus exist and are caused by a complex interaction of genetics and environmental 
factors, viral infection and autoimmune disease have been implicated (Paik et al., 
1982; Kataoka et al., 1983; Sandler et al., 2000; Shewade et al., 2001). While 
exogenous insulin and other medications can control many aspects of diabetes, 
numerous complications affecting the vascular system, kidney, retina, lens, peripheral 
nerves and skin are common and are extremely costly in terms of longevity and 
quality of life. Increased oxidative stress is a widely accepted participant in the 
development and progression of diabetes and its complications (Baynes et al., 1999). 
Diabetes is usually accompanied by increased production of free radicals (Chang et 
al., 1993; Young et al., 1995; Baynes et al., 1999) or impaired antioxidant defenses 
(Halliwell and Gutteridge, 1990; McLennan et al., 1991; Saxena et al., 1993). 
Mechanisms by which increased oxidative stress is involved in the diabetic 
complications are partly known, including activation of transcription factors, 
advanced glycated end products (AGEs) and protein kinase C. Depending on the 
etiology of the diabetes mellitus, factors contributing to hyperglycemia include 
reduced insulin secretion, decreased glucose utilization and increased glucose 
production. The metabolic dysregulation associated with diabetes mellitus causes 
secondary pathophysiologic changes in multiple organ systems that impose a 
tremendous burden on the individual with diabetes. In the United States, diabetes 
mellitus is the leading cause of end-stage renal disease (ESRD), non traumatic lower 
extremity amputations, and adult blindness (Powers, 2008). It also predisposes to 
cardiovascular diseases. In diabetes mellitus, low insulin levels prevent cells from 
absorbing glucose, as a result glucose builds up in the blood. When glucose-laden 
blood passes through kidneys, all the excess glucose cannot be absorbed. This excess 
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glucose secreted in urine along with water and electrolytes as well as ions required by 
cells to regulate the electric charge and flow of water molecules across the cell 
membrane. This causes polyurea, polydipsia and weight loss as classical symptoms of 
the diabetes. These symptoms together with a random plasma glucose concentration 
>11.1 mmol/L (200mg/dL) is sufficient for the diagnosis of diabetes mellitus although 
fasting plasma glucose is the most reliable and convenient test for identifying diabetes 
in asymptomatic individuals (Powers, 2008). 
Classification of diabetes mellitus 
Diabetes mellitus is classified on the basis of the pathogenic process 
that leads to hyperglycemia (American Diabetes Association, 2007). The two broad 
categories of diabetes mellitus are designated as type I and type II. Both types of 
diabetes are preceded by a phase of abnormal glucose homeostasis as the pathogenic 
processes progresses. Type I diabetes is the result of complete or near-total insulin 
deficiency. Type II is a heterogeneous group of disorders characterized by variable 
degrees of insulin resistance, impaired insulin secretion, and increased glucose 
production. Distinct genetic and metabolic defects in insulin secretion give rise to the 
common phenotype of hyperglycemia in type II diabetes mellitus and have important 
potential therapeutic implications now that pharmacologic agents are available to 
target specific metabolic derangements. Type II diabetes mellitus is preceded by a 
period of abnormal glucose homeostasis classified as impaired fasting glucose (IFG) 
or impaired glucose tolerance (IGT). The term insulin-dependent diabetes mellitus 
(IDDM) and noninsulin-dependent diabetes mellitus (NIDDM) are obsolete. Since 
many individuals with type II diabetes eventually require insulin treatment for control 
of glycemia, the use of term NIDDM generated considerable confusion. Other 
etiologies for diabetes mellitus include specific genetic defects in insulin secretion or 
action, metabolic abnormalities that impair insulin secretion, mitochondrial 
abnormalities and a host of conditions that impair glucose tolerance. The etiologic 
classification of diabetes mellitus is illustrated in Table 1. Maturity onset diabetes of 
the young (MODY) is a subtype of diabetes mellitus characterized by autosomal 
dominant inheritance, early onset of hyperglycemia (usually < 25 years), and 
impairment in insulin secretion (Powers, 2008). 
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II. 
TABLE 1 
Etiologic classification of diabetes mellitus 
Type I diabetes (P-cell destruction, usually leading to absolute insulin deficiency) 
A. Immune Mediated. 
B. Idiopathic. 
Type II diabetes (may range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly insulin secretory defect with insulin 
resistance). 
III. Other specific types of diabetes 
A. Genetic defects ofP- cell function 
characterized by mutations in: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Hepatocyte nuclear 
transcription factor (HNF) 4a 
(MODY 1). 
Glucokinase (MODY 2). 
HNF-la(M0DY3). 
Insulin promoter factor-1 (IPF-
1; MODY 4). 
HNF-1 p (MODY 5). 
Neuro Dl (MODY 6). 
Mitochondrial DNA 
B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. Pancreatectomy 
3. Neoplasia 
4. Cystic Fibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
D. Endocrinopathies 
1. Acromegaly 
2. Gushing's syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
E. Drug- or chemical-induced 
1. Pentamidine 
2. Nicotinic acid 
3. Glucocorticoids 
4. Thyroid hormone 
5. Diazoxide 
6. p- adrenergic agonists 
7. Phenytoin 
8. a- interferon 
9. Protease inhibitor 
F. Infections 
1. Congenital rubella 
2. Cytomegalovirus 
3. Coxsackie 
G. Uncommon forms of immune-
mediated diabetes 
1. "Stiff Person" syndrome 
2. Anti-insulin receptor antibodies 
H. Other genetic syndromes 
sometimes associated with 
diabetes 
1. Down' s syndrome 
2. Klinfelter's syndrome 
3. Turner's syndrome 
4. huntington's chorea 
5. Myotonic dystrophy 
6. Porphyria 
IV. Gestational Diabetes Mellitus 
(GDM) 
Source: Adapted from American Diabetes Association, 2007. 
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Type I diabetes mellitus 
Absolute insulin deficiency caused by autoimmune-mediated destruction of 
pancreatic P-cells characterizes type I diabetes. This condition is also called '"insulin-
dependent diabetes" or "juvenile diabetes." The main cause of the beta cell loss is a T-
cell mediated immune attack (Rother, 2007). It is thought to be caused by a combina-
tion of environmental factors and viral infection, superimposed on a genetic 
susceptibility. It accounts for -10% of those with diabetes in the Unhed States, but the 
prevalence may be increasing. The disorder may be further sub classified into type lA 
if autoimmune markers are found, usually at the time of diagnosis (A Report on 
Diabetes care, 1997) Type IB diabetes is an absolute insulin deficiency in which no 
autoimmune markers can be identified. Type IB diabetes may be more common in 
people of Asian heritage (Abiru et al., 2002). Type I diabetes is a multifactoral 
autoimmune disease thought to arise from a complex interaction between both genetic 
susceptibility and environmental insult(s). Several autoantibody (Table 2) markers 
have been detected in autoimmune diabetes including islet cell antibodies (ICA), 
insulin autoantibodies (lAA) (Atkinson et al., 1992), glutamic acid decarboxylase-65 
(GAD-65) autoantibodies (Jun et al., 2002) and antibodies to tyrosine phosphatases 
IA-2 and IA-2P (Lan et al., 1996; Lu et al., 1996). There is a strong association of 
type I diabetes with individuals who possess particular HLA haplotypes. HLA DR4-
DQ8 and DR3-DQ2 are present in > 90% of children with type IA diabetes (Powers, 
2008). Furthermore, 30-50% of patients with type lA diabetes are heterozygotes for 
HLA DR4-DQ8 and DR3-DQ2, whereas this combination of alleles is only present in 
-2.4% of the general population (Devendra and Eisenbarth, 2003). Most people with 
these HLA alleles do not develop type I diabetes, demonstrating that other factors are 
involved in the development of the disease. Many triggers have been proposed for the 
development of type I diabetes in genetically susceptible individuals. Viruses such as 
enteroviruses, coxackie virus and rubella have been proposed as culprits but have not 
been definitively shown to induce type I diabetes (Lammi et al., 2005). Food additives 
or toxins, such as nitrosamines, have also been proposed as a cause of diabetes 
(Helgason et al., 1981). Some investigators have also implicated cow's milk as an 
initiating factor in the development of autoimmunity in type I diabetes (Oute et al., 
1999). Whatever initiating mechanism is, the autoimmune destruction of p-cells leads 
TABLE 2 
Major autoantigens in type I diabetes 
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S. No. Characteristics GAD65 IA-2 Insulin 
1 Amino Acid length 585 979 51 
2 Molecular weight (Da) 65,000 106,000 6,000 
3 Chromosome lOpll 2q35 llpl5 
Cell type in which 
expressed 
Neuroendocrine Neuroendocrine Pancreatic 
pancreatic islet pancreatic islet islet |3 ceil 
cells cells 
5 Intracellular location Neuron-like 
small vesicles 
Secretory Secretory vesicles 
vesicles 
6 Function 
Converts Enzymatically Ligand for the 
glutamic acid to inactive insulin receptor; 
GAB A; member of PTP regulation of blood 
inhibitory family glucose 
neurotransmitter 
Source: Notkins & lemmark, J. Clin. Invest, 108, 2001. 
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to a progressive decline in the body's insulin secretory capacity. Eventually, this 
decline manifests itself in hyperglycemia after a large carbohydrate load, such as a 
meal or a glucose tolerance test. When -80% of p-cells have been destroyed, patients 
develop the first clinical symptoms of diabetes. Interestingly, the rate of (3-cell decline 
can vary based on age, with older patients who develop type I diabetes typically 
experiencing a much more gradual decline in p-cell mass (Powers, 2008). 
Type II diabetes mellitus 
Type II diabetes is a heterogeneous group of conditions that constitute -90% 
of diabetes. Like type I diabetes, type II diabetes also involves both genetic 
susceptibility and environmental factors, although the genetic component may be 
greater than in type I diabetes. It is caused by a combination of insulin resistance and 
relative insulin deficiency with increased hepatic glucose production. It is important 
to note that some individuals experience predominantly insulin resistance and others 
insulin deficiency. Insulin resistance is generally thought to precede insulin 
deficiency. Obesity is associated with increased insulin resistance and may be the 
reason that, type II diabetes is more common in obese individuals. The precise 
mechanism by which obesity leads to insulin resistance is not completely described 
but may be related to several biochemical factors, such as free fatty acids, leptin, 
tumour necrosis factor-a and other substances. In addition, many genetic 
polymorphisms may play a part in insulin resistance, possibly through post-insulin 
receptor signal transduction mechanisms (Powers, 2008). Overweight and obesity are 
strongly associated with development of type II diabetes and may be responsible for 
the majority of the growing diabetes pandemic (Wannamethee and Shaper 1999). 
Furthermore, weight loss is strongly associated in prospective studies with decreased 
progression from impaired glucose tolerance (IGT) to type II diabetes (Knowler et al, 
2002). Insulin resistance alone, however, does not cause diabetes. Most obese people 
do not develop type 2 diabetes, despite increased insulin resistance (Polansky, 2000). 
For type II diabetes to emerge, there must also be relative insulin deficiency. Before 
type II diabetes develops, the pancreatic P-cells increase their production of insulin to 
compensate for increased insulin resistance. It has been proposed, that there is 
measurable P-cell hypertrophy present in obese subjects who do not have diabetes. 
For unclear reasons, P-cell secretory capacity gradually declines in some individuals. 
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leading to the development of type 11 diabetes. As P-cell insulin secretory capacity 
declines, type II diabetes begins to develop. Initially, hyperglycemia is only observed 
after large meals, as in type II diabetes. As |3-cell function declines further, however, 
hyperglycemia becomes more severe. Studies have suggested that 40% of P-cell mass 
may be lost in individuals who have glucose intolerance, and ~60% may be lost when 
clinical type II diabetes develops (Butler et al., 2003). Hepatic insulin resistance and 
relative insulin deficiency also lead to increased hepatic gluconeogenesis, which 
further worsens hyperglycemia. Eventually, the degree of hyperglycemia worsens and 
becomes virtually universal if left untreated (Powers, 2008). The cause of [3-cell 
failure in type II diabetes is unknown. In addition to a genetic predisposition, studies 
have also demonstrated higher rates of apoptosis and decreased P-cell mass in patients 
with type II diabetes (Butler et al, 2003). There are also increased amounts of 
amyloid deposits in the islets of patients with type II diabetes (Khan et al., 1999). 
Several authors speculate that increased insulin resistance may be a genetic trait that 
can be worsened by obesity and that p-cells compensate for this increased resistance. 
Some individuals, however, cannot maintain this compensation because of P-cell 
failure, which leads to the development of type II diabetes. 
Asian Indians are more prone to type II diabetes and premature coronary 
artery disease due to "Asian Indian Phenotype". The phenotype refers to certain 
unique clinical and biochemical abnormalities in Indians which include increased 
insulin resistance, greater abdominal adiposity i.e., higher waist circumference despite 
lower body mass index, lower adiponectin and higher high sensitive C-reactive 
protein levels (Mohan et al., 2007). 
Methylglyoxal and diabetes mellitus 
No matter the cause of diabetes, the result is always hyperglycaemia. This 
excess glucose metabolism drives several damage pathways and raises concentrations 
of the reactive dicarbonyl, methylglyoxal (MG). MG can modify the structure and 
fiinction of target molecules by forming advanced glycation end-products (AGEs) that 
act through their receptor (RAGE) to perpetuate vascular and neuronal injury 
responsible for long-term complications of diabetes. Diabetes patients suffer lower 
resistance to many common infections, although the cause for this lower resistance 
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remains elusive. It has been suggested that MG could be a missing link between 
hyperglycaemia and immune suppression in diabetes. The glycolytic by-product 
methylglyoxal (MG) is a potent modifier of immune components and function, 
inducing immune damage which might provide a link between hyperglycaemia and 
diabetes-related infection risk (Claire and Stella, 2009). 
MG and metabolic dysfunction in diabetes 
The reactive a-oxoaldehyde MG is formed as a natural by-product of several 
metabolic pathways, mainly from glycolysis but also from lipid peroxidation and 
threonine catabolism (Kalapos, 1999). To prevent cellular damage, MG is detoxified 
by defence components, including the specialised glyoxalase system, which converts 
a-oxoaldehydes to their respective hydroxyacids (Thornalley, 2003). In diabetes, the 
increased flux of glucose metabolism causes metabolic dysfunction. Higher rates of 
respiration through the electron transport chain within mitochondria lead to 
superoxide leakage, increased oxidative stress and activation of the nuclear enzyme, 
poly (ADP-ribose) polymerase-l (PARP). PARP activation depletes its substrate 
NAD"*" (slowing rate of glycolysis and electron transport) and inhibits glyceraldehyde-
3-phosphate (G-3-P) dehydrogenase (GAPDH) (Pacher and Szabo, 2005). By 
inhibiting the GAPDH conversion of G-3-P, glycolytic intermediates build up, 
compounded by increased glucose at the head of the chain. Glycolytic intermediates 
are pushed down their respective metabolic pathways (protein kinase C, polyol and 
hexosamine), altering cellular balance and causing damage through raised angiogenic 
factors, reduced nitric oxide and altered gene expression and protein function (Rolo 
and Palmeira, 2006). This damage, along with that from formation of advanced 
glycation end-products (AGEs), lies behind the vascular and neuronal complications 
of diabetes. The glycolytic intermediates fructose-1,6-diphosphate, G-3-P and 
glycerol phosphate are direct precursors of MG; thus, in diabetes, MG production is 
vastly increased. Furthermore, the glyoxalase defence against MG becomes 
overwhelmed, with activity of glyoxalase I decreased by oxidative stress and MG 
concentrations are able to rise (Thornalley, 2008). Therefore, MG blood levels are 2-
6 times higher in diabetes patients compared with controls (McLellan el ai, 1994). 
Because MG initially binds reversibly to tissues in vivo (Lo et ai, 1994), actual levels 
might be far higher (up to 100 times higher) than this measurement suggests and 
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concentrations probably vary locally depending upon availability of precursors and 
activity of defences. 
Role of MG in diabetes mellitus 
MG-induced AGEs in diabetes mellitus 
MG is the most important precursor of AGEs. Numerous studies show that 
accumulation of intracellular MG and formation of AGEs alter cell function and 
contribute to the development Of type II diabetes mellitus and diabetic complications 
such as atherosclerosis, nephropathy, and retinopathy. 
In cultured endothelial cells, MG accumulated rapidly under hyperglycemic 
conditions (Shinohara, et al., 1998). In addition, serum levels of AGEs increased in 
patients with type II diabetes and coronary artery disease (Kilhovd. et al., 1999). 
AGEs induce diabetic atherosclerosis by multiple ways. Argpyrimidine, the 
fluorescence product of the reaction of MG with arginine residues in protein, has been 
demonstrated to localize in atherosclerotic lesions, fatty streaks, lipid containing 
SMCs and macrophages in diabetic patients (Friedman, 1999; Oya, et al., 1999). A 
correlation of AGEs and severity of atherosclerotic lesions was also shown. AGEs 
decrease NO availability by quenching NO, impair LDL removal by trapping LDL in 
the sub endothelium and decrease LDL 39 receptor recognizing AGEs-modified LDL 
(Bucala, et al., 1994). Furthennore, AGEs enhanced VCAM-1 expression by 
activating NF-KB. VCAM-1 stimulates the migration of monocytes through 
endothelium, which is the first step of atherogenesis (Kunt, et al., 1999). 
The kidney is a key target of MG and AGEs mediated damage. Mouse renal 
damage was found after oral administration of MG. A 5-month treatment with MG 
resulted in elevated levels of collagen in kidney and increased glomerular basement 
membrane thickness (Golej, et al., 1998). Diabetic mice have significantly elevated 
renal AGEs, and these abnormalities have been linked to various structural aspects of 
diabetic nephropathy, including glomerular basement membrane thickening, 
glomerulosclerosis, and tubulointerstitial fibrosis (Soulis-Liparota, et al., 1995). 
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MG-induced hydroimidazolone increased selectively in retinas of 
streptozotocin-induced diabetic rats (Karachalias, et a/., 2003). In addition, MG-
modified CML was localized in retinal blood vessels of patients with type II diabetes 
and was found to correlate with the degree of retinopathy (Stitt, 2001). Furthermore, 
decreased eNOS expression was observed in retinal vascular endothelial cells exposed 
to AGEs, which may account for retinal microvascular abnormalities (Chakravarthy, 
era/., 1998). 
MG-induced oxidative stress in diabetes mellitus 
Growing evidence suggests that MG-induced oxidative damage is responsible 
for the development of diabetic complications. Type II diabetes mellitus patients 
without a history of acute cardiovascular events, such as myocardial infarction and 
unstable angina, during the previous 6 months were recruited. Compared to baseline, 
MG/AGEs rich, heat-processed food reduced macrovascular flow-mediated dilatation 
and decreased microvascular reactive hyperemia, indicating macro- and 
microvascular endothelial dysfunction. The impairment of postprandial flow-mediated 
dilatation may be the result of a combined effect of reduced NO production and 
increased NO scavenging, both decreasing NO bioavailability (Stirban, et al., 2006). 
Another study of three diabetic populations, the Overt Nephropathy Progressor 
/ Nonprogressor (ONPN) cohort (n = 14), the Natural History of Diabetic 
Nephropathy study (NHS) cohort (n = 110) and the Pima Indian cohort (n = 45), 
demonstrated that progression of diabetic nephropathy was significantly correlated 
with MG levels and oxidative stress (Beisswenger, et al., 2005). The oxidative stress 
in this study was verified by the reduced GSH levels in red blood cells of diabetic 
patients. In addition, MG modified renal mitochondrial protein in streptozotocin-
treated rats, leading to significantly increased production of mitochondrial O2'" and 
oxidative damage (Rosea, et al., 2005). Furthermore, exposure of human 
neuroblastoma SH-SY5Y cells to MG was associated with increased ROS production, 
leading to MG-induced cellular damage (de Arriba, et al., 2006). MG also induced 
diabetic neuropathy through oxidative stress-mediated activation of p38 MAPK. 
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MG and insulin 
Evidence shows that MG destroys pancreatic P-cells, decreases insulin 
secretion in response to glucose and alters insulin structure and function. MG caused a 
concentration-dependent increase of apoptotic pancreatic P-cells (Sheader, et al., 
2001). Addition of MG (0.5 or 1 mM) to single isolated rat pancreatic P-cells caused a 
rapid and marked depolarization, and this effect was reversible upon the removal of 
MG. MG also led to elevated cytosolic calcium concentration and intracellular 
acidification in intact rat islets (Cook, et al., 1998). Moreover, acute exposure of 
isolated mouse islets or p-cells to MG resulted in reduced insulin secretion in 
response to glucose (Pi, et al., 2007). 
Immune alterations in diabetes 
The damage of the immune system by MG glycation could be a link between 
diabetes and infection susceptibility (Claire and Stella, 2009). A commonly reported 
feature of diabetes is reduced production of the proinflammatory cytokine interferon-y 
(IFN- y) (Faresjo et al., 2006). Type I diabetes and Type II diabetes patients also show 
inhibited tumour necrosis factor-a (TNF-a) production and reduced expression of 
Tn'-associated chemokine receptors on peripheral blood cells (Lohmann et al, 2002), 
as well as reduced production of the antiviral cytokine IFN-a from dendritic cells 
(DCs). Type I diabetes patients have lower proportions of natural killer (NK) cells in 
peripheral blood (important in clearance of virus-infected cells) and a reduced activity 
of these cells (Rodacki et al., 2006) Diabetes is also associated with raised levels of 
serum adhesion factors, such as intercellular- and vascular-adhesion molecules 
(ICAM and VCAM) (Boulbou et al, 2005; Glowinska et al, 2005) and monocytes 
from type I diabetes patients show increased adhesion but decreased chemotactic 
migration towards proinflammatory chemokines (Bouma et a/.,2005). The 
chemotactic, phagocytic and microbicidal functions of neutrophils are also hindered 
(Alba-Loureiro et al.,2007). Increased cell death is associated with hyperglycaemia, 
with greater apoptosis of lymphocytes and neutrophils reported in type I diabetes and 
type II diabetes patients (Otton et al, 2004; Glisic-Milosavljevic et al, 2007). Loss of 
these cell types might hinder both innate and adaptive responses to any infection. 
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Together, these studies illustrate that hyperglycaemia impacts many different 
facets of immune function. Any one aspect of these diabetes-associated deficits, 
including reduced leukocyte migration, impaired killing mechanisms or lower 
lymphocyte proliferation, might be enough to suppress infection clearance. MG 
appears to be a potent modifier of immune function in vitro and seems to be able to 
produce effects which confirm some of the in vivo findings described in diabetes 
patients. Reduced stimulation of T cells, altered cell phenotype and hindered cytokine 
responses caused by MG might underlie reduced infection clearance in diabetes. 
Free radicals and diabetes mellitus 
Excessively high levels of free radicals cause damage to cellular proteins, 
membrane lipids and nucleic acids and eventually cell death. Various mechanisms 
have been suggested to contribute to the formation of these reactive oxygen-free 
radicals. Glucose oxidation is believed to be the main source of free radicals. In its 
enediol form, glucose is oxidized in a transition-metal dependent reaction to an 
enediol radical anion that is converted into reactive ketoaldehydes and to superoxide 
anion radicals. The superoxide anion radicals undergo dismutation to hydrogen 
peroxide, which if not degraded by catalase or glutathione peroxidase, and in the 
presence of transition metals, can lead to production of extremely reactive hydroxyl 
radicals (Wolff and Dean, 1987; Jiang et al, 1990). Superoxide anion radicals can 
also react with nitric oxide to form reactive peroxynitrite radicals (Halliwell and 
Gutteridge, 1990; Hogg et al., 1993). Hyperglycemia is also found to promote lipid 
peroxidation of low density lipoprotein (LDL) by a superoxide-dependent pathway 
resulting in the generation of free radicals (Kawamura et ah, 1994; Tsai et al., 1994). 
Another important source of fi-ee radicals in diabetes is the interaction of glucose with 
proteins leading to the formation of an Amadori product and then advanced glycation 
endproducts (AGEs) (MuUarkey et al., 1990; Hori et al, 1996). Similar reactions are 
also found to occur with nucleic acids and their bases where glucose and other 
glycating agent reacts with free amino groups of guanine and less common to adenine 
to form AGEs, hence also called DNA-AGEs. These AGEs, via their receptors 
(RAGEs), inactivate en2ymes and alter their structures and functions (McCarthy et 
al., 2001), promote free radical formation (Baynes and Thorpe, 1999), and quench 
and block anti proliferative effects of nitric oxide (Wautier et al., 1994; Vlassara. 
31 
1997). By increasing intracellular oxidative stress, AGEs activate the transcription 
factor NF-KB, thus promoting up-regulation of various NF-KB controlled target genes 
(Mohamed et al, 1999). NF-KB enhances production of nitric oxide, which is 
believed to be a mediator of islet beta cell damage. Considerable evidence also 
implicates activation of the sorbitol pathway by glucose as a component in the 
pathogenesis of diabetic complications, for example, in lens cataract formation or 
peripheral neuropathy (Kador et al, 1984; Greene et al, 1992; Obrosova et al, 1997). 
Efforts to understand cataract formation have provoked various hypotheses. In the 
aldose reductase osmotic hypothesis, accumulation of polyols initiates lenticular 
osmotic changes. In addition, oxidative stress is linked to decreased glutathione levels 
and depletion of NADPH levels (Cheng and Gonzalez, 1986). Alternatively, increased 
sorbitol dehydrogenase activity is associated with altered NAD* levels (Williamson et 
al, 1993), which results in protein modification by nonenzymatic glycosylation of 
lens proteins (Yano et al, 1989; Ramalho et al, 1996). Mechanisms linking the 
changes in diabetic neuropathy and induced sorbitol pathway are not well delineated. 
One possible mechanism, metabolic imbalances in the neural tissues, has been 
implicated in impaired neurotrophism (Mizisin et al, 1.997; Delcroix et al, 1998; 
Hounsom et al, 1998), neurotransmission changes (Ralevic et al, 1995; Kamei and, 
Ohsawa, 1996; Stevens et al, 2000), Schwann cell injury (Mizisin et al, 1998; 
Kalichman et al, 1998) and axonopathy (Chokroverty et al, 1988; Femyhough et al, 
1999). 
Epidemiology and prevalence of diabetes mellitus 
The worldwide prevalence of diabetes mellitus has risen dramatically over the 
past two decades, from an estimated 30 million cases in 1985 to 177 million in 2000 
(Fig. 2). Based on current trends, > 360 million individuals will have diabetes by the 
year 2030 (Wild et al, 2004). Estimates which have been produced by the 
International Diabetes Federation (IDF) is about 194 million individual worldwide to 
have diabetes in 2003 and is expected to increase to about 333 million by 2025. 
(International Diabetes Federation, Diabetes Atlas, 2006). 
Table 3 shows the 10 countries with the largest numbers of people 
with diabetes. As might be expected, the countries with the largest populations have 
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Africa 
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2030:18.2 million 
0 0 
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2000.82.7 milliwi \ • * 
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Prevalence of diabetes (%) in persons 35-64 years 
~n<3 rr^ — — 3-5 6-8 >8 
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Fig. 2 Worldwide prevalence of diabetes mellitus. 
Source: Adapted from Wild, S. et al, diabetes care (2004) 27, 2004. 
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TABLE 3 
Top Ten countries for numbers of people aged 20-79 years with diabetes 
in 2010 and 2030. (Number of diabetic peoples, in millions). 
S.No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Country 
India 
China 
USA 
Russia 
Brazil 
Germany 
Pakistan 
Japan 
Indonesia 
Mexico 
Year, 2010 
50.8 
43.2 
26.8 
9.6 
7.6 
7.5 •• 
7.1 
7.1 
7.0 
6.8 
S.No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Country 
India 
China 
USA 
Pakistan 
Brazil 
Indonesia 
Mexico 
Bangladesh 
Russian 
Egypt 
Year, 2030 
87.0 
62.6 
36.0 
13.8 
12.7 
12.0 
11.9 
10.4 
10.3 
8.6 
Source: Shaw et al, diabetes research and clinical practice 87, 2010 
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the highest number of persons with diabetes. Only Bangladesh and Nigeria of the 
world's 10 most populous countries are not among the 10 countries with the highest 
diabetes numbers (replaced by Germany and Mexico) for 2010. There are marked 
differences between developed and developing countries. For developing countries, 
adult diabetes numbers are likely to increase by 69% from 2010 to 2030, compared to 
20% for developed countries, whereas total adult populations are expected to increase 
by 36% and 2% respectively (Shaw et al. 2010). 
There is considerable geographic variation in the incidence of both type 1 and 
type II diabetes mellitus. Scandinavia (Finland) has the highest incidence of type I 
diabetes mellitus, whereas in Pacific Rim regions (Japan, China), its prevalence is 
least. Northern Europe and the United States have an intermediate rate. Much of the 
increased risk of type I diabetes mellitus is believed to reflect the frequency of high 
risk HLA alleles among ethnic groups in different geographic locations. The 
prevalence of type II diabetes mellitus and its harbinger, IGT, is highest in certain 
pacific islands, intermediate in countries such as India and the United States, and 
relatively low in Russia. This variability is due to genetic, behavioural and 
environmental factors. 
India is now being termed the "diabetes capital of the world" as it leads the 
world with largest number of diabetic subjects. WHO report shows that 32 million 
people in India had diabetes in the year 2000 and is expected to increase about 80 
million by 2030. The IDF estimated the total number of diabetes subjects to be around 
36 million in India in 2003 and this is further set to rise to 73.4 million by the year 
2025. Another report published recently, estimated it to be 50.8 million by the year 
2010 and will shoot up to 87.0 million by the end of year 2030 (Shaw et al, 2010). 
Diabetes is the leading cause of mortality. A recent estimate suggested that 
diabetes is the fifth leading cause of death worldwide and is responsible for almost 3 
million deaths annually, which is a 1.7-5.2% of deaths worldwide. 
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Objective 
Recently it has been demonstrated that like proteins, DNA is susceptible to 
nonenzymatic attack by sugar affecting the structure, stability and conformation of 
DNA molecule. Although the nonenzymatic glycation of biomolecules occurs 
naturally, in some metabolic disorders such as diabetes, the formation and 
accumulation of AGEs occurs faster. This rapid formation and accumulation of AGEs 
is caused not only by D-glucose itself, but also by certain glucose-derived dicarbonyl 
intermediates such as methylglyoxal (MG), which is a potent precursor of AGEs. The 
highly reactive electrophile MG, a break down product of carbohydrate is a major 
environmental mutagen, an off-shoot product of glycolysis which is generated from 
deprotonation of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. It is 
also produced from lipid peroxidation and acetone metabolism. Additional 
endogenous sources include catabolism of threonine and oxidative breakdown of 
DNA and RNA. MG mutagenicity has been reported in Escherichia Coli, wherein it 
causes mutations at G:C base pairs, as well as in Sacharomyces cerevisiae. It has been 
suggested that MG reacts with free amino groups of proteins and DNA under 
physiological conditions and forms advanced glycation end products resulting in the 
generation of hydroxyl (OH) and superoxide (02"') ions which play an important role 
in the pathophysiology of ageing and diabetic complications. Methylglyoxal reacts 
with 2'-deoxyguanosine via the classic amadori pathway and did not react appreciably 
with 2'-deoxyadenosine, 2'-deoxythymidine and 2'-deoxycytidine. However, reaction 
of double stranded DNA or guanine/ 2'-deoxyguanosine with MG in-vitro produces 
primarily N^-carboxyethyl-2'-deoxyguanosine (CEdG), as a major adduct. This adduct 
(CEdG) might be used as a useful biomarker for monitoring oxoaldehyde-induced 
stress in response to enhance glycolytic flux or environmental exposure to MG. 
In the present study commercially available human placental DNA has been 
modified by MG and lysine in the presence and absence of Cu^ "^ . The modifications 
on DNA were studied by ultraviolet, fluorescence and circular dichroism 
spectroscopy, thermal denaturation studies, nucIease-Sl digestibility, HPLC, LC-MS 
and ESI-MS. Comet assay was performed to detect alkali labile sites, single and 
double stranded DNA breaks on human lymphocytes exposed to MG alone, lysine 
alone and in combination of MG + lysine and MG + lysine + Cu^ "". The hydroxyl 
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("OH) and superoxide (02'") radicals generated in MG + lysine + Cu^ ^ system have 
been also quantitated. Polyclonal antibodies against native and MG-Lys-Cu'^ '^  
modified human placental DNA have been generated in experimental animals. The 
specificity of induced antibodies has been evaluated by competition ELISA and gel 
retardation assay. These antibodies have been used as an immunochemical probe to 
detect MG-Lys-Cu^ "^  induced damage in the DNA, isolated fi-om diabetic patients. In 
order to assess the possible role of MG-Lys-Cu^ "^  modified DNA in the etiology of 
type I diabetes mellitus, sera firom diabetes patients have been assessed for their 
binding to native and MG-Lys-Cu^ "^  modified human placental DNA. Furthermore, 
binding of serum antibodies from type II diabetes patients with native and MG-Lys-
Cu^ "^  modified human placental DNA has been also evaluated. 
r 
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Materials 
Chemicals 
Methylglyoxal (MG), thiobarbituric acid (TBA), 2 deoxy-D-ribose, 
cytochrome-C, catalase, nuclease SI, anti-human and anti-rabbit IgG alkaline 
phosphatase conjugates, methylated bovine serum albumin (MBSA), p-nitrophenyl 
phosphate, superoxide dismutase (SOD), ethidium bromide, Coomassie Brilliant Blue 
G-250, sodium dodecyl sulphate, Tween-20, Protein A-agarose (2.5ml pre-pack 
column), Freund's complete & incomplete adjuvants, agarose, proteinase K, 
maimitol, histopaque 1077, low melting point agarose (LMPA), sodium azide and 
dialysis tubing were purchased from Sigma Chemical Company, U.S.A. Pyridoxal 
phosphate (PLP) was from Calbiochem, U.S.A. Dihydroxy acetone (DHA) was from 
Merck, Germany. Ficoll 400 and xylene cyanole FF were purchased from Pharmacia 
Fine chemicals, Sweden. Lysine was from Sisco research laboratory. Triton X-100 
was procured from Hi-Media. Trizma base was from Spectrochem, Mumbai, India. 
ELISA plates (96 wells) were purchased from NUNC, Denmark. Acrylamide. 
bisacrylamide, ammonium persulphate and N,N,N',N'-tetramethylethylenediamine 
(TEMED) were from Bio-Rad Laboratories, U.S.A. EDTA, (disodium salt), silver 
nitrate, dimethyl sulphoxide (DMSO), chloroform, D-mannitol, methanol, glacial 
acetic acid, iso-propanol, sodium chloride, sodium carbonate, sodium nitrite, sodium 
hydroxide, sodium bicarbonate, copper sulphate, magnesium chloride, trichloro 
acetic acid, manganese dioxide and potassium chloride were from Qualigens, India. 
Diphenylamine and ethanol were chemically pure. All other reagents/chemicals were 
of the highest analytical grade available. 
Equipments 
Shimadzu UV-1700 Spectrophotometer equipped with a thermo-programmer 
and controller unit, Spectrofluorometer (Shimadzu, RF-5301), Spectropolarimeter 
(Jasco J-815), ELISA microplate reader (Labsystem Multiskan EX, FINLAND), 
ELICO pH meter (LI-120), UV-transilluminator (Vilber Lourmat, France), Agarose 
and polyacrylamide gel electrophoresis assemblies (Genei, India), Avanti 30 table top 
high speed refrigerated centrifuge (Beckman, USA). Gel-doc (Bio-Rad laboratories. 
U.S.A), Agilent 1100 HPLC system (Palo Alto, California) and C-18 column 
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(Synergi, U.S.A), an orthogonal time of flight (TOF) mass spectrometer (Applied 
Biosystems, Mariner atmospheric pressure ionization TOF workstation, Framingham, 
MA, USA) equipped with Standard ESI source and LC-MS; Micromass Quattro II 
triple quadrupole mass spectrometer (Beverly, MA) coupled with HPLC were the 
major equipments used in this study. 
Collection of sera 
Fasting blood samples of diabetic patients, both type I and II were obtained 
from J.N. Medical College Hospital, A.M.U, Aligarh. None of the diabetic patients 
had other autoimmune diseases. Specifically, there were no cases of lupus or other 
connective tissue disorders. Normal human sera were obtained from healthy subjects. 
Samples were collected in a glass test tube and left to clot for 30 min at 37°C. Serum 
was separated by centrifugation at 3000 rpm for 10 min. Serum samples were heated 
at 56°C for 30 min to inactivate complement proteins and stored in aliquots at -20°C 
with 0.1% sodium azide as preservative. 
Methods 
Purification of human placental DNA 
Commercially available human placental DNA was purified free of proteins 
and single stranded regions (Ali et ai, 1985). DNA (2 mg/ml) was dissolved in 0.1 X 
SSC buffer, pH 7.3 and extracted with an equal volume of chloroform-isoamyl 
alcohol (24:1) in a stoppered container and shaken for 1 hr. The aqueous layer 
containing DNA was separated from organic layer and re-extracted with chloroform-
isoamyl alcohol mixture. DNA was precipitated with two volumes of chilled absolute 
ethanol and collected on a glass rod. After drying in air, the DNA was dissolved in 
acetate buffer (30 mM sodium acetate containing 30 mM zinc chloride, pH 5.0) and 
treated with nuclease 81 (150 units/mg DNA) at 37°C for 30 min to remove single 
stranded regions. The reaction was stopped by adding one-tenth volume of 200 mM 
EDTA, pH 8.0. Nucleases SI treated DNA was extracted twice with chloroform-
isoamyl alcohol and finally precipitated with two volumes of chilled ethanol The 
precipitate was dissolved in the required buffer. 
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Determination of DNA concentration 
DNA concentration was estimated colorimetricaily by the method of Burton 
(1956) using diphenylamine reagent. This assay depends upon a color reaction of 
deoxyribose. Exposure of DNA to strong acids removes the purine bases, leaving a 
polymer knovra as apurinic acid. With the release of purine, the exposed reactive 
aldehyde group of deoxyribose reacts with diphenylamine producing blue color, 
which serves as the basis for estimating DNA concentration. 
Crystallization of diphenylamine 
Diphenylamine (2g) was dissolved in 200 ml boiling hexane. After adding 
0.5g of activated charcoal the hot mixture was filtered through Whatman filter paper 
(No.l) and the filtrate was kept overnight at 4°C. The preparation was finally dried at 
room temperature before use. 
Preparation of diphenylamine regent 
To 750 mg of recrystallized dipenylamine was added 50 ml of glacial acetic 
acid followed by 0.75ml concentrated sulphuric acid. The regent was prepared fresh 
before use. 
Procedure 
Varying amounts of DNA in 1.0 ml of assay volume was mixed with 1.0 ml of 
IN perchloric acid and incubated at 70°C for 15 min. One hundred microlitre of 5.43 
mM acetaldehyde was added followed by 2.0 ml of freshly prepared diphenylamine 
reagent. The contents were mixed and incubated at room temperature for 16-20 hr for 
colour development. Absorbance was read at 600 nm and DNA concentration in 
unknown samples was determined from the standard plot of purified calf thymus 
DNA. 
Determination of protein concentration 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
2-* 
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Protein estimation by Folin's-Phenol reagent 
Protein estimation by this method utilizes alkaU (to keep the pH high), Cu 
ions (to chelate proteins) and tartarate (to keep the Cu^^ ions in solution at high pH). 
(a) FoUn-Ciocalteau reagent 
The Folin-Ciocalteau reagent was diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as under: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium-potassium tartarate. 
The working reagent was prepared fresh by mixing components (i) and (ii) in 
50:1 ratio. 
(c) Procedure 
Varying amounts of protein in 1.0 ml of volume was mixed with 5.0 ml of 
freshly prepared alkaline copper reagent and incubated at room temperature for 10 
min. One ml of working Folin-Ciocalteau reagent was added followed by 30 min 
incubation at room temperature. The absorbance was monitored at 660 nm. Protein 
content of unknown sample was determined from the standard plot of bovine serum 
albumin. 
Protein estimation by dye-binding method 
This assay is based on the change in absorption maxima of an acidic solution 
of Coomassie Brilliant Blue G-250 from 465 nm to 595 nm when protein binds to the 
dye. Both hydrophobic and ionic interactions stabilize the anionic form of the dye, 
causing a visible color change. 
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Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 
95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid added. The resulting 
solution was diluted to a final volume of 1 litre and filtered through whatman filter 
paper (No.l) to remove the undissolved particles. 
Protein assay 
To one ml of solutions containing 10-100 mg protein was added 5 ml of dye 
solution and contents were mixed by vortexing. The absorbance was read at 595 nm 
after 5 min against a reagent blank. 
Modification of human placental DNA by methylglyoxal (MG) and 
lysine in presence of Cu 
Human placental DNA was modified by methylglyoxal and lysine in the 
presence and absence of Cu^ "*" as described by Kang (2003) with slight modification. 
37.8 |iM of human DNA was thoroughly mixed with methylglyoxal (40 mM), lysine 
(40 mM) and Cu^ "^  (300 p.M) in 10 mM soditim phosphate buffer, pH 7.4 containing 
150 mM NaCl and incubated at 37°C for 24 hr. followed by extensive dialysis against 
PBS to remove unbound constituents. 
Spectroscopic analysis 
The ultraviolet absorption profile of native human placental DNA and 
modified DNA was recorded in the wavelength range of 200-400 nm on Shimadzu 
UV-1700 spectrophotometer. 
Fluorescence analysis 
Fluorescence emission profile of native human placental DNA and modified 
DNA were recorded on Shimadzu RF-5301 spectrofluorometer. Native and modified 
DNA were excited at 370 nm and emission profile was recorded at 450 nm. 
Circular dichroism measurements 
Circular dichroism (CD) profile of native human placental DN A and modified 
human placental DNA were recorded on spectropolarimeter (Jasco J-815) in a 1 cm 
path length cell at 25°C. The wavelength range was from 220 nm to 400 nm and all 
the scans were recorded at an interval of 0.2 nm. The base line was corrected with 
PBS, pH 7.4 and the DNA was used at 37.8 |im concentration. Molar ellipticities [9 ] 
were calculated in terms of base pair concentration according to the following 
equation: 
[e]= ' lOcd 
where, [0] represents measured ellipticity in mdeg, 'c ' is the molar concentration of 
human placental DNA per base pair and 'd' is the path length. 
Thermal denaturation studies 
Thermal denaturation analysis of DNA was performed to ascertain the thermal 
stability of DNA constituent to modification. Mid point melting temperature (Tm), of 
native and modified DNA samples was determined by subjecting them to heat 
denaturation on Shimadzu UV-1700 Spectrophotometer equipped with a thermo-
programmer and controller unit (Habeeb et ai, 2005). All the samples were melted 
fi-om 30°C to 95°C at a rate of 1.0 °C/min. The change in absorbance at 260 nm was 
recorded with increasing temperature. 
Percent denattiration was calculated as per the following equation: 
A - A Percent denaturation = — ^ x 100 
A - A 
Where, AT = Absorbance at a temperature T°C. 
Amax =" Filial maximum absorbance on the completion of 
denaturation (95 °C). 
A30 = Initial absorbance at 30°C. 
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Measurement of superoxide anion 
The generation of O2' in the reaction mixture was determined by cytochrome-
c reduction assay (Beauchamp and Fridovich, 1971). A reaction mixture contained 
MG (40 mM) and lysine (40 mM) and 100 )iM cytochrome C in 10 mM phosphate 
buffer (pH 7.4). The reduction rate was determined as the increase in absorbance at 
550 nm for 10 min at room temperature. Absorbance was taken at the interval of 
every one min. 
Measurement of hydroxy! radical 
Detection of hydroxyl radicals was carried out by measuring thiobarbituric 
acid (TBA) reactive 2-deoxy-D-ribose oxidation products (Halliwell and Gutteridge. 
1981). Reaction mixtures containing 40 mM MG, 40 mM lysine in the presence and 
absence of 300 pM Cu^ "" were incubated at 37°C for 24 hr. The degradation of 2-
deoxy-D-ribose was measured by adding 1 mL of 2.8% (w/v) trichloroacetic acid, 1 
mL of 1% (w/v) thiobarbituric acid followed by heating at 100°C for 10 min. After 
cooling the absorbance was read at 532 nm. Because a generation of TBARS could be 
induced by the reaction of MG with lysine in absence of deoxyribose, the reaction 
mixture containing MG and lysine was used as the blank. 
Detection of strand breaks 
The strand breaks generated as a result of modification of human placental 
DNA by MG, Lys and Cu^ "^  were detected by nuclease SI digestibility assay. 
Gel preparation 
Agarose 0.8% in TAE buffer (40mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50 °C and then 
poured into the gel tray and allowed to solidify at room temperature. 
Agarose gel electrophoresis 
Native and modified human placental DNA were mixed with 1/10 volume of 
sample buffer (0.125% bromophenol blue, 30% Ficoll-400, 5 mM EDTA in 10 X 
44 
electrophoresis buffer) and loaded in the wells of 0.8% agarose gels. Electrophoresis 
was done for 2 hr at 40 mA and the gels were stained with ethidium bromide (0.5 
|j,g/ml), and viewed under UV light. 
Nuclease SI digestibility 
Native human placental DNA and the modified analogue were characterized 
by nuclease SI digestibility assay (Matsuo and Ross, 1987). One [ag each of native 
DNA and the modified DNA in acetate buffer (30 mM sodium acetate, 1 mM zinc 
sulphate, 100 mM sodium chloride, pH 4.6) were treated with nuclease SI (20 unit/|ig 
of DNA) for 30 min at 37°C. The reaction was stopped by adding one tenth volume 
of 200 mM EDTA, pH 8.0. The samples were subjected to agarose gel electrophoresis 
and viewed by illumination under UV light after ethidium bromide (0.5 \iglm\) 
staining. 
Synthesis of the standard, carboxyethyl deoxy guanosine (CEdG) 
The synthesis of CEdG was carried out as described by Seidel and 
Pischetsrieder, (1998) with slight modifications. Briefly, 50 mg of deoxy-guanosine 
suspended in 1ml of 100 mM phosphate buffer (pH, 7.4), was incubated with 100 mg 
of dihydroxyacetone at 70°C in a shaking water bath. It got dissolved at 70°C in the 
course of reaction after 24 hr. CEdG was isolated by preparative HPLC using 50 mM 
ammonium acetate buffer solution and methanol as eluents. 
'H N M R of the standard CEdG 
' H NMR spectra were recorded on a Bruker DRX-300 MHz FT NMR 
spectrometer. AH samples of NMR spectroscopy were first lyophilized and prepared 
using DMSO as a soluent. The chemical shifts in parts per million (ppm) are 
expressed with respect to tetra methyl silane (TMS) as a reference. 
Detection of a glycated product, CEdG in modified human placental 
DNA by HPLC and LC-MS 
An Agilent 1100 capillary HPLC System equipped with a Synergi Cig 
analytical column was used for HPLC analysis of native and modified analogue of 
human placental DNA. General chromatographic conditions were as follows: 
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Ci8 column (2 mm x 150 mm with 4 |am particle size); eluent A, 5 mM aqueous 
ammonium acetate buffer, pH 7; eluent B, Acetonitrile (CH3N) gradient solution- the 
CH3N concentration was raised from 0 to 4.0% in the first 5 min; from 4.0 to 6.5% 
over 30 min; held at 6.5% for 5 min, and then raised to 90% to wash residual material 
off the column at a constant flow rate of 500 ^L/min. DNA bases were detected by 
DAD at 254 nm, their absorption maximum. LC- MS analyses of CEdG standard 
were carried out using a Micromass Quattro Ultima Triple Quadrupole Mass 
Spectrometer interfaced to an Agilent 1100 capillary HPLC system. 
Characterization of DNA-AGEs by electrospray ionization mass 
spectrometry 
An orthogonal time of flight (TOP) mass spectrometer (Applied Biosystems 
Mariner Atmospheric Pressure Ionization TOP Workstation, Pramingham, MA, USA) 
equipped with standard electrospray ionization source was used. The mass spectral 
data were collected at positive ion polarity. Nitrogen was used as the nebulizer, heater 
and collision gas. The sciex heater was set to 350°C and the spray tip potential was set 
at 4,000 V. The instrument was outfitted with an integrated syringe pump with a dual 
syringe rack for direct infusion onto the mass spectrometer. The mass spectrometry 
system was operated on full scan mode (m/z 100-1000). Spectral acquisition was 
performed every 2 s and a total of ten spectra were accumulated. The final spectrum 
depicts an average of 4-6 scans. 
Quenching studies 
Quenching studies were preformed to ascertain the type of radical causing 
damage to the human placental DNA. The effect of various quenchers like catalase 
(50 units/ml), superoxide dismutase (SOD, 600 imits/ml), hydroxyl radical scavengers 
(D-mannitol 50 mM each), nitric oxide trapping agent (Carboxy-PTIO at 25 mM), 
antioxidants (uric acid at 0.1 mM) and metal ion chelator (EDTA at 20 mM) on 
human placental DNA modification were studied by incubating DNA 25 ixg/m\ in 10 
mM sodium phosphate buffer, pH 7.4 containing MG (40 mM), lysine (40 mM) and 
Cu (300 ixm) at 37°C for 24 hr. Percent quenching was calculated from absorbance 
at A260 nm. 
« 
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AGE inhibition study 
AGE inhibition was performed using a carbonyl trapping compound, D-
Penicillamine (1 mM) and pyridoxal phosphate (10 mM) on human placental DNA. 
The modifications were studied by incubating DNA 25 ng/ml in 10 mM sodium 
phosphate buffer, pH 7.4 containing MG (40 mM), lysine (40 mM) and Cu^ "^  (300 
IxM) at 37°C for 24 hr. Percent DNA quenching was calculated from absorbance at 
A26onm. AGE inhibition was further confirmed from absorbance at A330 nm. 
Genotoxicity of advanced glycation endproducts by single cell gel 
electrophoresis (SCGE); comet assay 
Lymphocyte isolation 
Blood was obtained from a healthy male volunteer (myself). Lymphocytes 
were separated from heparinised whole blood. Briefly, 3 ml of blood was drawn 
through venous puncture and added to 3 ml of PBS and layered over 2 ml of 
histopaque 1077 and centrifiiged at 800 X g for 2 min. The visible 'buffy' coat was 
aspirated into 3-5 ml of PBS and centrifuged at 250 X g for 10 min to pellet the 
lymphocytes. The pellet was resuspended in 1 ml of RPMI media and counted over a 
Haemocytometer. Approximately 10,000 cells per 100 )il of medium are taken for 
each dose of the test material. 
Alkaline comet assay 
Comet assay was performed with human lymphocytes following the method of 
Singh et al. (1998) with slight modification. Freshly isolated cells were treated with 
Lysine (40 mM) only, MG (40 mM) only, and in combination of MG + Lysine (40 
mM each) and MG + Lysine (40 mM each) + Cu^ "" (300 ^M) for 24 hours at 37"C. 
Untreated lymphocytes served as control. The lymphocytes ~ 10,000 cells, both treated 
and untreated, were suspended in 100 \i\ of Ca^ "^  and Mg^ '*' free Dulbecco's PBS (1 L 
packet: add 990 mL dH20, adjust pH to 7.4 and make up to 1 L) and mixed with 100 
i^l of 1% LMP agarose. The cell suspension (80 \i\) was then layered on one third 
frosted slides, pre-coated with 1% normal agarose and kept at 4°C for 10 min. After 
gelling, a layer of 90 ^1 of 0.5% LMP agarose was added. The cells were then 
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lysed in a lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Trizma base, pH 10.0 
containing 1% Triton X-100) for overnight. After washing with MQ water, the slides 
were subjected to DNA denaturation in cold electrophoretic buffer (300 mM NaOH/ 1 
mM EDTA, pH 10.0) at 4°C for 20 min. Electrophoresis was performed at 300 mA. 
24 V (0.74 V/cm) at 4°C. The slides were then washed three times with neutralization 
buffer (0.4 M Tris, pH 7.5). All preparative steps were conducted in dark to prevent 
secondary DNA damage. The slides were stained with ethidium bromide (10 )ig/ml) 
for 5 min and covered with coverslip. 
Analysis of cells 
A total of 50 cells from each slide were selected randomly and analyzed by 
image analysis using Komet 5 image analysis software developed by Kinetic Imaging. 
Ltd. Liverpool, UK. Observations were made at 400 X magnifications using an 
epifluorescent microscope linked to a CCD camera to assess the quantitative and 
qualitative extent of DNA damage in the cells by measuring the length of DNA 
migration and the percent DNA in tail. Therefore, percentage of tail DNA represents 
the average of total 50 individual cells. The three independent readings for each 
sample were averaged fVirther to arrive at a final value for each sample. The mean 
value of all the 5 samples was averaged to get the average for each treatment as well 
as control also. 
Isolation of DNA from lymphocytes 
Human DNA was isolated from lymphocytes of normal and diabetic patients 
as described by Ashok and AH (1998). The lymphocytes were lysed by lysis buffer 
(10 mM Tris, 2 mM EDTA, 400 mM NaCl, containing 1% SDS and Img/ml 
proteinase K, pH 7.4) 
Procedure 
The lymphocytes were resuspended in lymphocyte lysis buffer, incubated at 
50°C for 1 hr and overnight at 37 °C with constant shaking. Equal volume of 
chloroform-isoamyl alcohol (24:1) was added and the sample extracted for 15 min 
and left to stand for 30 min. The aqueous layer was removed carefully and the 
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extraction step was repeated 2-3 times. To the aqueous layer was added one-tenth 
volume of 3 N sodium acetate, pH 5.2 and 2 volumes of cold absolute ethanol to 
precipitate DNA. The DNA was collected by centrifugation, washed once with 70% 
ethanol, allowed to dry and subsequently dissolved in PBS, pH 7.4. Absorbance of 
DNA solution was monitored at 260 nm and 280 nm to ascertain its purity and 
concentration. 
Immunization schedule 
Female rabbits weighing 1- 1.5 Kg were immunized in duplicates with native 
and modified human placental DNA (50 [ig each) respectively. DNA samples were 
complexed with equal amount of methylated BSA in 1:1 ratio (w/w) emulsified with 
an equal volume of Freund's complete adjuvant and injected intramuscularly at 
multiple sites of the animal. Booster injections were given in Freund's incomplete 
adjuvant at weekly intervals. During the course of immunization, each animal 
received 350 |ig antigen. Seven days post boost test bleeds were used to find out the 
titre of induced antibodies. Marginal ear vein of immunized animals was punctured 
and blood was carefully collected to prevent hemolysis. Serum was separated and 
complement proteins were inactivated by heating at 56°C for 30 min. Pre-immune 
blood was collected prior to immunization. The sera were stored in small aliquots at -
20°C with 0.1% sodium azide as preservative. 
Isolation of IgG on protein A-agarose 
Serum IgG was isolated by affinity chromatography on Protein A-agarose 
affinity column. Serum (0.5ml) diluted with equal volume of PBS, pH 7.4 was applied 
to column (12 mm x 45 mm) equilibrated with the same buffer. The wash through 
was recycled 2-3 times. Unbound IgG was removed by extensive washing with PBS, 
pH 7.4. The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride 
(Goding, 1976) and neutralized with 1 ml of IM Tris-HCl, pH 8.5. Three ml fractions 
were collected and read at 251 and 278 nm. IgG concentration was determined 
considering 1.40 OD28o= 1.0 mg mammalian IgG/ml. 
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SDS-Polyacryiamide gel electrophoresis 
The homogeneity of purified IgG was ascertained by polyacrylamide gel 
electriphoresis under non-reducing conditions (Laemmli, 1970). Tlie following stock 
solutions were prepared. 
Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
of bisacrylamide in distilled water to a final volume of 100 ml. The solution was 
filtered and stored at 4°C in an amber colored bottle. 
Resolving gel buffer 
A stock solution was prepared by dissolving 36 gm Tris base in 48 ml of 1.0 N 
HCI, pH was adjusted to 8.8 and the final volume brought to 100 ml with distilled 
water. 
Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH was adjusted to 8.3 and volume adjusted to one litre. 
Procedure of PAGE 
Glass plates separated by 1.5 mm thick spacer were sealed with 1% agar6se 
from sides and bottom. The non-reducing gel was prepared, poured between the glass 
plates and allowed to polymerize at room temperature. 
Protein sample (IgG) was mixed with one-fourth volume of sample buffer 
(10% glycerol and 0.002% bromophenol blue in 10 times concentrated 0.5 M Tris-
HCl, pH 6.8) and loaded into the well for electrophoresis at 70 voks for 4 hr in Tris-
glycine buffer. The gels were stained with silver nitrate, which involved fixing the 
protein bands for 10 min in a mixture of 40% methanol and 13.5% formaldehyde 
followed by 2x washing with distilled water, at an interval of 5 min. Then the gel was 
immersed in 0.02% sodium thiosulphate solution for 1 min followed by two washings 
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with distilled water at an interval of 20 sec. The gel was immersed in 0.1% silver 
nitrate solution for 10 min and finally washed with distilled water. 
The gel was then immersed in the developer (3% sodium carbonate. 2% 
sodium dithiosulphate and 0.05% formaldehyde) to facilitate staining and on 
appearance of visible bands, the reaction was stopped by a stopper solution (10% 
acetic acid and 10 % methanol). 
Recipe for 7.5% SDS-PAGE 
Solution 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10%SDS 
1.5% ammonium persulphate 
TEMED 
Stacking Gel 
1.25 ml 
2.5 ml 
-
5.65 ml 
0.1ml 
0.5 ml 
0.75 1^ 
Resolving gel 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15^ 11 
Immunological detection of antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and 
gel retardation assay. 
Enzyme linked immunosorbent assay 
Following reagents were prepared and used in ELISA, 
Tris buffered saline (TBS): 10 mM Iris, 150 mM NaCl, pH 7.4. 
Tris buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM NaCl, 
2.68 mM KCl, pH 7.4 containing 500 ^L Tween 20 per litre. 
Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodi 
bicarbonate, pH 9.6 containing 2 mM magnesium chloride. 
um 
Substrate: 500 ^g p-nitrophenyl phosphate (PNPP) per ml of carbonate-bicarbonate 
buffer, pH 9.6. 
51 
Procedure 
ELISA was carried out on flat bottom polystyrene plates as described earlier 
(Ali and Alam, 2002). Briefly, microtitre wells were coated with one hundred 
microlitre of 2.5 |ag/ml of DNA (in TBS, pH 7.4) and incubated for 2 hr at 37°C and 
overnight at 4°C. Each sample was coated in duplicate and half of the plate, devoid of 
antigen, served as control. The test-plate wells were emptied and washed thrice with 
TBS-T to remove the unbound antigen. Unoccupied sites were blocked with 150 |LI1 of 
1.5 % non-fat dry milk (in TBS, pH 7.4) for 4-5 hr at 4°C followed by single wash 
with TBS-T. In direct binding ELISA, antibodies were directly added into antigen-
coated wells and incubated for 2 hr at 37°C and overnight at 4°C respectively. The 
wells were emptied and extensively washed with TBS-T. Anti-immunoglobuUn G 
alkaline phosphatase conjugate was added to each well and incubated at 37'^ C for 2 hr 
and then the plates were washed thrice with TBS-T followed by a single wash with 
distilled water. Para-nitrophenyl phosphate was added and the developed color was 
read at 410 rmi on a microplate reader. The results were expressed as mean of 
difference of absorbance values in test and control wells (Atest - Acomroi)-
Competition ELISA 
The specific binding characteristics of antibodies were ascertained in 
competitive binding assay. Varying amounts of inhibitors (0-20 \xglm\) were mixed 
with constant amount of antiserum or IgG. The mixture was incubated at room 
temperatvire for 2 hr and overnight at 4°C. Immune complex thus formed was coated 
in the wells instead of the serum. The remaining steps were the same as in direct 
binding ELISA. 
Percent inhibition was calculated using the formula: 
Percent inhibition = I '"'""^ x 100 
"uninhibited 
Gel retardation assay 
Antigen-antibody specificity was further confirmed by the gel retardation 
assay. A constant amount of DNA antigen (1 jag) was mixed with varying amounts of 
IgG (Habeeb et al., 2005) and incubated for 2 hr at 37°C and overnight at 4°C. At the 
end of incubation, one-tenth volume of sample buffer was added to antigen-antibody 
complex and electrophoresed on 1% agarose gel in TAE buffer (pH 7.9) for 2 hr at 30 
mA current. The gels were stained with ethidium bromide (0.5 mg/ml) and visualized 
under UV light and photographed. 
J* 
I J 
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Ultraviolet absorption spectral studies of native and MG-Lys-Cu'^ 
glycated human DNA 
Pilot experiments were undertaken to work out the time of incubation and 
optimum concentration of MG, lysine and Cu^"*" needed to modify the DNA. Human 
DNA (37.8 \xM) was incubated with MG, lysine and Cu^ "" along with respective 
controls for different time intervals (3, 6, 12 and 24 hr) at 37 "C. Maximum 
hyperchromicity at 260 nm was obtained at 24 hr incubation mixture and further 
incubation did not result in any change in the hyperchromicity. Therefore, for further 
characterization, human DNA was incubated for 24 hr with 40 mM each of 
methylglyoxal and lysine in presence and absence of copper sulphate (Cu . 300|iM) 
in phosphate buffer saline was used. Native and modified DNA samples were 
subjected to UV- spectroscopical analysis on UV-1700 spectrophotometer. A 
characteristic peak at 260 nm was observed with native DNA (Fig. 3). However, upon 
modification with methylglyoxal + lysine (in absence of Cu^^  ions), 68% 
hyperchromicity was observed in comparison to native human DNA. While DNA 
modified with methylglyoxal + lysine (in presence of Cu^ "^ ) exhibited further increase 
in hyperchromicity, which was 76% above that of native DNA. Furthermore, a new 
peak, more of a shoulder, appeared at 330 nm in the modified samples. This might be 
due to glycated nitrogenous bases of DNA. The controls, Cu , lysine, lysine + Cu , 
MG, and MG + Cu^ "^  treated DNA did not show appreciable hyperchromicity under 
similar conditions. 
Agarose gel electrophoresis of native and MG-Lys-Cu^^ glycated 
human DNA 
Electrophoresis of native and modified DNA was performed on 0.8% 
agarose gel. The gel pattern (Fig. 4) shows an increase in the mobility of glycated 
DNA with increasing incubation time (lanes 2- 5). Maximum mobility was observed 
at 24 hr incubation, and further incubation did not have any consequential effect on 
DNA migration pattern. The increase in mobility may be due to the generation of 
single stranded breaks by glycation induced intermediates which may cause the 
fonmation of small size DNA having faster mobility compared to native DNA of lane 
1. 
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210 260 310 360 
Wavelength (nm) 
410 
Fig. 3 Ultraviolet absorption spectra of native human DNA (—); human DNA 
modified with 300 nM Cu^ ^ (-); 40 mM lysine ( ); 40 mM lysine + 300 
... * -^.2+ ( ). 40 mM MG (-); 40 mM MG + 300 i^M Cu^ "" (-); 40 ra" ' 
.2+ MG + 40 mM lysine (-) and 40 mM MG + 40 mM lysine + 300 ^ Cu 
' ^ ^ ^ ^ ^ k *^ - " --^-^t? 55 
^tiaa Un\rt^ 
Fig. 4 Agarose gel electrophoresis of native and modified human DNA. DNA 
samples from lane 2-5 are treated with MG-lysine (40 mM each) and Cu^^ 
(300 ^iM). 
Lane 1: Native human DNA. 
Lane 2: Modified human DNA with 3 hr. incubation. 
Lane 3: Modified human DNA with 6 hr. incubation. 
Lane 4: Modified human DNA with 12 hr. incubation. 
Lane 5: Modified human DNA with 24 hr. incubation. 
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Fluorescence studies of native and MG-Lys-Cu glycated human 
DNA 
Generation of fluorogenic AGEs in glycated-DNA samples was measured 
using excitation wavelength of 370 nm (A^ x) and emission wavelength of 450 nm (A^ nO 
(Table 4). This is a characteristic excitation and emission wavelength of AGEs 
fluorophor. Under identical conditions, native human DNA alone does not give any 
fluorescence. Glycation of DNA by methylglyoxal and lysine in the presence copper 
sulphate generated fluorescent DNA-AGEs characterized by emission maxima of 450 
nm. An increase of 76.2% of fluorescence intensity was observed in glycated DNA 
when compared to native form (Fig. 5). 
Circular dichroism of native and MG-Lys-Cu^* glycated human DNA 
Circular dichroism is used for elucidating conformational changes in 
biomacromolecules, which measures differential absorption of right and left circularly 
polarized light. The CD spectra of nucleic acids resuh primarily due to the spatial 
asymmetry of the constituent nucleotides. The CD profile of human DNA (37.8 ).iM), 
was recorded at a wavelength range of 220 - 400 nm Vv'hich exhibited a negative peak 
at 243 nm, and a positive peak at 275 nm. (Fig. 6). Structural changes in DNA were 
evaluated by ellipticity measurements. The CD signal of modified analogue shifted 
from 275 to 278 nm in the direction of higher wavelength, which is indicative of 
structural changes in DNA. When native DNA was compared with the modified 
DNA, it showed an increase in ellipticity from 6.64 to 8.47 mdeg at 275 nm. This 
increase in ellipticity corresponds to 27.56 % structural loss in modified DNA. The 
structural loss in DNA after modification might be due to unstacking of bases as a 
result of helix destabilization. 
Genotoxicity of advanced glycation end-products in human 
lymphocytes by single cell gel electrophoresis (comet assay) 
The photographs of comets seen on treatment of lymphocytes with different 
combinations of MG (40 mM), lysine (40 mM) and Cu^ "^  (300 |^ M) are shown in 
Fig. 7. A comet with a tail is indicative of DNA breakage in single cell gel 
electrophoresis. The results clearly establish that MG in combination with lysine 
is capable of DNA breakage in lymphocytes as evident from the formation of distinct 
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TABLE 4 
Fluorescence characteristics of native and modified human DNA 
Parameter Native DNA Modified DNA 
Fluorescent intensity (If) 13.6 44.14 
Wavelength for max If 426 450 
Stokes shift (nm) - 24 
Ratio of quantum efficiency 3.25 1 
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n I I 
380 400 420 440 460 
Wavelength (nm) 
480 500 
Fig. 5 Fluorescence emission spectra of native human DNA (—) and modified 
-..2+ human DNA with 40 mM MG + 40 mM lysine + 300 ^M Cu^ (—-). 
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Wavelength (nm) 
Fig. 6 Circular dichroic spectra of native human DNA (—) and modified human 
DNA with 40 mM MG + 40 mM lysine + 300 ^M Cu^ * (—-). 
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(D) 
Fig. 7 Single cell gel electrophoresis of human lymphocytes showing comets after 
treatment with MG or lysine and Cu^ ,^ (A) untreated, (B) treated with 40 
mM lysine, (C) with 40 mM MG, (D) with 40 mM MG + 40 mM lysine 
and (E) with 40 mM MG + 40 lysine + 300 .^M Cu. All the lymphocytes 
were treated for 24 hour at 37 °C. 
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tail from the diffused head. However, in the presence of Cu^^ the damage of 
lymphocyte DNA was found to be enhanced by 36% (Fig. 7 E). This suggests that 
Cu^ "" has enhanced the genotoxicity of MG+Lys system by increasing free radical 
(O2" and *0H) generation. Furthermore, MG and lysine alone did not cause a 
significant damage to the lymphocyte DNA. 
The DNA damage parameters i.e. olive tail moment (OTM), mean 
percentage of tail DNA and tail length were also measured (Figs. 8-10) and found to 
be significantly increased in MG-Lys-Cu^"^ system as compared to MG-Lys system. 
A marked increase in OTM (316%) and mean percentage of tail DNA (246%) was 
observed in MG-Lys-Cu^"^ treated lymphocytic cells \vhen compared to control 
(imtreated lymphocytes). Furthermore, there was a pronounced increase in tail length, 
which was found to be 92% as compared to control. 
Nuclease SI digestibility of native and MG-Lys-Cu^^ glycated human 
DNA 
Native and modified DNA were digested with nuclease SI (20 units/mg 
DNA) for 30 minutes and electrophoresed on 0.8% agai'ose to visualize the generation 
of single strand breaks. The controls were native and modified DNA samples, 
untreated with nuclease S1. Modified DNA showed decrease in fluorescence intensity 
following nuclease SI digestion. On the other hand nuclease SI treated and untreated 
native DNA showed almost identical electrophoretic migration pattern and 
fluorescence intensity (Fig. 11) .These observations clearly demonstrate that sufficient 
distortions (formation of single strand breaks) are caused in the helical structure of 
DNA by MG-Lys-Cu^"^ treatment, rendering it susceptible to digestion by single 
strand specific nuclease SI. 
Thermal denaturation of native and MG-Lys-Cu^^ glycated human 
DNA 
Thermally induced transitions were measured spectrophotometrically at 260 
nm by heating nucleic acid samples at a rate of 1 °C/ minute. Melting profile of 
modified and unmodified human DNA were analysed in the temperature range of 
30 C to 95 C. Increase in absorbance at 260 nm was taken as a measure of 
helix denaturation. The process was characterized by determining the percent DNA in 
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Fig. 9 DNA damage (% DNA in tail) in the comet assay in peripheral lymphocytes 
after treatment with lysine (40 mM), MG (40 mM), MG + lysine (40 mM 
each) and MG + lysine (40 mM each) + Cu^* (300 ^M). 
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Fig. 10 DNA damage (Tail length, |^ m) in the comet assay in peripheral 
lymphocytes after treatment with 40 mM of lysine; 40 mM of MG; MG + 
lysine (40 mM each) and MG + lysine (40 mM each) + Cu^ "" (300 ^iM). 
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Fig. 11 Nuclease SI digestibility of native and modified DNA. Lane 1 contains 
native DNA, while Lane 2 contains native DNA treated with nuclease SI 
for 30 min; Lane 3 contains modified DNA and Lane 4 contains modified 
DNA treated with nuclease SI for 30 min. Electrophoresis was carried out 
on 0.8% agarose gel for 2 hr at 30 mA. 
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denatured state as a function of temperature. The melting temperature, T,„. of native 
DNA was found to be 86 °C, while in case of modified DNA it was recorded at 76 ^^ C. 
which shows a significant decrease in the Tm value of modified DNA as compared to 
its unmodified native form (Fig. 12). A decrease of 10 °C in the T,,, value in case of 
modified human DNA point towards alterations in the DNA molecule as a result of 
modification that may be unstabilizing the helix. Generation of strand breaks and base 
modifications cause altered hydrogen bonding between base pairs, resulting in 
thermal susceptibility of the DNA molecule. Moreover, the melting curve for 
modified DNA indicated a progressive and heterogeneous local melting with the 
increase in temperature as compared to more homogenous global melting in the 
control. Early onset of melting in the case of modified DNA is a definite indication of 
structural instability consequent to modification. The thermal denaturation 
characteristics of native and modified DNA are listed in Table 5. 
Quenching studies 
The modification of human DNA in the present study is a result of production 
of 'OH and 02*". Its in vitro generation was confirmed by the use of different 
quenchers of various radicals. Quenchers like SOD, mannitol, EDTA and catalase 
were exploited to study their quenching effect on MG-Lys-Cu^^ modified human 
DNA. As evident from the figure 13, the hydroxyl radical (*0H) trapping agent 
(mannitol) and superoxide radical (Oa'") trapping agent (SOD) strongly inhibited 
(82.6% and 78.3%, respectively) the modification by MG-Lys-Cu^^ system, thereby 
indicating the involvement of these radicals. Whereas EDTA showed marked 
inhibition of 69%. Moreover, uric acid, an antioxidant inhibited DNA modification to 
the extent of 46%. 
Quantitation of hydroxyl radical in MG-Lys-Cu system 
The generation of hydroxyl radicals in the MG-Lys-Cu^* system was 
measured with thiobarbituric acid-reactive substance (TEARS). The incubation of 2-
deoxy-D-ribose with lysine and MG produced 13 nmol TBARS mf' (Fig. 14). 
However, reaction of MG with lysine in the presence of Cu^ "^  enhanced it to 24 nmol 
TBARS ml"'. Radical scavengers like mannitol, catalase and a metal ion chelator, 
desferrioxamine significantly inhibited the production of TBARS (Fig. 15). TBARS 
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100 
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Fig. 12 Thermal melting profile of native human DNA (n) and modified human 
DNA (•). 
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TABLE 5 
Ultraviolet and thermal denaturation characteristics of native and 
modified human DNA 
Parameter Native DNA Modified DNA 
Absorbance ratio (A260/A280) 1-76 1.4 
Hyperchromicity at 95 °(%) 36.5 24 
Melting temperature (Tm), °C 86 76 
Onset of duplex melting, "C 72 36 
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Fig. 13 Effect of various scavengers of free radical (mannitol, SOD), metal ion 
chelator (EDTA) and antioxidant (uric acid) on human DNA 
modification induced by MG-Lys-Cu^ "" system. 
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Fig. 14 Generation of hydroxyl radicals during the glycation reaction of lysine with 
MG in the presence of Cu^ "^ . The reaction mixtures contained 100 mM 2-
deoxy-D-ribose in 10 mM phosphate buffer at pH 7.4 and the following: 
40niM MG, 40mM lysine, 300|aM Cu^"*" with their different controls as 
depicted in diagram. Data represent the means ± S.D. (n=4). 
71 
40 
26 
f 20 
0 
Sis 
(0 
a: 
5 J 
0 
-1 
' 1 lii" *• 
• 
h 1-' 1 
1 
"5 h " 
s li 1 1 1 
••r . , „ ; • • ' 
• •I 1 1 
I 
'!" . 
T 
i 
II hi i 1 
T 
i 
, 
T 
__J 
- 1 
KO" 
•^ 
vO ^ ^ 
/ 
«P^ A 
. ^ 
Fig. 15 The reaction mixtures contained 100 mM 2-deoxy-D-ribose along with 40 
mM each of MG and lysine and 300 t^M Cu'" in the presence of radical 
scavenger, mannitol (50 mM), catalase (CAT) (2mg/ml) and a metal ion 
chelator, Desferrioxamine (DFXA) (lOmM). Data represent the means + 
S.D. (n=4). 
72 
generation was inhibited upto 71.7% when mannitol was used as scavenger. However, 
both catalase and DFXA inhibited TBARS equally, which was found to be almost 
67%. The result suggests that the MG-mediated hydroxyl radical generation may be 
caused by traces of transition metals. Furthermore, it is also being suggested that the 
redox reactions of copper may facilitate the generation of hydroxyl radical by reaction 
of MG and lysine. 
Quantitation of superoxide anion in MG-Lys system 
Superoxide generation was quantitated by cytochrome c reduction experiment. During 
incubation of MG with lysine, the formation of superoxide anion was gradually 
increased in time dependent manner. The incubation of MG (40 mM) with lysine (40 
mM) produced 28.2 nmol 02"" ml'' h"' compared to 2.46 nmol O2'" ml" ' h"' with MG 
(40 mM) alone and 1.96 nmol O2" ml"' h"' with lysine (40 mM) alone (Fig. 16). 
Superoxide dismutase (SOD) inhibited the superoxide radical generation. As evident 
from figure 17, on increasing concentration of SOD, the superoxide generation was 
gradually decreased. 
Anti-glycation study 
Anti-glycating agent D-penicillamine (1 mM) and pyridoxal phosphate 
(PLP) (10 mM) showed remarkable inhibition of 55% and 73% respectively in DNA 
modification as analyzed at 260 nm. However, at 330 nm D-penicillamine and PLP 
showed still higher inhibition of 69%) and 85%> respectively (Fig. 18). The enhanced 
inhibition at 330 nm is due to the formation of AGEs at this wavelength range (330-
360 nm) (Schmitt et al., 2005). This clearly indicates the formation of AGEs in the 
MG-Lys-Cu^^ modified human DNA. 
Synthesis and characterization of N^-(l-Carboxyethyl)-2-
deoxyguanosine (CEdG) 
Synthesis of the standard, CEdG was performed as described by (Seidel and 
Pischetsrieder, 1998) with slight modifications. After final preparation, CEdG was 
isolated by preparative HPLC using 50 mM ammonium acetate buffer solution and 
methanol as eluents. The elution of CEdG was obtained at a retention time of 14.399 
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Fig. 16 Generation of the superoxide anion in the glycation reaction of lysine with 
MG. Reduction of cytochrome c was measured by increasing 
concentrations of reaction products. The reaction mixture contained 10 |iM 
cytochrome c in 10 mM phosphate buffer at pH 7.4 and the following: 40 
mM MG (n); 40 mM lysine (•); 40 mM MG and lysine (A). The 
absorbance changes were monitored at 550 nm for 10 min at room 
temperature. 
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MG+Lys SOD(1) SOD (2) SOD (3) 
Fig. 17 Superoxide formation during the glycation reaction of lysine by MG. MG 
(40 mM) and lysine (40 mM) was reacted in presence of various 
concentrations of superoxide dismutase, 50 units (1), 100 units (2) and 500 
units (3). 
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Fig. 18 Effect of antiglycating agent D-Penicillamine (] mM) and ovridoxal 
phosphate (10 mM) on the modification of DNA induced by M S Ly -
Cu system. Percent DNA modification was calculated at 260 nm and 
330 nm after 24 hr incubation. 
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min when UV detector was used for the experiment. However, deoxyguanosine (dG) 
gave elution at a retention time of 9.1 min (Fig. 19). 
Nuclear magnetic resonance of CEdG 
For structural assignment of the compound, the CEdG peak was isolated by 
HPLC and then subjected to ' H N M R analysis. Resonance signals can be identified 
and characterized in ' H NMR spectrum of CEdG (Fig. 20), recorded in DMS0-d6. 
' H NMR (400MHz, DMS0-d6, 20 °C) assignment for CEdG: 6 10.6 (s,lH. Nl-H), 
6 7.93 (s, IH, C8-H), 6 6.76 (d, IH, C2-NH), 5 6.12 (dd, IH, Cl'-H), 6 5.3 (d, IH, 
C3'-0H), 5 4.89 (s, IH, C5'-0H), 5 4.36 (m, IH, C2-NH-CH.), 5 4.18 (q, IH, C2-NH-
CH), 6 3.81 (m, 1H,C3'-H), 6 3.5 (ddd, 2H, CS'-Ha), 5 2.64 (ddd, IH. C2'-H), 5 1.39 
(d, 3H, C2-NH-CH-CH3). 
The ' H NMR analysis indicated a -CHX-CH3 group bound to the purine 
(guanine) ring. The chemical shifts (6), 4.18 ppm (q, IH, C2-NH-CH) and 1.39 ppm 
(d, 3H, C2-NH-CH-CH3) respectively, is attributed to the carboxyethyl group of the 
standard carboxyethyl-deoxyguanosine (CEdG). 
Characterization of native and MG-Lys-Cu^^ glycated human DNA 
by HPLC 
Figures 21 and 22 show the representative HPLC chromatograms of acid 
hydrolysed samples of native and modified human DNA respectively. Well defined 
peaks at retention time 4.467 min, 7.332 min, 8.727 min were observed in native 
DNA. However, in the case of modified DNA these peaks shifted to 6.748 min, 8.455 
min and 12.399 min respectively, suggesting considerable change in the DNA bases. 
The extra peak at a retention time of 14.249 min in the acid hydrolysate of modified 
DNA is characteristic of N^-(l-Carboxyethyl)-2-deoxyguanosine (CEdG) adduct. This 
is in conformity with the standard CEdG results wherein also when deoxyguanosine 
was exposed to dihydroxyacetone, a distinct peak at retention time of 14.399 min was 
observed (Fig. 19). The CEdG adduct is a marker of glucose and MG induced DNA 
glycation. 
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Fig. 19 Representative HPLC chromatogram of the reaction of 2'- deoxyguanosine with 
dihydroxyacetone. 
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Fig. 20 'H NMR spectra of the standard CEdG. 
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Fig. 21 Representative HPLC chromatogram of acid hydrolysate of native 
human DNA. 
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Fig. 22 Representative HPLC chromatogram of acid hydrolysate of modified human 
DNA. 
Detection of N^-(l-Carboxyethyl)-2-deoxyguanosine (CEdG) formed 
in modified human DNA by LC-MS 
The UV spectrum of the adduct showed the maxima at 254 nm same as that 
for unmodified deoxy-guanosine, indicating that it is the modification of same 
nucleoside. The standard (CEdG) and modified DNA samples were then analyzed by 
mass spectrometer for full scan in negative mode, giving evidence for the adduct 
formed [M- H]~ at m/z values of 338 (Figs. 23-25). In addition, the observed masses 
corresponded with the calculated masses for single charged ions [M- 1]~ of the 
nucleoside plus 1 equivalent of MG (m/z 338 for dOuo). Whereas, we did not find 
peak at m/z value of 338 for native DNA. 
Characterization of DNA-AGEs by electrospray ionization mass 
spectrometry (ESI-MS) 
In an attempt to confirm the formation of Schiff base and amadori product in 
glycated DNA, mass spectrometry was used to analyze the hydrolysed glycated 
human DNA. Figures 26-27 show the respective mass-spectral profiles of hydrolyzed 
native and MG-Lys-Cu^"^ glycated human DNA. The ion at m/z 341 is consistent with 
a [Schiff base+H]"*^  molecule resulting from the condensation reaction of dG (Mr 
285.26) with methylglyoxal (Mr 70.06) in a dehydration reaction involving the loss of 
a water molecule. The ion at m/z 679 is consistent with the formation of a [Schiff 
base+H]"^ dimer product. The ion at 268 is speculated to result from the loss of a 
hydroxyl group from dG. The ion with m/z 385 is assumed to be fragment formed by 
the degradation of methylglyoxal reacting with Schiff base product, or its enaminol or 
Amadori intermediates. 
Immunogenicity of MG-Lys-Cu^^ modified human DNA 
The antigenicity of MG-Lys-Cu^* modified human DNA was evaluated by 
inducing antibodies in female rabbits. Antigenic specificity of the induced antibodies 
was assayed by direct binding and competition ELISA. The binding of these 
antibodies to the immunogen and native human DNA was further checked by gel 
retardation assay. 
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Fig. 24 Full scan LC-MS spectral analysis of hydrolyzed native human DNA (Img/ml). 
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Fig. 25 Full scan LC-MS spectral analysis of hydrolyzed modified human DNA (Img/ml). 
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Fig. 26 Full scan ESI-MS spectral analysis of native human DNA (Img/ml) of HPLC 
resolved products. 
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Fig. 27 Full scan ESI-MS spectral analysis of modified human DNA (Img/ml) of HPLC 
resolved glycated products. 
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Antibodies against MG-Lys-Cu^^ modified human DNA 
Antiserum obtained from immunized animal was subjected to direct binding 
immunoassay on immunogen coated polystyrene microtitre plates. The antiserum 
showed a high titre (> 1: 12800) in direct binding ELISA while preimmune serum, 
used as control, showed feeble binding on immunogen coated plates (Fig. 28). The 
specificity of induced anti-MG-Lys-Cu^"^ modified human DNA antibodies was 
evaluated by competitive inhibition ELISA. A maximum of 62.2% inhibition in 
antibody binding was observed at 20 |ig/ml of the immunogen (Fig. 29). The 
concentration for 50% inhibition was 10.1 ^ig/ml. While MG-Lys-Cu^'' modification 
of human DNA rendered it highly immunogenic, the native counterpart did not 
produce any appreciable immune response in experimental animals (Fig. 30 & 31 
respectively). 
Purification and characterization of serum IgG 
Immunoglobulin G was isolated from preimmune and immune rabbit serum by 
affmity chromatography on Protein A-agarose column (Fig. 32). The purity of IgG 
was ascertained by SDS-polyacrylamide gel electiophoresis in absence of a reducing 
agent. Appearance of a single band in SDS-PAGE under non reducing condition 
(Fig.32 inset) establishes the purity of IgG. Direct binding ELISA of the purified anti-
MG-Lys-Cu "^ -DNA IgG showed strong binding towards its immunogen (Fig. 33). 
However, the preimmune IgG showed negligible binding. The specificity of anti-MG-
Lys-Cu "^" modified human DNA IgG was evaluated by competition ELISA, wherein 
88.5% inhibition in the antibody binding was achieved by the MG-Lys-Cu^^ modified 
human DNA, while native DNA could cause only 35.2% inhibition in antibody 
binding (Fig. 34). Fifty percent inhibition for MG-Lys-Cu'^ modified human DNA 
binding was observed at an inhibitor concentration of 2.8 ^g/ml. 
Band shift assay 
Antigen-antibody interaction was further evaluated by band shift assay. 
Constant amount of human DNA or its MG-Lys-Cu^" modified form was incubated 
with varying amount of anti-MG-Lys-Cu'^-DNA IgG for 2 hr at 37 °C and overnight 
at 4 C. The resulting immune complex was then electrophoresed on 0.8% agarose 
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Fig. 28 Level of induced antibodies against MG-Lys-Cu modified human DNA. 
Direct binding ELISA with preimmune serum (n) and immune serum (•). 
The microtitre wells were coated with MG-Lys-Cu^ "^  modified human 
DNA (2.5 ng/ml). 
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Fig. 29 Inhibition ELISA of serum antibodies against MG-Lys-Cu^^ modified 
human DNA (- • -) and preimmune serum (- n -). MG-Lys-Cu '^^  modified 
human DNA was used as a coating antigen (2.5 }ig/ml) as well as an 
inhibitor. 
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Fig. 30 Level of induced antibodies against native human DNA. Direct binding 
ELISA with preimmune serum (D) and immune serum (•). The microtitre 
wells were coated v^ dth native human DNA (2.5 [ig/m 
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Fig. 31 Inhibition ELISA of anti-native human DNA antibodies (- • -) and 
preimmune (- a -) sera. Native human DNA used as a coating antigen (2.5 
)ig/ml) as well as an inhibitor. 
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Fig. 32 Elution profile of anti-MG-Lys-Cu^^ modified human DNA IgG on 
Protein-A agarose affinity column. Inset: SDS-PAGE of purified IgG on 
7.5% polyacrylamide ge 
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Fig. 33 Binding of affinity purified anti-MG-Lys-Cu modified liuman DNA IgG 
(•) and preimmune IgG (n) to MG-Lys-Cu modified human DNA. 
Microtitre plates were coated with MG-Lys-Cu modified human DNA 
(2.5 i^g/ml). 
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Fig. 34 Inhibition of anti-MG-Lys-Cu^ "*" modified human DNA IgG binding by 
native human DNA (- n -) and modified liuman DNA (- • -) sera. The 
microtitre plate was coated with MG-Lys-Cu^ "^  modified human DNA 
(2.5 ^ tg/ml). 
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for 2 hr at 30 mA. Figiire 35 (a) shows the binding of IgG to MG-Lys-Cu^^ modified 
human DNA. With the increase in the amount of IgG, there was an increase in the 
formation of high molecular weight immune complexes, which resulted in retarded 
mobility and increased fluorescence intensity near the well. However, under similar 
experimental conditions the unmodified human DNA failed to show the shift in its 
mobility when incubated with anti-MG-Lys-Cu^''-DNA IgG [Fig.35 (b)]. These 
results clearly indicate that epitopes on native human DNA and its modified 
counterpart have quite distinct recognition. 
Immuno-crossreactivity of anti-MG-Lys-Cu^^ modified human DNA 
antibodies 
Antigenic specificity of the induced anti-MG-Lys-Cu^"^ modified human DNA 
antibodies was investigated by competitive inhibition ELISA. The induced antibodies 
exhibited a wide range of heterogeneity in recognizing varied inhibitors that include 
nucleic acid polymers and bases. A maximum of 89.5% inhibition of the anti-MG-
Lys-Cu '^*'-DNA IgG was observed with the immunogen as an inhibitor (Fig. 34). The 
induced antibodies were highly specific for MG-Lys-Cu^"^ modified human DNA as 
only 2.8 ^ig/ml inhibitor was required to cause 50% inhibition. While, native human 
DNA caused considerably reduced inhibition (35.1 %) in antibody activity (Fig. 34). 
Native, ROS and MG-Lys-Cu^"^ modified calf thymus DNA inhibited the 
induced antibodies by 33.3%, 48.6% and 64.2% respectively (Fig. 36). Whereas ROS 
modified human DNA showed maximum inhibition of 57.1% at 20 )ag/ml. To achieve 
50% inhibition, 13.2 |a.g/ml MG-Lys-Cu^"^ modified calf thymus DNA was required. 
However, for ROS modified hiiman DNA, 50% inhibition was attained at an inhibitor 
concentration of 15.1 )j,g/ml. 
Plasmid DNA, its ROS and MG-Lys-Cu^^ modified forms caused 32.1%, 
43.9% and 54.2% inhibition respectively in the binding of the immune IgG to the 
modified DNA (Fig. 37). The amount of MG-Lys-Cu^"^ modified plasmid required for 
50% inhibition was 19.3 |ig/ml. 
Lymphocyte DNA of human origin modified by MG-Lys-Cu^"^ and 
ROS showed the maximum inhibition of 72.5% and 59% respectively (Fig. 38), while 
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Fig. 35 Band shift assay of anti-MG-Lys-Cu^^ modified human DNA-IgG binding to 
(a) MG-Lys-Cu^^ modified human DNA and (b) native human DNA. 
Electrophoresis was carried out on 0.8% agarose gel for 2 hr at 30mA. 
(a) MG-Lys-Cu^^ modified human DNA (0.5 |^g, Lane 1) was incubated with 
10, 20, 40 and 60 |^ g of anti-MG-Lys-Cu^^ modified human DNA-IgG 
(lanes 2-5) for 2 hr at 37 V and overnight at 4 "C. 
(b) Native human DNA (0.5 |ig, Lane 1) was incubated with 10, 20, 40 and 60 
i^g of anti-MG-Lys-Cu^^ modified human DNA-IgG (lanes 2-5) under 
identical conditions. 
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,2+ Fig. 36 Inhibition of anti-MG-Lys-Cu modified human DNA IgG binding by 
calf thymus DNA (- A -), ROS modified calf thymus DNA (- • -), ROS 
modified human DNA (- n -) and MG-Lys-Cu^ "^  modified calf thymus 
DNA (- • -). The microtiter plate was 
modified human DNA (2.5 ng/ml). 
coated with MG-Lys-Cu 
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Fig. 37 .2+ Inhibition of anti-MG-Lys-Cu modified human DNA IgG binding by 
plasmid DNA (- A -), ROS modified plasmid DNA (- D -), and MG-Lys-
Cu^ "^  modified plasmid DNA (- • -). The microtiter plate was coated with 
,2+ MG-Lys-Cu^^ modified human DNA (2.5 ^ g/ml). 
99 
90-
100 
0.01 
^' I I I I I 11 I I I I I I I I I I I I I M I I 
0.1 1 10 
Inhibitor Concentration, pg/ml 
100 
.2+ Fig. 38 Inhibition of anti-MG-Lys-Cu modified human DNA IgG binding by 
lymphocyte DNA (- • -), ROS modified lymphocyte DNA (- a -), and 
MG-Lys-Cu^ "^  modified lymphocyte DNA (- • -). The microtiter plate was 
coated with MG-Lys-Cu^ "^  modified human DNA (2.5 ng/ml). 
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native lymphocyte DNA inhibited 34.5% binding of immune IgG to immunogen. 
Fifty percent inhibition of antibody activity was achieved with 8.8 |ag/ml of MG-Lys-
Cu^ * modified lymphocyte DNA and 17.8 |xg/ml of ROS modified DNA. 
The DNA bases guanine, cytosine, adenine, thymine and their ROS (*0H) 
modified and MG-Lys-Cu^ "^  modified forms were used as inhibitors of antibody 
binding activity. Guanine showed a moderate inhibition of 38 percent. In contrast, 
ROS and MG-Lys-Cu^ "^  modified guanine were potent inhibitors showing maximum 
inhibition of 59% and 78% respectively (Fig. 39). The amount of ROS-guanine and 
MG-Lys-Cu^ "^  modified guanine required for 50% inhibition in antibody activity was 
16.6 |a,g/ml and 8.9 |Ag/ml respectively. Adenine caused inhibition 29% inhibition, 
whereas its ROS modified form was a moderate inhibitor, showing a maximum of 
54% inhibition in antibody activity. In contrast, MG-Lys-Cu modified form was 
found to be a potent inhibitor, showing a maximum inhibition of 65% (Fig. 40). The 
amount of MG-Lys-Cu^^ modified adenine for 50% inhibition was 14.2 [ig/ml, 
whereas 19.4 |ag/ml was required in the case of ROS-modified adenine to get 50 %> 
inhibition in the antibody activity. Thymine and its ROS-modified form produced 
26% and 32% inhibition respectively (Fig. 41), whereas MG-Lys-Cu^^-thymine 
showed a moderate inhibition of 43%i. In contrast, cytosine and its ROS and MG-Lys-
Cu^ * modified forms showed a maximum of 27%, 43% and 47% inhibition 
respectively (Fig. 42). Binding characteristics of the induced antibodies against MG-
Lys-Cu^ "*"- DNA have been summarized in Table 6. 
Binding of autoantibodies against native and MG-Lys-Cu^^ modified 
human DNA in diabetes patients 
In this clinical study, we have randomly selected total 85 cases of both 
diabetes type I (40 samples) and type II (45 samples). The sera were obtained from 
patients attending J.N. Medical College and hospital, A.M.U., Aligarh after the 
informed consent. Sera from age and sex-matched normal healthy individuals served 
as control. All sera were diluted to 1:100 in TBS-T and subjected to direct binding 
ELISA on solid phase separately coated with equal amounts of human DNA and 
MG-Lys-Cu^ "" modified human DNA. Out of total 40 type I diabetes sera, 27 samples 
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Fig. 39 Inhibition of anti-MG-Lys-Cu "^^  modified human DNA IgG binding by 
guanine (- • -), ROS modified guanine (- n -), and MG-Lys-Cu^^ 
modified guanine (- • -). The microtiter plate was coated with MG-Lys-
Cu^ ^ modified human DNA (2.5 ^ g/ml). 
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Fig. 40 .2+ Inhibition of anti-MG-Lys-Cu modified human DNA IgG binding by 
adenine (- • -), ROS modified adenine (- n -), and MG-Lys-Cu^ "^  
modified adenine (- • -). The microliter plate was coated with MG-Lys-
.2+ Cu modified human DNA (2.5 ^ g/ml). 
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Fig. 41 ,2+ Inhibition of anti-MG-Lys-Cu modified human DNA IgG binding by 
thymine (- • -), ROS modified thymine (- D -), and MG-Lys-Cu^^ 
modified thymine (- • -). The microtiter plate was coated with MG-Lys-
Cu^ "^  modified human DNA (2.5 i^ g/ml) 
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Fig. 42 Inhibition of anti-MG-Lys-Cu "^^  modified human DNA IgG binding by 
cytosine (- A -), ROS modified cytosine (- n -), and MG-Lys-Cu^^ 
modified cytosine (- • -). The microtiter plate was coated with MG-Lys-
Cu^ "^  modified human DNA (2.5 ng/ml). 
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TABLE 6 
Cross-reaction of anti-MG-Lys-Cu^^ 
Inhibitors 
MG-Lys-Cu^"^- human 
DNA 
Native human DNA 
Native calf thymus DNA 
ROS calf thymus DNA 
ROS human DNA 
MG-Lys-Cu^^- calf 
thymus DNA 
Native plasmid 
ROS plasmid 
MG-Lys-Cu^'^-plasmid 
Native human 
lymphocyte DNA 
ROS human lymphocyte 
DNA 
9+ 
MG-Lys-Cu - human lymphocyte DNA 
Native guanine 
ROS guanine 
MG-Lys-Cu^*-guanine 
Native adenine 
ROS adenine 
MG-Lys-Cu^'^-adenine 
Native thymine 
ROS thymine 
MG-Lys-Cu^'^-thymine 
Native cytosine 
ROS cytosine 
MG-Lys-Cu^"*"-cytosine 
Maximum% 
inhibition at 20 
|ig/ml 
89.5 
35.1 
33.3 
48.6 
57.1 
64.2 
32.1 
43.9 
54.2 
35 
59 
72.5 
38 
60 
78 
29 
54 
65 
26 
32 
43 
27 
39 
48 
modified human DNA IgG 
Concentration 
for 50%inhibition 
{\ig/m\) 
2.8 
-
-
-
15.1 
13.2 
-
-
19.3 
-
17.8 
8.8 
-
16.6 
8.9 
-
19.4 
14.2 
-
-
-
-
-
-
Percent 
relative 
affinit)' 
100 
-
-
-
18.5 
21.2 
-
-
14.5 
-
15.7 
31.8 
-
16.8 
31.4 
_ 
14.4 
19.7 
_ 
« 
. 
_ 
_ 
-
Microtitre plates were coated with MG-Lys-Cu^"" modified human DNA (2.5^g/ml). 
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67.5%), (Figs. 43-46) showed higher binding with MG-Lys-Cu^ "" modified human 
DNA, while in type II diabetes only 16 sera (35.5%) out of 45 samples tested, showed 
enhanced binding with modified human DNA as compared to the native form. 
The serum samples which showed enhanced binding were considered for 
further studies, while samples whose absorbance was less than or equal to control 
were not included. 
Immuno-crossreactivity of autoantibodies from diabetes type I 
patients 
Competition ELISA was carried out to analyze the specific binding of 
circulating autoantibodies in type I diabetic patients sera for native and MG-Lys-Cu 
modified human DNA. 
In the 27 sera chosen from type I diabetes patients, which showed enhanced 
bindmg, the observed maximum inhibition with MG-Lys-Cu^ "" modified human DNA 
was in the range of 46.9 to 63.1% while with native human DNA it ranged from 22 to 
33% (Figs. 47-55). Mean inhibition for the entire sample tested with native human 
DNA was 27+3.8%, while for MG-Lys-Cu^ "" modified human DNA, it was 
54.95±5.4%. The above results have been summarized in Table 7. 
Purification of IgG from the sera of type I diabetes patient 
IgG was isolated on a protein A-agarose column fi'om selected high binding 
sera of type I diabetes patients. The purified IgG eluted as a symmetrical single peak 
on the affinity column (Fig. 56). IgG purity was confirmed by a single homogeneous 
band on SDS-PAGE under non-reducing conditions (Fig. 56 inset). 
Binding of IgG from different diabetes type I patients to native and 
MG-Lys-Cu^ modified human DNA 
Purified IgG firom type I diabetes patients, were subjected to direct binding 
ELISA, on a microtitre plate coated with native human DNA and MG-Lys-Cu^ "^  
modified human DNA to evaluate the amount required for antigen saturation. The 
saturation for modified human DNA was obtained at 50 fj,g/ml of IgG, while for 
native human antigenic saturation could not be ascertained because of its negligible 
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NHS 1 3 4 5 6 7 
Serum Samples 
8 10 
Fig. 43 Direct binding ELISA of serum autoantibodies from type I diabetes 
patients (no. 1-10) to native (•) and MG-Lys-Cu^^ modified human DNA 
(•). Normal human sera (NHS) served as negative control. The plate was 
coated with MG-Lys-Cu^^ modified human DNA (2.5 i^g/ml) 
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Fig. 44 Direct binding ELISA of serum autoantibodies from type I diabetes 
patients (no. 11-20) to native (•) and MG-Lys-Cu^^ modified human DNA 
(•). Normal human sera (NHS) served as negative control. The plate was 
coated with MG-Lys-Cu^ "^  modified human DNA (2.5 |ig/ml). 
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Fig. 45 
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Serum Samples 
28 29 30 
Direct binding ELISA of serum autoantibodies from type I diabetes 
patients (no. 21-30) to native (•) and MG-Lys-Cu^ "*^  modified human 
DNA (•). Normal human sera (NHS) served as negative control. The 
.2+ plate was coated with MG-Lys-Cu modified human DNA (2.5 i^g/ml). 
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Fig. 46 Direct binding ELISA of serum autoantibodies from type I diabetes 
2+ patients (no. 31-40) to native (•) and MG-Lys-Cu modified human DNA 
(•). Normal human sera (NHS) served as negative control. The plate was 
coated with MG-Lys-Cu^^ modified human DNA (2.5 Hg/ml). 
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Fig. 47 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o, A, D) and MG-Lys-Cu^ "^  modified human DNA 
(•, • , • ) . Sera 1, 3 and 4 were analyzed on the microtitre plate coated 
,2+ 
with MG-Lys-Cu^ modified human DNA (2.5 ^ g/ml). 
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Fig. 48 Competitive inhibition of serum autoantibodies in type I diabetes 
patients by native human DNA (o, A, n) and MG-Lys-Cu^^ modified 
human DNA (•, A, • ) . Sera 7, 8 and 9 were analyzed on the microtitre 
plate coated with MG-Lys-Cu^ "^  modified human DNA (2.5 (ig/ml). 
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Fig. 49 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o, A, D) and MG-Lys-Cu^ "^  modified human DNA 
(•, A, • ) . Sera 10, 11 and 14 were analyzed on the microtitre plate 
.2+ 
coated with MG-Lys-Cu modified human DNA (2.5 |ig/ml). 
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Fig. 50 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o, A, D) and MG-Lys-Cu modified human DNA 
(•, • , • ) . Sera 15, 17 and 18 were analyzed on the microtitre plate coated 
with MG-Lys-Cu^ "^  modified human DNA (2.5 (ig/ml). 
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Fig. 51 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o, A, D) and MG-Lys-Cu^* modified human DNA 
(•» ^ . •)• Sera 20,21 and 22 were analyzed on the microtitre plate coated 
with MG-Lys-Cu^ "" modified human DNA (2.5 ng/ml). 
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Fig. 52 Competitive inhibition of seram autoantibodies in type I diabetes patients by 
native human DNA (o, A, n) and MG-Lys-Cu^ "^  modified human DNA (•, 
A, • ) . Sera 23, 24 and 25 were analyzed on the microtitre plate coated with 
MG-Lys-Cu^ "^  modified human DNA (2.5 i^g/ml). 
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Fig. 53 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o, A, n) and MG-Lys-Cu^* modified human DNA 
(•, '^ » •)• Sera 28,29 and 31 were analyzed on the microtitre plate coated 
with MG-Lys-Cu '^' modified human DNA (2.5 ^g/ml) 
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Fig. 54 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o. A, n) and MG-Lys-Cu^ "*^  modified human 
DNA (•, • , • ) . Sera 32, 34 and 36 were analyzed on the microtitre plate 
coated v^th MG-Lys-Cu^* modified human DNA (2.5 Hg/ml). 
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Fig. 55 Competitive inhibition of serum autoantibodies in type I diabetes patients 
by native human DNA (o, A, • ) and MG-Lys-Cu^ "^  modified human 
DNA (•, • , • ) . Sera 37, 38 and 39 were analyzed on the microtitre plate 
coated with MG-Lys-Cu^ "^  modified human DNA (2.5 |ag/ml). 
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TABLE 7 
Competitive inhibition data of serum autoantibodies in type I 
diabetes patients 
Sera no 
01 
03 
04 
07 
08 
09 
10 
11 
14 
15 
17 
18 
20 
21 
22 
23 
24 
25 
28 
29 
31 
32 
34 
36 
37 
38 
39 
Mean ± SD 
Maximum 
Native human DNA 
26.8 
22.9 
29.6 . 
24.5 
28.8 
31.0 
24.0 
27.4 
30.7 
26.8 
28.0 
30.0 
29.0 
26.0 
20.8 
22.0 
24.8 
28.0 
29.0 
31.0 
33.0 
26.0 
27.8 
24.0 
24.7 
20.2 
31.7 
26.98±3.8% 
percent inhibition at 20 |ag/ml 
MG-Lys-Cu^"^ modified human DNA 
51.0 
54.0 
49.0 
52.8 
58.0 
46.9 
50.0 
53.0 
61.0 
52.5 
62.0 
58.0 
54.0 
62.0 
48.0 
50.0 
63.1 
57.0 
47.0 
48.0 
61.3 
62.0 
55.7 
49.1 
62.8 
58.6 
52.8 
54.8±5.4% 
The microtitre plates were coated with MG-Lys-Cu modified human DNA 
(2.5^g/ml). 
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Fraction Number 
Fig. 56 Elution profile of IgG from the serum sample of diabetes type I patients 
on Protein A-agarose affinity column. Inset: SDS- PAGE of purified IgG 
on 7.5% polyacrylamide gel. Similar pattern was obtained in all sera. 
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binding. Therefore, for type I diabetes, IgG concentration was kept constant (50 
|ig/mi) in all further experiments unless indicated. 
The binding specificity of the isolated IgG, towards native and MG-Lys-Cu'"^  
modified human DNA, was evaluated by inhibition ELISA. The IgG was mixed with 
varying amounts of native or MG-Lys-Cu modified human DNA (0-20 |ig/ml) and 
mcubated for 2 hr at 37 °C and overnight at 4 °C. The inhibition results of type I 
diabetic sera IgG have been presented in Figs. 57-61. The observed antibody (IgG) 
inhibition ranged firom 59-69% when modified human DNA was employed as 
inhibitor, while with the native human DNA it varied fi-om 27-36%; maximum 
inhibitor concentration being 20 fxg/ml in both the cases. The mean of inhibitions for 
various sample tested with the MG-Lys-Cu'^ '^  modified human DNA was 66.2±7.1%, 
while with native human DNA, it was 31.3±3.2%. Table 8 summarizes the inhibition 
data of isolated IgG of diabetes type I group. 
Band shift assay 
Band shift assay was performed for the visual detection of interaction of native 
and MG-Lys-Cu^ "*" modified human DNA with purified IgG from type I diabetes 
patients IgG. Constant amount of antigens were incubated with increasing 
concentration of IgG for 2 hr at 37 °C and overnight at 4 °C, resulted in a proportional 
increase in the formation of high molecular weight immune complexes as visualized 
by retarded mobility and gradually increased band intensity near the wells in agarose 
gel electrophoresis. Normal human IgG incubated under identical conditions did not 
show immune complex formation (Fig. 62 a & b). 
Detection of antibodies against native and MG-Lys-Cu^^ modified 
human DNA in diabetes type II patients 
Forty five samples fi-om diabetes type II patients were analysed for native and 
MG-Lys-Cu^ "^  modified human DNA by direct binding ELISA. Sera from normal 
healthy individuals served as controls. Out of 45 serum sample only 16 sera (35.5%), 
exhibited enhanced binding with MG-Lys-Cu^ "" modified human DNA as compared to 
the native DNA (Figs. 63-66). However, the binding in diabetes type II patients 
was found appreciably lower than in type I patients. The specific binding of serum 
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Fig. 57 Inhibition of IgG, isolated from the sera of type I diabetes patients, by 
native (o, A, D) and MG-Lys-Cu^ "*" modified human DNA (•, A, • ) . The 
microtitre plates were coated with MG-Lys-Cu^ "^  modified human DNA 
(2.5 i^g/ml). The above plot shows the inhibition in IgG isolated from 
serum samples 3, 7 and 8. 
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Fig. 58 Inhibition of IgG, isolated from the sera of type I diabetes patients, by 
native (o. A, D) and MG-Lys-Cu^^ modified human DNA (•, • , • ) . The 
microtitre plates were coated with MG-Lys-Cu modified human DNA 
(2.5 p,g/ml). The above plot shows the inhibition in IgG isolated from 
serum samples 14,15 and 17. 
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Fig. 59 Inhibition of IgG, isolated from the sera of type I diabetes patients, by 
.2+ native (o, A, D) and MG-Lys-Cu^ modified human DNA (•, A, • ) . The 
microtitre plates were coated with MG-Lys-Cu^ "^  modified human DNA 
(2.5 |J.g/ml). The above plot shows the inhibition in IgG isolated from 
senim samples 18,21 and 24. 
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Fig. 60 Inhibition of IgG, isolated from the sera of type I diabetes patients, by 
native (o, A, D) and MG-Lys-Cu^^ modified human DNA (•, A, • ) . The 
microtitre plates were coated with MG-Lys-Cu^ "^  modified human DNA 
(2.5 (ig/ml). The above plot shows the inhibition in IgG isolated from 
serum samples 25, 31 and 32. 
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Fig. 61 Inhibition of IgG, isolated from the sera of type I diabetes patients, by 
native (o, A, D, 0) and MG-Lys-Cu^"^ modified human DNA (•, • , • , 
• ) . The microtitre plates were coated with MG-Lys-Cu^"" modified human 
DNA (2.5 ng/ml). The above plot shows the inhibition in IgG isolated 
from serum samples 34, 37, 38 and 39. 
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TABLE 8 
Competitive inhibition data of IgG isolated from type I diabetes 
patients 
Sera no 
03 
07 
08 
14 
15 
17 
18 
21 
24 
25 
31 
32 
34 
37 
38 
39 
Mean ± SD 
Maximum percent inhibition 
Native human DNA 
28.0 
29.6 
31.7 
33.8 
30.1 
28.0 
33.8 
35.6 
31.0 
31.0 
35.0 
28.0 
34.8 
29.3 
27.0 
36.7 
31.46±3.2% 
MG-Lys •Cu^^ 
1 at 20 \xgjm\ 
modified human DNA 
62.1 
60.7 
65.1 
68.0 
61.9 
69.0 
64.1 
65.8 
68.1 
69.6 
68.1 
68.9 
63.5 
67.3 
65.0 
61.9 
65.5617.1% 
The microtitre plates were coated with MG-Lys-Cu^* modified human DNA 
(2.5^g/ml). 
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Fig. 62 Band shift of IgG fi-om diabetic patient using (a) native and (b) MG-Lys-
Cu^^ modified human DNA. Varying concentrations of IgG were incubated 
with a constant amount of DNA (0.5 i^g) for 2 hr at 37 "C and overnight at 4 
^C. Electrophoresis was carried out on 0.8% agarose gel for 2 hr at 30mA. 
Lane 1 contains native (or modified) human DNA while lanes 2-5 contain 
native or MG-Lys-Cu modified human DNA with 20, 40, 60 and 80 ^g of 
IgG from type I diabetes patient. 
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Fig. 63 Direct binding ELISA of serum autoantibodies from type II diabetes 
patients (no.1-11) to native (•) and MG-Lys-Cu^ "^  modified human DNA 
(•). Normal human sera (NHS) served as negative control. The plate was 
.2+ 
coated with MG-Lys-Cu modified human DNA (2.5 jig/ml). 
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Fig. 64 Direct binding ELISA of serum autoantibodies from type II diabetes 
patients (no. 12-22) to native (•) and MG-Lys-Cu^ "^  modified human 
DNA (•). Normal human sera (NHS) served as negative control. The 
.2+ plate was coated with MG-Lys-Cu modified human DNA (2.5 i^g/ml). 
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Fig. 65 Direct binding ELISA of serum autoantibodies from type II diabetes 
2+ patients (no.23-33) to native (•) and MG-Lys-Cu modified human DNA 
(•). Normal human sera (NHS) served as negative control. The plate was 
coated with MG-Lys-Cu^^ modified human DNA (2.5 ng/ml). 
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Fig. 66 Direct binding ELISA of serum autoantibodies from type II diabetes 
2+, patients (no.34-45) to native (•) and MG-Lys-Cu modified human DNA 
(•). Normal human sera (NHS) served as negative control. The plate was 
coated with MG-Lys-Cu^^ modified human DNA (2.5 i^g/ml). 
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antibodies to native and MG-Lys-Cu modified human DNA was studied by 
competition inhibition solid phase assay. An inhibition in the range of 18% to 30.1% 
and 34.4% to 53% (Figs. 67-71) was recorded with native and MG-Lys-Cu^^ modified 
human DNA respectively. Mean inhibition for the entire sample tested with native 
human DNA was 23.9±3.0%, while for MG-Lys-Cu^^ modified human DNA, it was 
44.6±5.3%). The inhibition studies results have been summarized in Table 9. 
Purification of IgG from the sera of type II diabetes patient 
IgG was isolated from the selected high binding serum samples of type II 
diabetes patients on a protein A-agarose column. IgG purified by affinity 
chromatography eluted as a synametrical single peak (Fig. 72) and migrated as a 
single homogeneous band on SDS-PAGE under non-reducing conditions (Fig. 72 
inset). 
Binding of IgG from diabetes type II patients to native and MG-Lys-
Cu^ ^ modified human DNA 
Purified IgG from type II diabetes patients, were subjected to direct binding 
ELISA, on a microtitre plate coated with native human DNA and MG-Lys-Cu^^ 
modified human DNA to evaluate the amount required for antigen saturation. The 
saturation for modified human DNA was obtained at 80 |ug/ml of IgG, while for 
native human antigenic saturation could not be ascertained because of its negligible 
binding. Therefore, for type II diabetes, IgG concentration was kept constant (80 
|ig/ml) in all further experiments. 
The specific binding of the IgG isolated from type II diabetes patients was 
ascertained in competitive inhibition ELISA wherein an inhibition in the range of 
24% to 36% and 49% to 57% was recorded with native and MG-Lys-Cu^^ modified 
human DNA respectively (Figs. 73-75). Mean inhibition for the entire sample tested 
with native human DNA was computed to be 29.3±3.6%, while for MG-Lys-Cu^^ 
modified human DNA, it was 53±7.3%. Table 10 summarizes the inhibition data of 
isolated IgG of diabetes type II group. 
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Fig. 67 Competitive inhibition of serum autoantibodies in type II diabetes patients 
by native human DNA (o, A, D) and MG-Lys-Cu^ "^  modified human DNA 
(•, A, • ) . Sera 2, 7 and 8 were analyzed on the microtitre plate coated 
.2+ 
with MG-Lys-Cu modified human DNA (2.5 |ag/ml). 
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Fig. 68 Competitive inhibition of serum autoantibodies in type II diabetes 
patients by native human DNA (o, A, D) and MG-Lys-Cu modified 
human DNA (•, • , • ) . Sera 19, 12 and 15 were analyzed on the 
microtitre plate coated with MG-Lys-Cu^ "^  modified human DNA (2.5 
^g/ml). 
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Fig. 69 Competitive inhibition of serum autoantibodies in type II diabetes 
patients by native human DNA (o, A, n) and MG-Lys-Cu^"^ modified 
human DNA (•, • , • ) . Sera 19, 20 and 24 were analyzed on the 
microtitre plate coated with MG-Lys-Cu^ "^  modified human DNA (2.5 
^g/ml). 
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Fig. 70 Competitive inhibition of serum autoantibodies in type II diabetes 
patients by native human DNA (o, A, D) and MG-Lys-Cu modified 
human DNA (•, • , • ) . Sera 26, 29 and 31 were analyzed on the 
microtitre plate coated with MG-Lys-Cu^"^ modified human DNA (2.5 
ixg/ml). 
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Fig. 71 Competitive inhibition of serum autoantibodies in type II diabetes 
patients by native human DNA (o, A, D, 0) and MG-Lys-Cu^ "^  modified 
human DNA (•, • , • , •) . Sera 32, 37, 38 and 45 were analyzed on the 
microtitre plate coated with MG-Lys-Cu modified human DNA (2.5 
M'g/nil). 
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TABLE 9 
Competitive inhibition data of serum autoantibodies in type II 
diabetes patients 
Sera no 
02 
07 
08 
10 
12 
15 
19 
20 
24 
26 
29 
31 
32 
37 
38 
45 
Mean ± SD 
Maximum 
Native human DNA 
28.2 
22.8 
30.1 
24.6 
26.0 
22.0 
20.9 
18.0 
16.8 
21.0 
24.0 
26.0 
27.0 
22.0 
29.0 
25.0 
23.9±3.0% 
percent inhibition at 20 \ig/ml 
MG-Lys-Cu^ "^  modified human DNA 
49.0 
51.0 
53.0 
50.0 
38.6 
43.2 
48.0 
46.0 
37.0 
44.0 
47.0 
49.0 
41.3 
36.5 
46.0 
34.4 
44.62±5.3% 
The microtitre plates were coated with MG-Lys-Cu^ "^  modified human DNA 
(2.5^g/ml). 
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Fig. 72 Elution profile of IgG from the serum of diabetes type II patients on 
Protein A-agarose affinity column. Inset: SDS- PAGE of purified IgG on 
7.5% polyacrylamide gel. 
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Fig. 73 Inhibition of IgG isolated from type II diabetes patients (samples 2, 7 and 
8) by native (o, A, D) and MG-Lys-Cu^ "^  modified human DNA (•, A, • ) . 
The microtitre plates were coated with MG-Lys-Cu modified human 
DNA (2.5 ng/ml). 
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Fig. 74 Inhibition of IgG isolated from type II diabetes patients (samples 10, 19 
and 29) by native (o, A, D) and MG-Lys-Cu modified human DNA (•, 
A, • ) . The microtitre plates were coated with MG-Lys-Cu^^ modified 
human DNA (2.5 ng/ml). 
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Fig. 75 Inhibition of IgG isolated from type II diabetes patients (samples 31 and 
38) by native (o. A) and MG-Lysine-Cu^ "^  modified human DNA (•, A). 
The microtitre plates were coated with MG-Lys-Cu^ "^  modified human 
DNA (2.5 i^g/ml). 
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TABLE 10 
Competitive inhibition data of IgG isolated from type II diabetes 
patients 
Sera no 
02 
07 
08 
10 
19 
29 
31 
38 
Mean ± SD 
Maximum percent inhibition at 20 ^g/ml 
Native human DNA 
29.0 
24.0 
33.0 
27.0 
25.0 
29.0 
32.0 
36.0 
29.3±3.6% 
MG-Lys-Cu^ "*" modified human DNA 
53.0 
55.0 
57.0 
54.0 
52.0 
51.0 
53.0 
49.0 
53±7.3% 
The microtitre plates were coated with MG-Lys-Cu^^ modified human DNA 
(2.5^g/ml). 
1* 
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Endogenous MG is mainly formed spontaneously during glycolysis as a result 
of fragmentation and elimination of phosphate from glyceraldehyde-3-phosphate 
(G3P) and dihydroxyacetone phosphate (DHAP) (Thomalley, 1996). Normally, 40-
67% of MG is formed firom G3P and 33-60% from DHAP, depending on the 
DHAP/G3P molar ratio (Phillips and Thomalley, 1993). G3P and DHAP can be 
converted to MG enzymatically (Ray and Ray 1981; Pompliano et ai, 1990) and 
nonenzymatically (Richard, 1991). Triosephosphate isomerase can convert both G3P 
and DHAP to MG. Triosephosphate isomerase is a very effective catalyst of 
isomerization and is present at very high cellular concentrations (Albery and Knowles 
1976). Therefore, a significant concentration of cellular MG might be generated by 
triosephosphate isomerase even though its catalysis of degradation of G3P and DHAP 
to MG is very slow. DHAP can also be catalyzed to MG by methylglyoxal synthase in 
goat liver (Ray and Ray 1981). The instability of G3P at physiological pH was first 
reported in 1969 (Mel'nichenko et al., 1969). This was followed by a study which 
found two reaction products, inorganic phosphate and MG, from nonenzymatic G3P 
reaction at pH 7.7, in the presence of increasing concentrations of the buffer catalyst 
lysine (Bonsignore et al., 1973). Currently, it is accepted that the deprotonation of 
G3P or DHAP to an enediolate phosphate followed by the cleavage of phosphate 
group from the carbon skeleton results in the formation of MG (Richard, 1993). An 
estimated rate of nonenzymatic MG formation is 0.1 mmol/L/day (Richard, 1991). 
Under physiological conditions, minor sources of MG formation include metabolism 
of acetone from lipolysis and metabolism of threonine from protein catabolism 
(Casazza et ai, 1984; Lyles and Chalmers 1992). The conversion of acetone to MG 
involves two enzymes, acetone monooxygenase which converts acetone to acetol and 
acetol monooxygenase (AMO) which converts acetol to methylglyoxal. 
Semicarbazide-sensitive amine oxidase (SSAO) is a group of enzyme containing 
quinine and copp6r. Because SSAO contains a cofactor having carbonyls, it is 
sensitive to semicarbazide inhibition (Lyles, 1996). This enzyme is present in two 
forms, a soluble form in plasma and a membrane-bound form in tissues. Both forms 
can convert amino acetone to MG (Lyles, 1996). Increased SSAO activities are 
associated with diabetic complications, vascular disorders and heart disease. Under 
physiological conditions vascular endothelial cells are the major source of circulating 
SSAO (Stolen et al., 2004). 
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Exogenous sources of MG include many food products, beverages (alcohol, 
tea, soft drinks, coffee etc.) (Nemet et al., 2006). During food processing and storage, 
MG is formed as a by-product. For example, MG level in honey is in the range of 0.4-
5.4 mg/kg, which comes from sugar degradation during the heating processes applied 
in manufacturing and storage (Nemet et al., 2006). MG formation was also observed 
during the heating of glucose, fiructose and maltulose. There are different amounts of 
MG in dairy products and alcoholic drinks coming from fermentation. In addition, 
cigarette smoking is also an exogenous source of MG. Gas chromatographic 
measurement revealed MG levels of 13.5-59.6 |a,g/cigarette (Fujioka and Shibamoto 
2006). MG is found in plants, too. It has been reported that MG concentration is 30-75 
micromolar in various plant species and it can be increased up to 6-fold by stress 
conditions such as salinity, drought and cold (Yadav et al., 2005). 
MG is mainly degraded to D-lactate via glyoxalase system. The glyoxalase 
system consists of two enzymes, glyoxalase I and glyoxalase II and a cofactor, 
reduced glutathione (GSH) (Racker, 1951). 
Apart from glyoxalase system, the non-glyoxalase metabolism of MG also 
exists. For example, (a) Aldose reductase catalyzes the conversion of MG to acetol 
(95%) and D-lactaldehyde (5%), with NADPH as a cofactor (Vander et al., 1992). (b) 
MG reductase catalyzes the reduction of MG to L-lactaldehyde (Ting et al., 1965). (c) 
MG dehydrogenase catalyzes the oxidation of MG to pyruvate (Ray and Ray, 1982). 
MG is often found at high levels in the blood of diabetic patients, where it 
covalently depletes glutathione (GSH), leading to serious toxicological effects. In 
comparison to the parent sugar, MG is more likely to cross-link with the amino 
groups of various proteins, forming stable end products called advanced glycation end 
products (AGEs) (Bourajjaj et al., 2003). In addition, MG may modify cross-Jinked 
lysine and arginine residues, leading to alterations in the protein characteristics 
(Vander et al., 1992). The reaction of proteins with MG has been shown to produce 
reactive oxygen species (ROS) such as O2 during the glycation reaction (Yim et al., 
1995); ROS and oxidative stress can damage many biological molecules (e.g., DNA) 
and cause various cell injuries. Studies have shown that oxidative stress and AGE 
formation are associated with impaired cognitive processes in diabetic patients 
148 
(Messier and Gagnon, 1996; Kyriaki, 2003), suggesting that this may be linked to MG 
toxicity. 
The consumption of 2-3 cups of coffee per day can lead to a daily MG intake 
of up to 1 mg (Kasai et al, 1982). The concentration of MG in blood samples from 
normal controls was about 1 \xM whereas this level was increased 5-6 fold in blood 
samples of diabetes patients with insulin dependent diabetes mellitus and 2-3 fold in 
blood samples of non-insulin-dependent diabetes mellitus (McLellan et al., 1994), and 
may persist for several months or years in diabetic patients. The concentration of MG 
in human lenses is normally about 20 times higher than in plasma (Phillips and 
Thomalley, 1993). It has been shown that physiological levels of MG can induce 
DNA cleavage and ROS generation and decrease cellular adhesion in mononuclear 
cells (Chan and Wu, 2006). A higher concentration can be more deleterious. 
Methylglyoxal is well known to modify many different compounds in the cell, 
including free amino acids (Lo et al, 1994; Takahashi, 1977) proteins (Lo et al, 
1994; Westwood et al, 1994) and nucleic acids (Krymkiewicz, 1973). It has been 
shown that methylglyoxal reacts with guanine residues in DNA to form a tricyclic 
compound (Shapiro et al, 1969, Vaca et al, 1994). Thus, methylglyoxal may induce 
mutations by reacting with guanine residues and by the subsequent formation of 
mispairs. Indeed, methylglyoxal is mutagenic in Salmonella typhimurium strains 
containing the pKMlOl plasmid, Escherichia coli WP2 uvrA and WP2 mrA 
pKMlOl, and Saccharomyces cerevisiae strain D7 (Bronzetti et al, 1987). In cultured 
CHO cells, MG induced sister chromatid exchanges, single-stranded DNA breaks and 
DNA-protein crosslinks have been reported (Brambilla et al, 1985). 
Diabetes affects more than 180 million people worldwide (World Health 
Organization, Diabetes Fact Sheet, 2006). About 5-10% of these cases are Type 1 
diabetes (American Diabetes Association, 2007). TIDM usually results from the 
body's failure.to produce insulin. This leads to hyperglycemia, and insulin therapy is 
required to control blood glucose levels. Glucose forms reversible early glycation 
products with proteins and DNA. Glycated hemoglobin ((HbAlC) is used to assess 
long-term glycemic control in diabetes. Early glycation products may undergo further 
rearrangement and oxidation to produce advanced glycation end products (AGEs) 
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which alters the structure of proteins and DNA irreversibly (Thomalley el ai, 1999). 
Reactive carbonyl species (RCS) such as methylglyoxal and glyoxal can also form 
AGEs. In fact, RCS are 20,000 times more reactive than glucose in glycation 
processes (Thomalley, 2005). In diabetes mellitus, RCS may arise from various 
sources. Methylglyoxal is formed through enzymatic and non-enzymatic degradation 
of glucose, and thus in hyperglycemic conditions they may be produced in excess 
(Phillips and Thomalley, 1993; Wells-Knecht et ai, 1995; Thomalley et ai, 1999; 
Beisswenger et ah, 2001). Altered glucose metabolism may result in an increased 
formation of methylglyoxal via the polyol pathway (Phillips and Thomalley, 1993; 
Chang et al., 2002). Increased protein and lipid catabolism may also be seen in poorly 
controlled diabetes producing elevated levels of aminoacetone and acetone, which are 
precursors of methylglyoxal (Kalapos, 1999). Methylglyoxal form AGEs by binding 
with free sulfliydryl and amino groups of proteins (Thomalley, 2003; Zeng and 
Davies, 2005), resulting in endothelial dysfunction (Rodriguez-Manas et ai, 2003; 
Wautier and Schmidt, 2004) and oxidative stress (Kislinger et ai, 2001; Scivittaro et 
al., 2000; Wu, 2005). There is a growing body of evidence that methylglyoxal- and 
glyoxal-derived AGEs are involved in the complications of diabetes including 
nephropathy, neuropathy and retinopathy (Hammes et ai, 1999; Misselwitz et al., 
2002; Lieuw-A-Fa et al., 2004; Hwang et ai, 2005). 
Sugars and other reactive carbonyl compounds bind spontaneously to 
nucleophilic amino groups of amino acids and proteins in a nonenzymatic process 
(glycation) (Maillard, 1912). It is well established that proteins are readily glycated in 
vivo. The first glycation product to be detected in vivo was hemoglobin (Hb) Ale, the 
Amadori product of Hb A (Koening et al., 1977). In vivo, early glycation products, 
such as the amadori product, are further converted into the heterogeneous group of 
advanced glycation end-products (AGEs). AGEs accumulate on serum proteins and in 
various tissues, particularly during aging, diabetes and renal failure (Viassara et al., 
1994). Elevated AGE levels contribute to the development of diabetic and uremic 
complications, such as atherosclerosis (Park et al., 1998), nephropathy and 
retinopathy (Singh et al., 2001). In analogous reactions, glycation may also affect 
DNA. In vitro, nucleobases and dsDNA react with sugars in a similar way as proteins 
(Lee and Cerami, 1987; Knerr and Severin, 1993; Singh et al., 2001). The exocyclic 
amino group of 2D-deoxyguanosine is particularly prone to glycation reactions, 
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leading to the formation of N -carboxyethyl, N -carboxymethyl, N -(l-carboxy-3-
hydroxypropyl), and N^-(l-carboxy-3,4,5-trihydroxypentyl) modifications, as well as 
cyclic dicarbonyl adducts (Knerr & Severin 1993; Ochs & Severin 1994; Larisch et 
al., 1998; Seidel & Pischetsrieder, 1998). The two diastereomers of N^-carboxyethyl-
2D-deoxyguanosine (CEdGA,B) are stable reaction products that are formed from a 
variety of glycating agents, such as glucose, ascorbic acid, glyceraldehyde, 
dihydroxyacetone (DHA), or methylglyoxal (Larisch et al., 1998; Seidel & 
Pischetsrieder 1998; Frischmann et al., 2005). Recently, carboxyethylated 
nucleobases were detected in human urine (Schneider et al., 2004), indicating the 
formation of DNA-AGEs in healthy humans. A significantly increased number of 
CEdG positive cells were immunostained in glomeruli of patients with diabetic 
nephropathy as compared to healthy controls (Li et al., 2006), as well as in glomeruli 
of diabetic rats (Nakamvira et al., 2007). DNA AGEs are potentially genotoxic 
compounds because they induce depurination (Seidel & Pischetsrieder, 1998) as well 
as single strand breaks and lead to mutations (Pischetsrieder et al., 1999) in vitro. 
The reaction of methylglyoxal with amino acids generates crosslinked 
methylglyoxal dialkylimine cation radical, the enediol anion radical of methylglyoxal 
and the superoxide ion. A direct 1-electron transfer between a Schiff base 
methylglyoxal dialkylimine (or its protonated form) and methylglyoxal is responsible 
for the generation of the cross-linked radical cation and the radical counter anion of 
methylglyoxal. Under aerobic conditions, molecular oxygen can then accept an 
electron firom the methylglyoxal anion to generate the superoxide ion. The formation 
of methylglyoxal dialkylimine radical cation and the enediol radical anion of 
methylglyoxal are independent of molecular oxygen or metal ions. The later stage 
needs the presence of molecular oxygen. The formation of a-ketoaldehydes during 
glycation is a critical step that leads to protein cross-linking and formation of radical 
cation sites on the cross-linked proteins. The counter anions, superoxide and hydrogen 
peroxide generated from MG anion can initiate free radical chain reactions leading to 
damage of biomacromolecules in close proximity to reaction sites. (Suji and 
Sivakami, 2007) 
In the present study, human placental DNA was modified by 40 mM 
methylglyoxal (MG) and 40 mM lysine in the presence of 300 fiM (Cu^^) copper 
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sulphate. This reaction system (MG-Lys-Cu ) caused extensive damage to the human 
DNA, leading to the formation of single strand breaks and base modifications. The 
MG-Lys and MG-Lys-Cu system gave 67% and 76% hyperchromicity respectively 
compared to native double stranded analogue. However, when MG, lysine and Cu^* 
were individually incubated with human DNA under identical conditions, no 
significant change in hyperchromicity was found. Furthermore, MG-Cu^ "^  and Lys-
Cu^ "^  systems also did not show any detectable change in UV-spectral profile. The 
change in hyperchromicity of MG-Lys and MG-Lys-Cu^* system could be attributed 
to the single strand breaks, destabilization of hydrogen bonds, and modification of 
nitrogenous bases which resuU in the destruction of chromophoric groups through 
attack on the sugar-phosphate back bone. Furthermore, an interesting detail is the new 
additional peak found at about 330 run, when human DNA was incubated with MG-
Lys and MG-Lys-Cu^"^ systems. This could be attributed to the generation of DNA-
AGEs. MG-Lys-Cu^"^ derived DNA-AGEs show the highest absorbance, suggesting 
Cu"^ "^  enhances AGEs formation. A study by Schmitt (Schmitt et al, 2005) strongly 
supports our results where they found an extra peak in the same range of 320-330 nm 
when HSA was incubated with MG, suggesting the formation of glycation induced 
AGEs. From the UV absorbance data it can be concluded that absorbance between 
320 and 370 nm (Schmitt et al., 2005) can be used to judge the onset of AGE 
formation of DNA that are derived from the reaction with modifier (MG-Lys-Cu^^). 
Moreover, amino acids (lysine and arginine) treated with MG have been reported to 
give electron paramagnetic resonance signals (Pethig and Szent-Gyorgyi, 1977), 
indicative of the formation of free radicals ("OH and Oa""). The formation of free 
radicals ("OH and Oa*") in this study, was confirmed by quenching studies including 
superoxide dismutase (specific quencher for 02*~) and mannitol (*0H radical 
quencher). The results presented here, therefore, indicate that the glycation reaction of 
MG with lysine in the presence of Cu^ "^  may lead to oxidative damage of DNA 
through a mechanism that involves hydroxyl radicals. 
Hydroxyl radical production, expressed as TBARS nmole/ml, was found to 
increase as a function of MG and lysine. Addition of metal ions further increased the 
production of TBARS. MG-Lys and MG-Lys-Cu systems generated 13 and 24 nmol 
TBARS ml"' respectively. However, radical scavenger, catalase, and copper chelator 
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significantly inhibited the generation of hydroxy! radicals by the MG-lys-Cu ^ 
system. The result suggests that redox reactions of copper may be facilitating the 
generation of hydroxy I radical by the reaction of MG with lysine. 
Comet assay is well established as a sensitive method for detecting single or 
double strand breaks, alkali labile sites, abasic sites and relaxed chromatin formation 
in the DNA of single cells. The resulting DNA fragments move ahead of the intact 
nuclear DNA forming a comet-like structure as smaller fragments move faster than 
the larger fi-agments and the intact DNA. Therefore, comet assay can be used to test 
the genotoxicity of AGEs in cultured cells including freshly isolated human 
lymphocytes. Using the comet-assay as an endpoint for DNA damage, the study 
shows that MG-Lys and MG-Lys-Cu^ "^  treated human lymphocytes were genotoxic in 
human lymphocytes. However, MG and lysine alone did not cause any significant 
change in lymphocyte DNA. This is evident from the DNA breakage and subsequent 
formation of the comet tail. The results clearly establish that MG-Lys system is 
capable of DNA breakage in lymphocytes which is due to the foraiation of distinct tail 
from the diffused head. However, in the presence of Cu^ ^ the damage of lymphocyte 
DNA was found to be enhanced by 36% suggesting Cu enhances the genotoxicity of 
MG+Lys system by increasing free radical ('OH) generation, as discussed before. 
Furthermore, in MG-Lys-Cu treated lymphocytes, an increase in OTM, % DNA in tail 
and tail length was found to be 316%, 246% and 92% respectively when compared 
with untreated lymphocytes. 
Previously, it was shovm that an in vitro AGE-modified plasmid transformed 
into Escherichia coli resulted in an increased mutation frequency (Pischetsrieder et 
al., 1999). This yields the idea that glycating agents may directly exert modification 
of DNA and thus induce DNA-damaging or mutagenic effects. 
Appreciable evidence for generation of strand breaks (single and double) in 
the human DNA as a consequence of MG-Lys-Cu^ "^  modification was gathered by 
agarose gel electrophoresis. The electrophoretic pattern of MG-Lys-Cu^ "" glycated 
human DNA revealed an increasing mobility with increasing incubation time. It was 
observed that at 24 hr incubation the mobility of glycated DNA was maximum and 
further incubation did not have any consequential effect on migration pattern. This 
suggests that maximum damage to DNA was at 24 hr incubation. It may be due to the 
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generation of single strand breaks by glycation induced intermediates or free radical 
generation ('OH) or both, which may result in the formation of small size DNA 
showing faster mobility compared to the native form. 
Fluorescence spectra of both native and MG-Lys-Cu glycated human DNA 
was recorded in the wavelength range of 380-500 nm. Generation of fluorogenic 
AGEs in glycated-DNA samples was measured using excitation wavelength of 370 
nm (Xex) and emission wavelength of 450 nm (Xem) (Minorova et al, 2005). Under 
identical conditions, DNA alone does not give any fluorescence. Glycation of DNA 
by methylglyoxal and lysine generated fluorescent DNA-AGEs characterized by 
emission maxima of 450 nm. The fluorescence intensity increased upon incubation 
with copper sulphate suggesting that copper enhances the formation of DNA- AGEs. 
Earlier studies have demonstrated that the structural alteration in DNA 
following damage by various agents result in the generation of single strands in the 
DNA molecule (Shishido and Ando, 1974; Yamasaki et al., 1997). Native and 
modified DNA was subjected to digestion by nuclease SI, in order to confirm the 
generation of single strand breaks. The results show substantial digestion of modified 
DNA by nuclease SI, while native DNA remained unaffected. These observations 
clearly demonstrate that sufficient distortions are caused in DNA helix by MG-Lys-
Cu^ "^  system, rendering it susceptible to digestions by single strand specific nuclease 
SI. 
The CD spectrum of modified human DNA shows a decrease of 27.56 % in 
the positive ellipticity at 275 nm as compared to native form. The decrease in 
ellipticity with slight change in the peaks of native DNA after methylglyoxal 
modification may be due to unstacking of bases as a result of helix destabilization. 
The structural perturbations suggest unfolding of DNA which might be a result of 
single strand breaks. 
Stacking of bases and hydrogen bonding stabilize DNA structure and their 
disruption causes denaturation (Casperson and Voss, 1983; Thomas, 1993). The 
native human DNA, upon MG-Lys-Cu^ "^  modification, showed susceptibility to 
temperature when subjected to thermal denaturation studies. The melting temperature 
of the modified human DNA was found to be 10 °C less as compared to the melting 
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temperature of native human DNA, used as reference. This could be attributed to the 
presence of single strand regions in the modified DNA and also a partial destruction 
in secondary structure. The decrease in Tm, therefore, points towards the 
destabilization of base stacking and hydrogen bonding and consequent helix 
disruption. 
Several reports (Brownlee et al., 1984; MuUarkey et ai, 1990; Bucala et al, 
1991; Simpson et al, 1992) have shown that glycated protein generated superoxide 
anions, which initiated lipid peroxidation. During incubation of MG with lysine, the 
formation of superoxide anion was gradually increased in a time-dependent manner. It 
has also been reported that the incubation of threose with A^-acetyl-lysine produced 
16.2 nmol O2* "mf'h"' (Ortwerth et al, 1998). In this study, the incubation of MG 
with lysine produced 28.2 nmol O2*" mf'h"'. The result suggests that DNA strand 
breakage by MG-Lys-Cu^"^ system may be dependent on the formation of superoxide 
anion in this system. However, MG aijd lysine alone generated only 2.46 and 1.96 
nmol O2*" ml~'h~' respectively. The production of superoxide radical was gradually 
inhibited by increasing concentration of superoxide dismutase, further confirming the 
formation of superoxide radical. 
Glycation adducts of DNA may have potential as biomarkers since all 
nucleated cells contain the same DNA content and should reflect the relative level of 
MG in the target tissue. Reaction of double-stranded DNA with MG or glucose in 
vitro produces primarily A^'^-carboxyethyl-2'-deoxyguanosine (CEdG), suggesting to 
be the likely major adduct formed in vivo (Papoulis et al, 1995; Frischmann et al, 
2005). This implies that CEdG might be a useful biomarker for monitoring 
oxoaldehyde-induced stress in response to enhanced glycolytic flux or environmental 
exposure to MG. The preparative HPLC was employed for the synthesis of the 
standard, carboxyethyl deoxyguanosine (CEdG). The standard adduct, CEdG formed 
by preparative HPLC was further proved by nuclear magnetic resonance analysis. The 
retention time of the synthesized CEdG was found to be 14.399 min. The HPLC 
performed for native and glycated DNA showed remarkable difference in peak 
retention times. The extra peak at a retention time of 14.249 min in modified DNA is 
characteristic of N^-(l-Carboxyethyl)-2-deoxyguanosine (CEdG) adduct. This is in 
accordance with the standard CEdG results wherein also when deoxyguanosine was 
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exposed to dihydroxyacetone, a distinct peak at retention time of 14.399 min was 
observed. However, native DNA did not showed the pealc at this retention time. The 
LC-MS technique was performed so as to detect the glycated adduct, CEdG formed 
with the double stranded human DNA. The acid hydrolysate of MG-Lys-Cu'^ 
glycated human DNA showed a m/z value of 338 in the negative ion mode. This is in 
conformity with the standard, CEdG wherein also we obtained the m/z value of 338, 
which is the characteristic of CEdG adduct formed with human DNA. 
For a typical nonenzymatic glycation reaction to occur, the carbonyl group of" 
a reducing sugar must first react with the free amino groups of a protein lo form a 
Schiff base with the latter and the intermediate then undergoes an Amadori 
rean'angement to generate a stable ketoamine product. Recently, it has been reported 
that the reaction of deoxy-guanosine (dG) with MG proceeds via Amadori pathway 
(Li et ah, 2008). In our case the ESI-MS, mass-spectroscopic data has shown similar 
resuhs, i.e., the reaction of human DNA with MG-Lys-Cu""^ proceeds via the classic 
Amadori pathway and yields glycation-like products similar to those generated 
between a nucleoside and a carbohydrate. This is in conformity with the results we 
obtained for ESI-MS. The ion at m/z 341, 679, 268 and 385 is consistent with a 
[Schiff base+H]" ,^ [Schiff base+H]'^dimer product, dG-HiO and a fragment formed by 
the degradation of MG reacting with the Schiff base product, or its enaminoi or 
Amadori intermediate respectively. 
Native double stranded DNA (B- conformation) per se is non immunogenic 
(Isenberg et al., 1994; Habib ei a!., 2005), whereas upon modification with 
carcinogens, drugs, hormones, free radicals etc., DNA undergoes structural 
perturbations wliich lead to the generation of neo-epitopes on the molecule which are 
recognized as foreign by the immune system and hence induces the immune response. 
Immunization with single stranded DNA can elicit a limited antibody response, while 
double stranded RNA, RNA-DNA hybrids, DNA modified with carcinogens, drugs 
etc. or DNA complexes with DNA binding proteins are effective immunogens 
(Stollar, 1975; Anderson et al., 1988; Desai et al., 1993; Moinuddin and Ali. 1994: 
Dixit et al, 2005; Habib et al., 2005; Khan et al., 2006). In contrast to native 
mammalian DNA (B-form), bacterial DNA is a stronger immunogen (Krieg, 2002). 
Moreover, the initial immune response to DNA is dominated by lower affinity IgM 
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Ab primarily specific for single stranded (ss), denatured mammalian DNA. As the 
immune response progresses, the Ab isotype switches to IgG and the Ab acquires 
increasing affinity for native, double stranded (ds) DNA (Tillman et al., 1992). 
Antibodies against MG-Lys-Cu modified human DNA were induced in rabbits 
by immunizing with MG-Lys-Cu modified human DNA complexed with methylated 
bovine serum albumin. The MG-Lys-Cu modified human DNA was a potent 
immunizing stimulus, inducing high titre antibodies. Antigenic specificity of anti-
MG-Lys-Cu modified human DNA IgG was ascertained by competitive binding 
assay. A maximum of 88.5% inhibition in the antibody activity was obtained at 
inhibitor (immunogen) concentration of 20 ng/ml and just 2.8 |j,g/ml of the inhibitor 
concentration caused 50% inhibition, clearly indicating very high specificity and 
affinity of the induced antibodies towards the immunogen, i.e. the MG-Lys-Cu 
modified human DNA. Low inhibition with native human DNA (35.1%) and 
moderate inhibition with MG-Lys-Cu modified calf thymus DNA (64.2%) and MG-
Lys-Cu modified human lymphocyte DNA (72.5%) was obtained. This shows that 
majority of the antibodies are directed towards the MG-Lys-Cu modified epitopes on 
the DNA. 
Visual detection of interaction between immune IgG and the immunogen was 
facilitated by the gel retardation assay. The result reflects high affinity of the induced 
antibodies for the immunogen. However, anti- MG-Lys-Cu- human DNA IgG did not 
show any appreciable binding with the native human DNA. These results further 
confirm that the induced antibodies are predominantly directed against the antigenic 
determinants generated as a result of MG-Lys-Cu modification of human DNA. 
Native calf thymus and plasmid DNA showed inhibitions of 33.3% and 32.1% 
respectively, whereas their MG-Lys-Cu modified forms showed enhanced inhibition 
of 64.2% and 54.2% respectively. These results demonstrate the preferential 
recognition of MG-Lys-Cu modified epitopes by the immune IgG. However, ROS-
modified form of calf thymus DNA and plasmid DNA inhibited antibody activity to a 
lesser extent possibly because the ROS modified epitopes are not so distinctly 
recognized by the induced antibodies. Amongst MG-Lys-Cu modified bases, guanine 
showed substantial inhibition (78%). Previous reports have demonstrated that guanine 
157 
or its nucleoside form (deoxyguanosine) is particularly susceptible to modification by 
reactive carbonyl species like methylglyoxal, glyoxal, glucose, etc. generating 
carboxyethyl deoxyguanosine (CEdG) as major adduct (Ochs and Severin, 1994; 
Papoulis et al, 1995; Seidel and Pischetsrieder, 1998; Frischmann et al., 2005). 
However, carboxyethyl guanosine (CEG), carboxymethyl deoxyguanosine (CMdG) 
and carboxymethyl guanosine (CMG) are also formed as minor adducts depending on 
the reaction conditions (Nissl et al., 1996). All these adducts are due to the attack of 
RCS on guanine residue of the DNA. 
Increased glycation and, in particular, accumulation of tissue and serum AGEs 
have an important role in the pathogenesis of diabetic complications. Studies in the 
past have focussed largely on long-lived extracellular proteins whereas more recent 
studies have highlighted the importance of intracellular glycation. The chemical 
nature of many AGEs, their synthesis in vivo and their precise role in the pathogenesis 
of diabetic complications is under intense investigation (Nessar Ahmed, 2005). 
Glycation is a major cause of spontaneous damage to cellular and extracellular 
proteins in physiological systems, accounting for 0.1-0.2% of lysine and arginine 
residues (Thomalley, 2003). Reactive dicarbonyl compounds formed endogenously, 
glyoxal, methylglyoxal and 3-deoxyglucosone, are potent glycating agents. Glycation 
by methylglyoxal is increased disproportionately compared to the increase in glucose 
concentration in experimental and clinical diabetes (McLellan et al., 1994). This may 
be attributed to the formation of methylglyoxal from triosephosphate accumulation in 
vascular cells suffering cytosolic hyperglycaemia(Brownlee, 2001). 
Type I diabetes is due to a deficiency of insulin as a result of destruction of the 
pancreatic P cells. At the time of clinical symptoms, 60-80% of the P cells are 
destroyed. Cells secreting glucagon, somatostatin and pancreatic polypeptide are 
generally preserved but may be redistributed within the islets. For years, the notion 
that T-lymphocytes played a crucial role in disease induction was considered such a 
sound dogma that interest in B-lymphocytes and auto-antibodies as pathogenic 
variables was largely relegated to second-class status. However, much of our 
knowledge regarding the pathogenesis and natural history of this disease has been 
obtained by analysis of subjects having type I associated auto-antibodies. While auto-
antibodies to more than two dozen auto-antigens have been associated with this 
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disease, a majority of interest has been directed to islet cell auto-antibodies (ICA), 
insulin auto-antibodies (lAA), glutamic acid decarboxylase (GAD) and tyrosine 
phosphatase-like IA-2 auto-antigen. These auto-antibodies, combined with other 
metabolic and genetic markers, are extremely effective for predicting eventual 
development of type I diabetes. 
Like type I diabetes, type II diabetes also involves both genetic susceptibility 
and environmental factors, although the genetic component may be greater than in 
type I diabetes. It is caused by a combination of insulin resistance and relative insuVm 
deficiency with increased hepatic glucose production. Insulin resistance alone, how-
ever, does not cause diabetes. Most obese people do not develop type 11 diabetes, 
despite increased insulin resistance (Polansky, 2000). Before type II diabetes 
develops, the pancreatic p-cells increase their production of insulin to compensate for 
increased insulin resistance. For unclear reasons, P-cell secretory capacity gradually 
declines in some individuals, leading to the development of type II diabetes. As P-cell 
insulin secretory capacity declines, type II diabetes begins to develop. Initially, 
hyperglycemia is only observed after large meals, as in type I diabetes. As p-cell 
function declines further, hyperglycemia becomes more severe. Several authors 
speculate that increased insulin resistance may be a genetic trait that can be worsened 
by obesity and that P-cells compensate for this increased resistance. Some individuals, 
however, caimot maintain this compensation because of P-cell failure, which leads to 
the development of type II diabetes. 
In view of this, the possible involvement of MG-Lys-Cu^"" modified human 
DNA in diabetes mellitus (both type I & II) was probed. Diabetes type I and II sera 
were screened for the presence of autoantibodies reactive to native and MG-Lys-Cu^"" 
modified human DNA. The binding of circulating autoantibodies from eighty five 
type I and II diabetes patients and twenty healthy normal subjects to native and MG-
Lys-Cu "^^  modified human DNA was studied by direct binding ELISA. Of the 40 sera 
in type I diabetes, 67.5% showed preferentially high binding to MG-Lys-Cu^"^ 
modified human DNA as compared to its native analogue. No appreciable binding 
either with native or MG-Lys-Cu^"^ modified human DNA was observed with serum 
antibodies from healthy normal subjects. Competition ELISA results showed 22 to 
33% inhibition in the type-I diabetes autoantibodies binding to native human DNA, 
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2+ whereas 46.9 to 63.1 % inhibition was observed with MG-Lys-Cu modified human 
DNA. These results indicate appreciable recognition of MG-Lys-Cu^^ modified 
human DNA by the autoantibodies in diabetes (type-I) patients. The binding 
specificity of the isolated IgG, towards native and MG-Lys-Cu^"^ modified human 
DNA was evaluated by competition ELISA. Immunoglobulin G (IgG) from diabetic 
patients (type-I) recorded an inhibition of 59% to 69% with the MG-Lys-Cu ^ 
modified human DNA, while with native human DNA it ranged from 27% to 36%. 
Appreciably high binding of affinity purified IgG towards MG-Lys-Cu '^ modified 
human DNA, is indicative of the generation of antibodies against RCS modified 
epitopes on the DNA molecules in diabetes. 
The strong binding of autoantibodies from diabetes type I patients to MG-Lys-
Cu^ "^  modified human DNA is evidence towards the involvement of modified bases 
and single strand regions in disease pathogenesis. The spontaneous production of 
auto-antibodies in type I diabetes might be a result of the generation of the antigenic 
epitopes on the DNA molecules that are recognized as 'non self by the body's 
immune system. It could, therefore, be one of the factors of the immune response in 
diabetes. 
In type II diabetes patients (total 45), 35.5%o serum samples showed low to 
moderate binding to MG-Lys-Cu^"^ modified human DNA as compared to its native 
analogue. The degree of binding was moderately higher than serum antibodies from 
normal healthy subjects. The moderate (average) recognition of MG-Lys-Cu^^ 
modified human DNA by the auto-antibodies in type II diabetes patients was further 
confirmed by competitive inhibition analysis. The inhibition in the antibody activity 
with MG-Lys-Cu^"^ modified human DNA was in the range of 34.4% to 53%, 
however for native human DNA it was found to be 18% to 30.1%. These results are 
distinct from type I diabetes. In type II diabetes, the recognition of auto-antibodies 
against MG-Lys-Cu^"^ modified human DNA is quite low as compared to type I 
diabetes. The IgG isolated from type II diabetes patients recorded an inhibition in the 
range of 24% to 36% and 49% to 57%, when MG-Lys-Cu^* modified human DNA 
and its native form were respectively used as inliibitors. The results show ample 
evidence of the involvement of MG-Lys-Cu^* modified human DNA in type I 
diabetes while the same is less established for the type II. 
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Based on above studies the following conclusions can be drawn-
1. MG-Lys-Cu^"^ modification of human DNA results in the formation of strand 
breaks and base modification. 
2. Fluorescence spectroscopy in combination with anti-glycation study (by D-
penicillamine and pyridoxal phosphate) supports the formation of glycation 
products. 
3. Comet assay shows the genotoxicity of advanced glycation. end-products formed 
by MG-Lys-Cu^^ system on the human DNA. 
4. Thermal denaturation studies show that modification has rendered the human 
DNA susceptible to rise in temperature. This shows the destabilization of helix. 
5. Estimation of free radicals ("OH and 02'~) and their quenching studies in the 
presence of specific quenchers confirms the formation of fi-ee radicals in MG-Lys 
and MG-Lys-Cu^"^ system respectively. 
6. Both HPLC and LC-MS supported the formation of the adduct, carboxy-ethyl 
deoxy-guanosine (CEdG) in modified human DNA. CEdG is a useful biomarker 
for monitoring oxoaldehyde-induced stress in response to enhanced glycolytic 
flux or environmental exposure to MG. 
7. ESI-MS data supports the formation of Schiff base, Schiff base dimer and amadori 
product in glycated human DNA samples. 
8. MG-Lys-Cu modification of human DNA renders it highly immunogenic 
inducing high titre antibodies in experimental animals. This shows the generation 
of neo-epitopes on the DNA molecule upon modification. 
9. The induced antibodies, though highly specific for the immunogen, also exhibited 
polyspecific binding. The antibodies showed binding with various nucleic acid 
conformers and nitrogenous bases significantly recognizing epitopes formed as a 
result of MG-Lys-Cu^^ modification. 
10. Diabetes type I auto-antibodies showed preferential binding to MG-Lys-Cu^^ 
modified human DNA as compared to the native form. This shows that RCS 
modified DNA could be an antigenic stimulus for these auto-antibody. 
11. Antibodies fi*om type II diabetes patients exhibited low to moderate binding with 
MG-Lys-Cu modified human DNA. This means that some type II diabetes 
patients (especially with secondary complications) develop antibodies against 
RCS modified DNA. 
The RCS system used in the study has direct physiological relevance as MG is 
formed endogenously and is enhanced 5-6 times in pathogenesis of diabetes and 
diabetic complications. Moreover, lysine is an essential amino acid which is present in 
most proteins and also a part of enzyme active site. It is also the preferred group for 
non enzymatic carbonyl group attachment and subsequent formation of AGEs. 
Methylglyoxal can readily react with lysine to form AGEs and generates free radicals. 
The generation of free radicals is enhanced in the presence of cu""^ , which is present in 
vivo in variety of enzymes like cytochrome c oxidase and superoxide dismutases. 
Thus MG-lys-Cu system can be very deleterious for macromolecules like DNA, 
proteins, lipids etc. The present study has probed the MG-lys-Cu^ "^  induced damage to 
DNA and the resulting immune response of the modified DNA and its role in the 
induction of antibody response in diabetes. 
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